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Different patterns of genomic instability have been described in sporadic colorectal
cancers. In a minor subset, deficient DNA mismatch repair causes a 'replication error
positive' (RER+) phenotype, while in the major (RER-) subset, a chromosomal instability
(CIN) phenotype with large-scale changes to chromosome number and structure has been
described. Chromosomal instability has previously been associated with alterations to the
p53 gene. Both patterns of genomic instability lead to further mutations. Data from
animal models indicate that both chromosomal double strand breaks and errors of
nucleotide mismatch repair engender apoptosis in normal cells. The question thus arises
whether cancer cells bearing such lesions show particular phenotypes, reflecting deficiency
of specific apoptotic pathways in their origin. Conversely, genes activating apoptosis may
be selected as targets for mutations in these genomically unstable cancer cells, as a wider
blockade of apoptosis may confer growth advantage and resistance to treatment.
Therefore, by examining RER+ and RER- sporadic colorectal cancers, this thesis (1) seeks
to delineate distinct chromosomal instability phenotypes associated with RER status, (2)
searches for mutations in three apoptosis genes {Fas, Bik, Bax) and one growth control
gene {TGFfiRII), and (3) examines sensitivity of these tumours, in vitro and in vivo to
therapies that deliver different types of DNA injury.
Chromosomal instability was studied in 17 colorectal cancer cell lines using
Spectral Karyotyping (SKY). RER- lines usually displayed extensive numerical and
structural variations with marked heterogeneity. Most RER- lines showed a tendency to
approach a near-triploid karyotype, and invariably had structural chromosomal changes
including unbalanced translocations. Marked clonal heterogeneity was observed among
cells of the same tumour line. Evidence of endoreduplication was much less frequent in
these colorectal cancer cells than for other cancers reported in the literature. A minor
subgroup of RER- lines retained a near-diploid karyotype, but displayed the same pattern
of structural rearrangements and heterogeneity observed in the near-triploid pattern.
Chromosomal gains and losses were in broad agreement with previously published data on
primary cancers, indicating that the patterns observed in these cell lines are likely to be
representative of primary colorectal cancers. In contrast, RER+ lines usually showed
marked stability of both chromosome number and structure. p53 mutation found in some
of these RER+ lines was not associated with aneuploid karyotypes. Extensive
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chromosomal instability was identified in 3 out of 8 RER+ lines, one of which showed a
pattern near triploid as commonly seen in RER- tumours. Two RER+ lines were near-
diploid and showed a striking and previously unreported tendency to acquire balanced
translocations. Potential mechanisms underlying these different patterns of genomic
instability are discussed.
Thirty-three primary (uncultured) colorectal carcinomas were chosen according to
their RER status for mutational analysis of apoptosis genes. Twelve of these were RER-,
18 were RER+ showing microsatellite instability at 2 or more microsatellite loci, and 3
tumours were RER+ with only one unstable microsatellite locus. A minimum of 5
microsatellite loci was examined in each case. Box gene mutations were detected in 50%
of RER+ tumours, but were not always present at all tumour sites and hence must
sometimes have arisen during tumour progression rather than in the founder clone. In
contrast, TGFf3RII mutations were found in 75% of the RER+ tumours, and were present
in all the sampled sites: these mutations must have arisen in the founder clone. RER+ and
RER- cancers were screened for mutations in the whole coding sequence of Fas and in a
trinucleotide repeat tract identified in Bik, but no mutations were found in either.
Representative colorectal cancer cell lines were investigated for any relationship
between mismatch repair and p53 abnormalities and responsiveness to anti-cancer
cytotoxic therapy. Cells were treated with cytotoxic agents and examined in vitro for
clonogenic survival and induction of apoptosis. Tumour cells from primary carcinomas
were implanted as xenografts in Severe Combined Immunodeficiency (SCID) syndrome
mice, and apoptosis was scored following treatment in vivo. Apoptotic response to
ionising radiation (IR) was present in tumours with intact p53, or functional DNA
mismatch repair, whereas response to 5-Fluorouracil (5FU) associated only with intact
p53. Increased tolerance of RER+ carcinoma cells to a methylating agent (Temozolomide)
was also observed. These data may help to inform the design of more effective therapeutic
protocols based on the commonly observed genotypic alterations in colorectal cancers.
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Different forms of genomic instability exist producing characteristic patterns of
abnormalities in genomic organization. Consistent patterns of instability found in
colorectal cancers reflect and may ultimately reveal the specific genetic defects that
underlie them. Depending on the nature of the underlying defect, patterns of genomic
instability may be related to the capacity of mutated cells to survive and replicate. Thus,
genes activating apoptosis may be selected as targets for mutation in these genomically
unstable cancer cells, as a wider blockade of apoptosis may confer growth advantage and
resistance to treatment. Hence, it is important to study patterns of genomic instability in
cancers in order to identify, more clearly, their causes and effects. Colorectal carcinoma is
a good model in this regard as two of the commonly observed genomic instability
phenotypes—microsatellite instability or 'replication error positive' (RER+) phenotype
and chromosomal instability (CIN)—were first described and also prevalent within
colorectal cancers. There are data suggesting that some apoptotic pathways are
deregulated in colorectal cancers. Furthermore, these tumours are notoriously resistant to
both chemotherapy and radiotherapy and most patients for whom surgery alone is not
curative are doomed to die of their disease. The basis of this resistance to therapy is still
not completely understood.
To introduce these issues, this chapter gives an overview of current knowledge of
the genetic events and environmental influences that play a role in sporadic colorectal
tumour development and responses to different treatment modalities. The specific types of
genomic instability pertinent to this study will be discussed, namely microsatellite
instability, chromosomal instability, and potential causative mechanisms including the role
of p53 and relevant apoptotic pathways. Finally, the aims and objectives of this project are
presented.
1
1.1. Clinical aspects and aetiology of colorectal cancer
1.1.1. Incidence and distribution of colorectal cancer
Large bowel cancer is the second most common cancer in western countries. Over
34,000 new cases of bowel cancer are diagnosed each year in the UK. Incidence varies
considerably worldwide. Within Britain bowel cancer is more common in Scotland than it
is in England and Wales (Cancer Research Campaign, 1999a). Incidence is increasing in
low-risk populations, such as Mediterranean countries, Central and South America, Asia
and Eastern Europe, as lifestyles become increasingly westernised (Weisburger, 1991).
Large bowel cancer accounts for 17,620 deaths per annum in the UK (11% of all cancer
deaths) (Cancer Research Campaign, 1999a). The risk of developing colorectal cancer
increases with age; the likelihood of developing cancer at age 30-34 is small (2.9/100 000)
compared with the risk at age 85 or older (531.6/100 000) (Levin & Dozois, 1991).
1.1.2. Natural history of colorectal cancers: the adenoma to carcinoma sequence
Adenocarcinoma accounts for more than 90% of colorectal cancers. Most sporadic
colorectal cancers are thought to develop via an earlier adenoma stage, progressing through
a number of histologically distinct steps, for which the term "adenoma to carcinoma
sequence" was coined (Muto et al., 1975). Single dysplastic crypts (uni-cryptal adenomas)
are thought to be the first manifestation of tumour development (Ilyas et al., 1999).
Adenomas can gradually grow in size. They show either tubular or villous architecture or
a combination. The cells show a range of nuclear pleomorphism from mild through
moderate to severe dysplasia, which may progress to malignant change resulting in local
invasion and eventual metastasis to distant sites. Several lines of evidence support this
model. The population distribution of adenomas reflects that of carcinomas, and migrants
acquiring increased risk of colorectal cancer through moving to areas with high cancer
incidence also acquire an increased risk of developing adenomas (Weisburger, 1991). The
distribution of adenomas throughout the large bowel is similar to that of carcinoma, with
an age of onset approximately 5 years earlier (Muto et al., 1975), consistent with
sequential progression. Foci of carcinoma can sometimes be found within adenomas, and
islands of residual adenoma may be seen adjacent to carcinomas suggesting common
origin (Lane, 1976). Although the progression from adenoma to carcinoma is thought to
occur in the vast majority of western colorectal cancers, it is possible that 'cle novo' cancers
sometimes arise without pre-existing adenoma. In particular, it has been suggested that
cancers with flat morphology may arise de novo in the Japanese population (Wada et al.,
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1996), though this is disputed (Owen, 1996). The process of tumour development
probably takes up to 20 years or more and not all adenomas will progress into carcinomas
(reviewed by Ilyas et al., 1999).
Recently it has been proposed that aberrant crypt foci 'ACF' (small areas of
epithelium with irregular glandular architecture but no evidence of dysplasia) are precursor
lesions which give rise to adenomas, however the data regarding mutations found in ACF
remains inconclusive and their relationship to adenomas remains unproven (Jen et al.,
1994b; Smith et al., 1994a; Yamashita et al., 1995; Nucci et al., 1997).
1.1.3. Treatment and prognosis of colorectal cancer
There are several systems for staging colorectal cancers including Dukes' staging
system, TNM staging system and the American Joint Committee on Cancer (AJCC)
staging system. The following discussion refers to AJCC stage. Each stage carries
specific prognostic and therapeutic implications (Cohen et al., 1997). Overall, prognosis
for this disease is relatively poor with an average five-year survival rate of 37% (Cancer
Research Campaign, 1999b). The tumour stage remains the main histopathological
predictor of survival (Laurent Puig et al., 1992). In addition, certain genetic factors have a
significant relationship with prognosis. Notably, relatively poor 5-year survival is
associated with alterations to the p53 gene and certain chromosomal alterations and
deletions, whereas several studies indicate improved survival in patients whose cancers
have a diploid karyotype and in patients whose tumours demonstrate microsatellite
instability (Jass et al., 1994; Bubb et al., 1996; Jass et al., 1998).
Surgery with resection of the primary tumour is recommended for all stages of
colon cancer. Nevertheless, a proportion of patients at each stage have residual
micro-metastasis, which are the targets of adjuvant therapy. 5-Fluorouracil (5-FU) alone
or in combination with levamisole—or less commonly 5-FU, levamisole, and leucovorin—
represent the standard adjuvant therapy. This treatment increases the 5-year overall
survival by 33% for stage III colon cancers (Moertel et al., 1990; Moertel, 1994; Moertel
et al., 1995; O'Connell et al., 1998). Minimal improvement in survival is observed in stage
IV with adjuvant therapy (Buroker et al., 1994). For stage II and III rectal
adenocarcinoma, pre-operative or post-operative combined radiation and chemotherapy
with 5-FU is considered beneficial (O'Connell et al., 1994). Many lines of treatment are
followed for metastatic colorectal cancers most of which use 5-FU or one of its new
derivatives, however, the main benefit is palliative (Cohen et al., 1997).
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1.1.4. Risk factors in the development of colorectal cancers.
1.1.4.1 Environmental and other non-genetic risk factors
It has long been postulated that dietary factors contribute to colorectal cancer
formation. Mutagens are present in the stool of many people who eat a western diet
(Reddy et al., 1989) and the nature of genetic and cellular damage initiated by dietary
components may determine subsequent genetic events, however, the exact role of these
dietary mutagens in the aetiology of colon cancer is still an interesting area requiring more
research. Principally, an increased risk of cancer is associated with a diet high in saturated
fats and meat and low in fibre, though the type of fat and fibre consumed is important.
Intake of calcium and certain vitamins may also reduce risk. Tobacco smoking and
excessive alcohol are associated with increased risk (Palmer & Bakshi, 1983; Weisburger,
1991; Cancer Research Campaign, 1993; Olsen et al., 1994). Dietary factors also have an
impact on the formation of adenomas (Winawer & Shike, 1992).
1.1.4.2 Interaction between environmental influences and molecular genetic pathways
Vegetables: One important constituent of vegetables is folate. Folate is central to
methyl group metabolism and may influence both methylation of DNA and the available
nucleotide pool available for DNA replication and repair. Folate deficiency produced large
numbers of tumours in rats and mice (Yunis & Soreng, 1984; Wagner, 1995; Potter, 1999).
Fibre ferments in the large bowel and produces short chain fatty acids, like butyrate, which
induce apoptosis in colonic cell lines (Hague & Paraskeva, 1995). More generally,
vegetables contain large numbers of anti-oxidants and bio-active compounds with potent
anti-carcinogenic properties, which may have protective effects (Wattenberg, 1978).
Meat: Cooked meat contains carcinogens like heterocyclic amines (such as PhIP:
2-Amino-l-methyl-6-phenylimidazo[4,5-b] pyridine) and nitrosamines which have been
shown to be carcinogenic in animals (Kakiuchi et al., 1995; Lynch et al., 1998) and
probably in humans (Bingham et al., 1996) via direct mutagenic effects on genes such as
the APC gene.
Bile acids: Secondary bile acids are formed after enzymatic deconjugation and
dehydroxylation of primary bile acids in the large bowel by anaerobic bacteria. It has been
shown that these compounds can have tumour-promoting capacities in animal experiments.
In epidemiological studies, colonic cancer risk is related to the faecal bile acid
concentration. Secondary bile acids are toxic to several cell systems at physiological
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concentrations. The exact mechanism by which these molecules exert their action is not
well understood (Nagengast et al., 1995).
Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs inhibit
cyclo-oxygenases (COX-1 and COX-2), which are responsible for metabolism of
arachidonic acid to prostaglandins. Decreased levels of prostaglandins are associated with
protection against tumour formation (Kalgutkar et al., 1998). NSAIDs produce inhibitory
effects on epithelial proliferation and promote apoptosis (Barnes et al., 1998) and have
effects on angiogenesis (Tsujii et al., 1998). More recently, NSAIDs have been suggested
to suppress tumour formation in HNPCC families by selecting for mismatch repair
proficient subsets of cells (Ruschoff et al., 1998). Therefore, clinical trials to establish the
efficacy of NSAIDs more generally are underway.
Tobacco: Tobacco smoke is a major source of wide variety of carcinogens which
may act in a way similar to those derived from meat.
Alcohol: Acetaldehyde may cause DNA adduct formation and inhibit DNA repair.
Alcohol may also exert effects through nutrient deficiency, particularly folate (Garro &
Lieber, 1990).
Physical activity: Exercise stimulates peristalsis, reduces exposure time, and has
favourable effects on the immune system (Potter et al., 1993). Furthermore, physical
activity is associated with a metabolic milieu that is less favourable to the growth of
cancers (McKeown-Eyssen, 1994).
Many risk factors tend to cluster in the lives of some individuals.
1.1.4.3 Genetic predisposition to colorectal cancers: high prevalence polymorphisms
1.1.4.3.1 N-Acetyltransferases (NAT1, NAT2) and Cytochrome P450 (CYP) enzymes:
Heterocyclic amines are thought to act as colorectal carcinogens and their
effectiveness may vary with differences in their metabolism which may be due to genetic
variability of at least 3 enzymes (NAT1, NAT2, CYP1A2). Therefore, polymorphisms of
these enzymes may influence the risk of colorectal neoplasia. Some studies suggest that
combined polymorphisms of NAT1, NAT2, and perhaps, CYP1A2 may bring about rapid
acetylation phenotype, which is associated with increased colorectal cancer risk, in the
presence of a high intake of meat (Chen et al., 1998; Potter, 1999). However, other studies
did not find any association between NAT1 and NAT2 polymorphisms and increased
colorectal cancer risk (Hubbard et al., 1997; Hubbard et al., 1998).
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1.1.4.3.2 Methyltetrahydrofolate reductase (MTHFR):
As noted above, folate and vitamin B12, a cofactor in the methyl group metabolism
pathway, are associated with reduced risk of colorectal neoplasia (Slattery et al., 1997).
MTHFR, a polymorphic enzyme, influences that association such that those at highest risk
for both adenomas and carcinomas have the variant (TT) genotype and low intake of
folates and vitamin B12 (Chen et al., 1996; Ma et al., 1997).
1.1.5. Predisposition to colorectal cancer and inherited syndromes
The high-risk, inherited cancer predisposition syndromes Familial Adenomatous
Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) are described
in the following discussion. In addition, several diseases (e.g. ulcerative colitis and
Crohn's disease), as well as rare polyposis syndromes, confer an increased risk of bowel
cancer and are described where relevant (Howe & Guillem, 1997; Howe et al., 1998; Ilyas
et al., 1999).
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1.2. Genetic pathways to colorectal cancer
Carcinogensis is a multi-step process of accumulating genetic changes resulting in
either activation of dominantly acting oncogenes or inactivation of tumour suppressor
genes (Foulds, 1958; Fearon & Vogelstein, 1990; Kinzler & Vogelstein, 1996; Bodmer,
1997). Each mutation alters the behavioral responses of cells giving some growth
advantage. The mutations, which occur, and the order in which they occur form the
genetic pathway. Histological progression in precursor lesions, showing progressive
increase in atypia leading to malignancy, may accompany the progressive accumulation of
these mutations (Muto et al., 1975; Ilyas et al., 1999). Tumours arising from a particular
tissue escape the same growth controls and hence may be expected to develop along
similar genetic pathways. However, genetic pathways for a particular tumour arising in a
particular tissue may vary according to the individual genetic background, regional
differences and the nature of the first mutation may have a strong influence on the
mutations to follow (Ilyas et al., 1999). Recent work had strengthened the proposal that a
certain degree of genetic instability is required to drive the generation of multiple
mutations found in malignant tumours (Lengauer et al., 1997; Cahill et al., 1998; Lengauer
et al., 1998; Cahill et al., 1999a). Clonal selection seems to be essential to drive the
accumulation of subsequent mutations in the progenitor cell, as waves of clonal expansion
give rise to daughter cells that have the growth advantage of cancer (Cahill et al., 1999b;
Tomlinson & Bodmer, 1999). A Diagrammatic illustration of the common genetic
pathways in colorectal cancer is presented in Figure 1.1.
The remainder of this Chapter describes the putative genetic pathways in colorectal




Genetic pathways to colorectal cancers
APC mutations are thought to initiate tumour formation in both sporadic and
inherited colorectal cancer; deregulation of apoptosis may be required at this stage.
Neoplasia progresses as a result of mutations in K-ras, and then one or more tumour
suppressor genes located on chromosome 18q, particularly those associated with the TGF(3
pathway, and p53. Mismatch repair gene mutations may speed up the tumorigenic process
by increasing the rate of mutation in these or other genes where 'target' repetitive
sequences are present, such as in the TGFJ3R1I, IGFIIR , Bax and E2F4.






1.2.1. The APC gene
Mutations of the Adenomatous Polyposis Coli {APC) gene, located on chromosome
5q21-5q22, (Bodmer et al., 1987; Leppert et al., 1987; Solomon et al., 1987) are the
earliest and commonest gene mutation in sporadic colorectal cancers (Nakamura et al.,
1992; Powell et al., 1992). Germ-line APC mutations are found in Familial Adenomatous
Polyposis (FAP) (Groden et al., 1991) which is an autosomal dominant condition
characterized by the development of hundreds to thousands of colorectal polyps as well as
other extra-colonic manifestations. Some of the polyps in FAP inevitably progress to
cancer, if left without surgical removal, when normal function of the remaining APC allele
is lost. Thus, APC functions as a classical tumour suppressor gene according to Knudson's
hypothesis (Knudson, 1971).
Mutations of the APC are almost all truncating mutations resulting in loss of the
downstream functional domains. The one important consequence of this is loss of the
ability to down-regulate P-catenin, an important molecule in the Wnt signalling pathway,
leading to increased nuclear signalling in association with the transcription factor Tcf-4
(Morin et al., 1996). One of the genes inappropriately activated in this pathway is c-myc,
thus linking APC pathway to apoptosis deregulation (He et al., 1998). APC mutations
probably disrupt pathways mediated through proteins that bind APC, some of which are
yet to be elucidated.
1.2.2. The K-ras genes
The Ras proteins are part of signal transduction pathways. Up to 50% of colorectal
carcinomas and adenomas more than 1 cm in diameter contain K-ras gain-of-function
missense mutations, predominantly in codons 12 and 13 (Bos et al., 1987; Bos, 1988).
Mutant K-ras, in conjunction with other oncogenes, is capable of transforming cells in
culture (Ruley, 1983). Furthermore, disruption of mutant K-ras in colorectal cancer cell
lines reduces the tumorigenic potential and aggressive phenotype with concomitant
reduction in expression of the c-myc oncogene (Shirasawa et al., 1993). Ras activation of
PI 3-kinase suppresses apoptosis but Ras also promotes apoptosis through the Raf pathway
[Kauffmann Zeh, 1997 #807]. Recently, however, other effects of mutant ras have been
reported. Active Ras can lead to phosphorylation of pro-caspase-9, thereby inhibiting
cytochrome-c-induced apoptosis (Cardone et al., 1998). Whereas, P-catenin activates
transcription from the cyclin Dj promotor, Ras signalling pathways can further increase
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cyclin Di transcription (Tetsu & McCormick, 1999). Cyclin D1 binds to cyclin-dependent
kinase (cdk) to bring about cell cycle progression through G1 to S phase and is an
attractive target in these pathways because of its possible role in allowing cell proliferation
under conditions that promotes differentiation and senescence in normal cells (reviewed by
McCormick, 1999). However, there have been several reports of K-ras mutations in
histologically normal colonic mucosa suggesting that dysplasia is seen only when K-ras
mutations occur in association with other mutations such as APC (Jen et al., 1994b).
1.2.3. The p53 gene
p53, the guardian of the genome, is a key molecule in the maintenance of genomic
integrity, and loss of normal p53 activity contributes to a wide variety of human cancers
(Hollstein et al., 1991; Lane, 1992; Hansen & Oren, 1997; Albrechtsen et al., 1999). p53
is a nuclear phosphoprotein which has the ability to regulate many cellular processes
including cell cycle progression and apoptosis via its sequence-specific transactivation
(SST)-dependent or -independent functions (Haupt et al., 1995; Gottlieb & Oren, 1998;
Sionov & Haupt, 1999). Figure 1.2 summarizes the roles of p53 in cellular responses to













1.2.3.1. The role ofp53 in cell growth arrest
p53 regulates vital checkpoints during the G1 and the G2 phases of the cell cycle
(Figure 1.2). The induction of p2JWAF,/c'P1 is responsible for G1 arrest (Waldman et al.,
1995), while the induction of 14-3-3o gene (Hermeking et al., 1997; Peng et al., 1997;
Chan et al., 1999), and to some extent that of the GADD45 gene (Wang et al., 1999),
mediates the G2 arrest. It has been also reported that p21 has a role in G2 arrest (Bunz et
al., 1998) and GADD45 can mediate G1 arrest (Kastan et al., 1992; Maity et al., 1994;
O'Connor et al., 1997). These checkpoints prevent damaged genomes from undergoing
DNA replication or mitosis. p21 mediates p53-dependent G1 arrest by inhibiting the
activity of cyclin-dependent kinases (CDKs), which phosphorylate the retinoblastoma
(RB-1) gene product. In its hypo-phosphorylated form, pRb sequesters the E2F
transcription factor, thereby preventing transition from G1 to S phase (Levine, 1997). In
addition, pRb recruits histone deacetylase (HDAS1) which blocks transcription by
promoting nucleosome compaction (Brehm et al., 1998). p21 also promotes growth arrest
by preventing proliferating cell nuclear antigen (PCNA) from activating DNA
polymerase-5 essential for DNA replication (Waga et al., 1994). p53 can also trigger
growth arrest in a p21-independent manner. By binding to cyclin H and p36Matl, p53
inhibits the protein kinase complex CDK7/CyclinHl/Matl (a CDK activating kinase
termed CAK kinase) that activates the CDK2/Cyclin, a kinase required for the Gl/S
transition (Schneider et al., 1998). p53 can also induce efficient G2 arrest via at least two
target genes: 14-3-3o and GADD45. The product of 14-3-3o gene sequesters the
phosphorylated form of cdc25C, a phosphatase of the cyclinB/cdc2 complex that is
essential for the G2/M transition (Peng et al., 1997). GADD45 disrupts cyclinB/cdc2
complex via direct interaction with cdc2 (Wang et al., 1999).
Although G2 arrest can occur in the absence of p21 or p53, both of these proteins
are essential for sustaining the G2 arrest after DNA damage (Bunz et al., 1998).
1.2.3.2 The role ofp53 in apoptosis
Several p53-induced target genes can promote apoptosis (Figure 1.2), although the
expression of each alone may be insufficient to cause significant cell death. Hence, the
apoptotic target genes of p53 may need to act in concert to induce significant cell death
(Sionov & Haupt, 1999). The apoptotic target genes of p53 may be divided into 2
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families: those acting on receptor signalling and those activating downstream effector
proteins.
p53-induced proteins acting at the receptor signalling level include the insulin-like
growth factor-1-binding protein 3 (IGF-BP3), which blocks the survival signalling by
IGF1 (Buckbinder et al., 1995). Combined to this, p53 can suppress the IGF1 receptor via
a SST-independent mechanism to ensure an efficient block of this survival pathway (Prisco
et al., 1997). p53 also activates an important death receptor, Fas/Apol/CD95, in response
to DNA damage; p53 responsive elements have been identified in the Fas gene (Owen-
schaub et al., 1995; Mueller et al., 1998; Mueller et al., 1999). In addition p53 may
facilitate the transport of Fas from Golgi to the membranes (Bennett et al., 1998). Fas is
essential for T-cell killing in response to anti-cancer drugs (Friesen et al., 1996), and for
Myc-mediated apoptosis (Flueber et al., 1997). Both responses are p53-dependent, hence
linking Fas to the apoptotic responses of p53. Further, p53-induced apoptosis is impaired
in Ipr (Fas-deficient mice) and gld (Fas ligand-deficient mice)-derived embryonic
fibroblasts (Bennett et al., 1998), but there is controversy regarding this (OGonnor et al.,
2000). p53 also induces another death receptor, KILLER/DR5, however, there is no direct
evidence for the involvement of this receptor in p53-induced apoptosis (Wu & Levine,
1997).
p53 is linked to the mitochondrial changes associated with early stages of apoptosis
via two routes: Bax and PIGs (p53-induced genes-products) that have potential to induce
oxidative stress. The Bax protein induces apoptosis via facilitating the release of
apoptosis-inducing factor (Apaf-1) and cytochrome c from the mitochondria, which
triggers caspase activation (Narita et al., 1998; Susin et al., 1999). Bax is essential for
p53-mediated apoptosis in brain tumours (Yin et al., 1997) and fibroblasts (McCurrach et
al., 1997), but not in thymocytes (Brady et al., 1996), suggesting that Bax may contribute
to p53-mediated cell death only partially. Polyak et al. (1997) isolated several PIGs with
the potential to elevate the level of ROS, which in turn signal to the mitochondria to induce
apoptosis (Polyak et al., 1997).
Induction of the afore-mentioned genes is dependent on p53-SST function, but, p53
may induce apoptosis via SST-independent function. The mechanisms underlying this
SST-independent apoptosis are poorly understood. Possible mechanisms include: (1) loss
of pRb function with consequent dergulation of E2F-1 which induces apoptosis (Dyson,
1998; Phillips et al., 1999); (2) suppression of genes essential for cell survival such as
those encoding Bcl-2, IGF-1R, microtubule-associated protein-4 (MAP4), inosine-5'-
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monophosphate dehydrogenase (IMPD), and presenilin-1 (Prisco et al., 1997; Liu et al.,
1998; Roperch et al., 1998; Sionov & Haupt, 1998); (3) direct interaction with apoptosis-
inducing proteins like helicases XPB and XPD (Wang et al., 1996); (4) p53 was shown to
cause caspase activation in cell free extracts (Ding et al., 1998).
1.2.3.3 The decision between growth arrest or apoptosis
The ability of p53 to promote both growth arrest and apoptosis raises intriguing
questions of what determines the choice between these two options. Factors determining
this choice include the following:
1.2.3.3.1 The cellular context
The cell type may affect the outcome of DNA damage-induced p53 response. T
lymphocytes usually respond to DNA damage by undergoing extensive apoptosis, while
fibroblasts enter cell cycle arrest (Bates & Vousden, 1999). The difference may be due to
the different physiologic functions as well as levels of expression of apoptotic and repair
proteins in each cell (Sionov & Haupt, 1999).
1.2.3.3.2 The efficiency ofDNA repair mechanisms
There is evidence suggesting that so long as DNA repair is not completed p53
remains active, while cells defective in DNA repair mechanisms are more prone to
p53-induced apoptosis. Repair mechanisms that have shown such an effect include
nucleotide excision repair (Dumaz et al., 1997), transcription coupled repair (McKay et al.,
1998), and 06-methylguanine-DNA methyltransferase-mediated repair of DNA adducts
(Maze et al., 1996).
1.2.3.3.3 Oncogenic composition of the cell: the pRb-E2F-1 balance
Activation of p53 in normal cells often results in cell cycle arrest whereas p53
activation in transformed cells generally induces apoptosis (Bates & Vousden, 1999). This
may be due to abrogation of the p53-pRb signalling pathway in the majority of cancers by
a variety of mechanisms. This results in the deregulation of E2F-1 with the consequent
induction of apoptosis (Dyson, 1998; Phillips et al., 1999). Introduction of p21 switches
the p53 response from apoptosis to growth arrest (Waldman et al., 1997), consistent with
the anti-apoptotic function of p21 (Asada et al., 1999).
1.2.3.3.4 Bax-Bcl-2 ratio
As shown in Figure 1.2, activated p53 induces Bax expression and suppresses
Bcl-2 expression. Whereas Bax activates, Bcl-2 prevents the release of Apaf-1 and
cytochrome c from the mitochondria (Susin et al., 1999). Mitochondrial disruption seems
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to be irreversible and prevention of this step appears to be critical in avoiding apoptosis.
Bcl-2 can also prevent apoptosis by blocking nuclear import of p53 in ElA-transformed
cells (Beham et al., 1997).
1.2.3.3.5 Growth and survival factors
These protect cells from the apoptotic responses to DNA damage by promoting
growth arrest (Lin & Benchimol, 1995). This effect may be explained by the cross talk
with the apoptosis signalling involving Bcl-2 family members (Dragovich et al., 1998).
Survival kinases and 14-3-3 proteins cooperate to inactivate Bad, a pro-apoptotic member
of the Bcl-2 family, by BH3 domain phosphorylation (O'Connor et al., 2000).
1.2.3.3.6 The intensity of the DNA damage and p53 expression levels
There are several lines of evidence that extensive DNA damage induces apoptosis
via high expression levels of p53 while mild DNA damage tends to trigger growth arrest
via inducing low levels of p53 expression (Bissonnette et al., 1997; Reinke & Lozano,
1997; Li & Ho, 1998).
1.2.3.3.7 Factors affecting p53 promotor specificity
There is a tight correlation between the induction of distinct sets of p53 target
genes and the ability of cells to arrest in G1 or undergo apoptosis. Data suggest that
different p53 mutations or p53-regulatory proteins can change the ability of p53 to
transactivate different gene promoters thus predisposing to either arrest or death (Wang &
Prives, 1995 ; Barlow et al., 1997; Flaman et al., 1998; Lee et al., 1998).
1.2.3.4. The role ofp53 in DNA replication and repair
It is suggested that p53, through its various biochemical activities and via its ability
to react with components of the repair and replication machinery, actively participates in
various processes of DNA repair and recombination. In particular, the 3'-5' exonuclease
activity of p53 is proposed to play a significant role in various aspects of DNA repair
(Albrechtsen et al., 1999; Janus et al., 1999). p53-mediated up-regulation of genes
involved in DNA repair, such as the two genes GADD45 (Kastan et al., 1992) and p48
xeroderma pigmentosum gene (Hwang et al., 1999), might be envisioned as a first step to
initiate a repair process. More recently, p53 was shown to induce a ribonucleotide
reductase gene, P53R2, that is directly involved in DNA repair, thus supplying stronger
evidence for p53 involvement in DNA repair (Tanaka et al., 2000). There is controversial
evidence suggesting a role for p53 in nucleotide excision repair (NER) (Ford & Hanawalt,
1995; Ford & Hanawalt, 1997). Data showing direct association of p53 with components
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of repair pathways provided clues as to how p53 is involved in DNA repair. Examples of
these proteins are members of the transcription factor IIH (TFIIH) multi-protein complex
that couples transcription with NER (Leveillard et al., 1996), and Cockayne syndrome B
protein (CSB) (Troelstra et al., 1990). p53 shows biochemical activities related to DNA
repair, it directly binds to double-stranded and single-stranded DNA in a non-sequence
specific manner (Steinmeyer & Deppert, 1988), to ends of double strand breaks (Bakalkin
et al., 1995), to Holliday junctions (Lee et al., 1997), and to DNA mismatches (Lee et al.,
1995). In this last respect p53 shows similarity to MSH2. In fact, p53 can bind to the
promoter region of hMSH2 gene thus suggesting a potential regulatory action of mismatch
repair (Scherer et al., 1996).
1.2.3.5 Mutation ofp53 in colorectal cancer
Alterations to, or loss of normal p53 function are associated with the transition
from benign adenoma to malignant colorectal carcinoma. Inactivation of p53 in sporadic
cancer often involves both alleles; allelic deletions occur in more than 75% of carcinomas
(Vogelstein et al., 1988; Cunningham et al., 1992), accompanied by mutations of the
second allele in 86% of cases with a lost allele (Baker et al., 1990). The key selective
advantage of p53 mutations is most probably resistance to apoptosis, as critical apoptotic
stress may arise through relaxation of cell-cell and cell-extracellular matrix adhesion at this
stage of tumour progression as a result of initiation of tumour cell invasion (Ilyas et al.,
1999).
1.2.4. Mismatch repair defects in colorectal cancer
1.2.4.1. HNPCC and microsatellite instability
The human DNA mismatch repair genes were identified largely by their homology
to bacterial or yeast genes and their involvement in HNPCC. The HNPCC syndrome is an
autosomal dominant disease that accounts for up to 5% of all colorectal cancers (Leach et
al., 1993). HNPCC patients may also develop endometrial and ovarian cancer and
sometimes cancers of the stomach, small intestine, hepatobiliary system, kidney and ureter.
HNPCC kindreds are defined classically by the Amsterdam Criteria, which includes onset
of histologically verified colorectal cancer in at least three relatives, one of them a first
degree relative of one of the other two; at least two successive generations affected; and
cancer onset under 50 years of age in at least one of the affected persons (Vasen, 1994).
The syndrome arises as a result of germ-line mutations in one of several DNA mismatch
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repair genes including predominantly hMSH2 and hMLHl and to a lesser extent hPMSl,
hPMS2, hMSH3 and hMSH6 (GTBP). Mutations in hMSH2 account for about half and in
hMLHl for about a quarter to a third of the HNPCC kindreds (Nystromlahti et al., 1994;
Beck et al., 1997).
1.2.4.2. The mismatch repair (MMR) system
The mismatch repair system recognizes and repairs nucleotide mismatches or
heteroduplex loops that arise during DNA replication particularly to repetitive DNA
sequences such as microsatellites. Microsatellites are short tandem repeat (mono-, di-, tri-,
or tetra-nucleotide) sequences distributed throughout the genome, but a clear
understanding of their function is still lacking. In human cells, insertion or deletion loops
at microsatellite sequences can be recognized by hMutSa (a heterodimer of hMSH2 and
hMSH6) or hMutSp (a heterodimer of hMSH2 and hMSH3) (Figure 1.3). Subsequent
recruitment of hMutLa (a heterodimer of hMLHl and hPMS2) to the altered DNA, targets
the DNA region for subsequent excision, resynthesis and ligation (reviewed by Boland,
1996). Tumours with MMR deficiency demonstrate marked instability of repetitive DNA
tracts such as microsatellites, a phenomenon that has been termed microsatellite instability
(MEM) or replication error positive (RER+) phenotype (Aaltonen et al., 1993; Ionov et al.,
1993; Thibodeau et al., 1993). Loss of MMR increases the mutation rate up to 100 fold at
repetitive sequences and RER+ tumours are said to have a 'mutator phenotype' (Parsons et
















1.2.4.3 MMR in sporadic colorectal cancers
In addition to the tumours in HNPCC patients, approximately 10-15% of sporadic
colorectal cancers are found to be RER+ although there is some disagreement as to exact
definition of the RER+ phenotype (Liu et al., 1995; Peltomaki, 1995; Bubb et al., 1996;
Konishi et al., 1996). RER+ cancers occur at an earlier age and stage of presentation than
RER- cancers and are predominantly right-sided. They tend to have either mucinous
histology or poor differentiation, with peri- and intra-tumoral lymphocytic infiltrates, they
may show more global hypermethylation and better prognosis (Jass et al., 1994; Jass et al.,
1998). In addition, in contrast to RER- sporadic colorectal cancers, RER+ cancers are
reported to have a near diploid karyotype (Dutrillaux, 1995; Muleris et al., 1995), and,
probably as a result, show low frequency of allelic loss (Thibodeau et al., 1993).
1.2.4.4. RER+ carcinogenesis
Several lines of evidence suggest that early development of RER+ tumours follow
the usual early carcingenetic steps of mutations in APC and K-ras, and that loss of
mismatch repair function does not give selective advantage in normal epithelium or early
adenomas (reviewed by Ilyas et al., 1999). However, one study suggests that loss of MMR
may have occurred before APC mutation in HNPCC cancers (Huang et al., 1996), but a
study of sporadic cancers did not show similar bias (Homfray et al., 1998). Irrespective of
when exactly the loss of MMR occurs, the phenotypic and genotypic evidence suggests
that tumours with loss of MMR probably develop in the later stages of carcinogenesis
along a genetic pathway different to RER- tumours. Loss of function mutations have been
found in four genes with exonic nucleotide repeat sequences in RER+, but not RER-,
cancers. These include TGF/3RII(Myeroff et al., 1995; Parsons et al., 1995), 1GFIIR
(Souza et al., 1996), Box (Rampino et al., 1997) and the cell cycle regulator E2F4 (Souza
et al., 1997). The frequency of mutations in these genes is variable and their relation to
each other is not completely known although mutations of TGF/1R1I and IGFIIR seem to
be mutually exclusive (Souza et al., 1996).
1.2.5. 18q deletion in colorectal cancers. SMAD genes and the TGFB pathway
1.2.5.1 candidate genes on 18q
More than 70% of colorectal cancers demonstrate deletions involving chromosome
18q (Vogelstein et al., 1988). Loss of this region characterises the progression from early
to late adenoma (Ookawa et al., 1993). Chromosome 18q status has strong prognostic
value in Dukes' stage B cancers, with loss predicting poor survival (Jen et al., 1994a).
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Originally, the key oncosuppressor gene important in 18q deletion was thought to be DCC
(Deleted in Colorectal Cancer) (Vogelstein et al., 1988), a cell adhesion-like molecule.
Later research revealed that this gene encodes a netrin-1 receptor, and is probably involved
in mediating axon guidance (Keino Masu et al., 1996). The relevance of this gene product
to colorectal tumorigenesis is not clear. Other tumour suppressor genes were subsequently
discovered on 18q, one of which was originally dubbed DPC4 (Deleted in Pancreatic
Cancer) (Hahn et al., 1996), but was later identified as one of the components of the TGFp
signalling pathway and is now designated SMAD4. Data about the frequency of SMAD4
mutations in colorectal cancers in the literature vary from 6 to 30% (Moskaluk & Kern,
1996; Thiagalingam et al., 1996). The SMAD2 gene, coding for another component of the
TGFP signalling pathway, is located close to SMAD4 (Eppert et al., 1996) and it was
shown that SMAD2 could be induced by Ras (de Caestecker et al., 1998). Since TGFp
signalling normally results in cell-cycle inhibition and cellular differentiation (Markowitz
et al., 1995), it thus appears that defects in the TGFp pathway, which may occur at
different levels in colorectal cancers due to alterations to SMAD4 or SMAD2 or both, may
play an important role in carcinogenesis (Myeroff et al., 1995; Grady et al., 1998; Grady et
al., 1999). It is worth noting that two further candidate genes are located on chromosome
18q: thymidylate synthase (TS) and Bcl-2. The roles of these will be discussed later.
1.2.5.2 Interactions with other molecules during colorectal carcinogenesis
As mentioned above, c-Myc transactivation was shown to be an important end
result of aberrant Wnt signalling. Furthermore, both activated c-Myc and Ras can
co-operate in cellular transformation in vitro. Upregulation of both molecules is necessary
for the induction of cyclin E-cdk2 activity (Facchini & Penn, 1998). c-Myc drives
progression around the cell cycle by activation of cyclin E-cdk2 complex through the
release of p27Kipl from this complex. Interestingly, the release of p27Kipl from cyclin
E-cdk2 is inhibited by TGFP (reviewed by Arends, 2000). It therefore appears that the
Wnt- and TGFP-signalling pathways converge on the p27Kipl and deregulation of both
might have a synergistic effect on the cell cycle, which might be crucial in colorectal
carcinogenesis (reviewed by Arends, 2000). This is further supported by the finding that
Ras accelerates p27Kipl degradation through activation of the MAP kinase pathway
(Kawada et al., 1997). Increased degradation of p27Kjpl has also been reported in
aggressive colorectal cancers (Loda et al., 1997).
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1.3 Apoptosis deregulation in colorectal cancers
Apoptosis (programmed cell death) is a mode of cell death in which single cells are
deleted showing characteristic morphological changes in the midst of living tissue (Kerr et
al., 1972). Apoptosis plays a critical role in many physiological and pathological
processes. Recent data suggest that loss of particular apoptotic pathways plays a major
role in carcinogenesis through permitting survival of genetically unstable cells. Clear
identification of these pathways in human tumours becomes an important aim, as it would
help define the molecular basis not only of carcinogenesis but also of tumour resistance to
various therapeutic measures.
1.3.1 Morphology of apoptosis
In vivo, an important difference between apoptosis and necrosis is that apoptotic
cells do not release their contents into the extra-cellular milieu and so do not induce an
inflammatory reaction, whereas necrotic cells do. Apoptotic cells first partially destroy
their genetic contents by DNA cleavage before being engulfed by phagocytes. This may
prove important when inducing death of virus-infected cells by activated cytotoxic T
lymphocytes (CTLs). Apoptotic cells rapidly shrink in volume, lose contact with their
neighbours and lose specialised surface elements such as microvilli and cell-cell junctions.
There is extraordinary cell surface convolution and blebbing (zeiosis) followed by
fragmentation of the cell into a series of membrane-bounded, condensed apoptotic bodies
(Arends & Wyllie, 1991). The endoplasmic reticulum dilates and fuses with the cell
surface. In the nucleus, chromatin condenses into dense caps under the nuclear membrane
and is cleaved by the action of endogenous endonucleases into oligo-nucleosomal
fragments that can be demonstrated by the characteristic 'ladder' on agarose gel
electrophoresis of extracted DNA (Wyllie, 1980). The nucleolus dissociates into a shower
of osmiophilic particles with retention of the fibrillar centre. Apoptotic cells are targets for
immediate phagocytosis either by phagocytes or adjacent viable cells (Arends & Wyllie,
1991). These characteristic morphological features of apoptosis persist for only a few
hours in the tissue (Wyllie et al., 1981).
1.3.2 Signalling cascades and mechanisms of apoptosis
The signal transduction cascades leading to apoptosis in a variety of cells seem to
ultimately converge to activate a common apoptotic programme centred on activation of
proteases currently known as 'caspases: cysteine-rich, aspartate-cleaving proteases'
(Alnemri et al., 1996). Proteins and molecules involved in apoptosis could be
schematically classified into signal sensors, transducers, and adaptors/regulator molecules.
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Signal sensors are devoid of catalytic activity but recruit catalytic enzymes (caspases),
which execute the death signal. Members of the NGF-TNF (nerve growth factor-tumour
necrosis factor) receptor super-family like Fas (Apo-1, CD95) are typical examples of
sensors, while the Bcl-2 family are the key regulators of apoptosis. The discussion that
follows concentrates on the role of these particular molecules (Fas and Bcl-2 family) in
colorectal carcinogenesis.
1.3.3 Fas (Apo-1, CD95)/Fas Ligand (FasL) pathway
Fas receptor is a key molecule in the induction of apoptosis (Itoh et al., 1991;
Oehm et al., 1992). It is a trans-membrane receptor belonging to the TNF receptor family
(Smith et al., 1994b). Binding of its ligand (FasL) (Suda & Nagata, 1994; Takahashi et al.,
1994) or cognate antibodies (Alderson et al., 1995; Ju et al., 1995) triggers apoptosis in
many cell types. Active Fas receptor also appears to be necessary for apoptosis initiated
by other stimuli inducing c-Myc protein expression (Hueber et al., 1997) and exposure to
DNA-damaging chemotherapeutic agents (Muller et al., 1997). Fas signal transduction
starts with trimerization of the receptor, induced by FasL binding. This activates a
protein-protein interactive domain (the so called death domain) to bind to an adaptor
protein, FADD/MORT1, which then recruits pro-caspase-8, thus forming the so-called
death-inducing signalling complex (DISC). The DISC then leads to cleavage of
pro-caspase-8 to caspase-8. Therefore, by a non-transcriptional mechanism, Fas triggers
activation of the caspase cascade and hence the terminal effector events of apoptosis
(reviewed by Wallach, 1997; Yuan, 1997). Recent evidence, however, suggests that the
Fas signalling pathway is significantly more complex and involves at least two major
pathways termed type I and type II. In type I cells, caspase-8 is recruited in sufficient
amounts at the level of the DISC to directly activate caspase-3, a central executioner
caspase (Scaffidi et al., 1998), whereas, if caspase-8 in the DISC is present at lower levels,
active caspase-8 then cleaves Bid (Luo et al., 1998), a Bcl-2 family member that causes
release of cytochrome-c (Kluck et al., 1997). On release from mitochondria, cytochrome-c
interacts with APAF-1 and pro-caspase-9 to form a complex known as the apoptosome that
cleaves pro-caspase-9 to caspase-9, which in turn activates caspase-3. This pathway is
termed type II (reviewed by Pinkoski et al., 2000). The existence of these two pathways
helps explain why in some circumstances, Bcl-2 is capable of preventing Fas-mediated
death, such as in type II cells but not type I cells (Scaffidi et al., 1998).
Not all Fas-bearing cells are susceptible to Fas-mediated killing. Expression of
apoptosis inhibitors such as the inhibitor of apoptosis protein (IAP) (Deveraux & Reed,
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1999) and FLICE inhibitory protein (FLIP) (Irmler et al., 1997), as well as , expression of
decoy receptors, DcRl and DcR2 that bind to FasL but do not transmit death signals
(Ashkenazi & Dixit, 1999), or secretion of soluble FasL that binds Fas and similarly does
not transmit death signals (Nagao et al., 1999), are all possible mechanisms of resistance to
Fas-mediated killing. In addition, A variety of tumour cells including colorectal cancer
cells have been shown to express FasL and may thus escape immune surveillance by
inducing apoptotic cell death in tumour infiltrating CTLs (reviewed by Walker et al.,
1998).
Fas protein is constitutively expressed in normal colorectal epithelium and most
colorectal adenomas, but is expressed in only a minority of carcinomas (Moller et al.,
1994). During colorectal malignant transformation, it appears that the constitutive
Fas-positive phenotype can change to an inducible INF-Y/TNF-a-sensitive Fas-positive
phenotype or to stable, clonal deficiency in Fas expression (Moller et al., 1994). The
mechanism responsible for these changes has not been established, however.
1.3.4. Bcl-2 family
The Bcl-2 family of proteins controls an important checkpoint prior to activation of
the caspase family of proteases in apoptosis. Bcl-2 is capable of inhibiting cell death
induced by various stimuli including chemotherapeutic agents. A large number of Bcl-2-
related proteins have been isolated and divided into three categories: (1) anti-apoptotic
members such as Bcl-2, BcI-Xl, Bcl-w, Mcl-1, Al (Bfl-1), and Boo, all of which exert
anti-apoptotic activity and share sequence homology within four Bcl-2 homology (BH)
regions 1-4; (2) pro-apoptotic members such as Bax, Bak, Bad, Mtd (Bok), Diva, which
share BH1-3; and (3) the pro-apoptotic BH3-only proteins Bik, Bid, Bim, Hrk, Blk, Bnip3
and Bnip3L. Bcl-2 family members have the ability to homodimerise or heterodimerise,
thus potentiating or inhibiting their activity (Reviewed by White, 1996; Brown, 1997;
Kroemer, 1997).
There is accumulating evidence that Bcl-2 family members exert their effect mainly
through controlling the apoptotic mitochondrial changes, mainly the release of cytochrome
c and Apaf-1, which trigger caspase activation (Narita et al., 1998; Susin et al., 1999). It
has been suggested that the Bcl-2 family might constitute a convergence point for various
apoptotic regulating signals. As discussed before, Bid is implicated in the Fas mediated
apoptosis and Bax in DNA damage-induced apoptosis.
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In the normal colonic crypt, Bcl-2 expression is restricted to the lower half,
suggesting a role in protecting the proliferating cells against apoptosis (Hockenbery et al.,
1991). Bcl-2 expression is retained in around half of all sporadic colorectal cancers, and
this is associated with poor prognosis (Ofner et al., 1995).
One prominent, widely expressed member of this family is Bax, a 21 KDa protein
with the capacity to homodimerise, to form a potent death inducer, or to heterodimerise
with other members of the Bcl-2 family (Oltvai et al., 1993). Bax is important for tumour
suppression in vivo (Yin et al., 1997), and as mentioned above, p53 can transactivate Bax
(Miyashita & Reed, 1995), whilst down-regulating Bcl-2 (Miyashita et al., 1994).
Recently, clonally expanded, inactivating mutations in Bax have been observed in a
proportion of colorectal cancers, together with evidence for underexpression of the Bax
protein in these tumours (Rampino et al., 1997; Ouyang et al., 1998; Yagi et al., 1998;
Yamamoto et al., 1998).
Bik is a potent death-inducing protein that interacts with the endogenous survival
promoting proteins, Bcl-2 and Bc1-Xl, and their functional viral homologues Epstein Barr
virus-BHRFl and Adenovirus ElB-19kDa. In baby rat kidney cells Bik has been shown to
be sufficient for induction of apoptosis in the presence of mutant p53 and low levels of
Bax, suggesting that it functions independently of both to induce apoptosis (Boyd et al.,
1995; Han et al., 1996). The significance of Bik expression in colorectal carcinogenesis
has not been explored hitherto.
1.3.5 c-mvc
The c-myc gene encodes a transcription factor and exerts diverse overall effects
including induction of apoptosis (Evan et al., 1992) and activation of the cell cycle. As
mentioned above, c-myc expression is an important end result of Wnt signalling. The c-
myc protein also binds to other transcription factors including p53 and pRb. As such, c-
myc is thought to be one of the crucial elements regulating the balance between cellular
proliferation and apoptosis, however, our understanding of the complex functions of c-myc
is still far from complete (reviewed by Arends, 2000).
Elevated levels of c-myc product are not seen in tumours with distant metastases,
or in the metastases themselves, indicating its involvement at an earlier stage of
development. Expression of the oncogene c-myc is frequently increased in sporadic
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colorectal cancer, sometimes due to amplification of the gene, However, it is not correlated
to clinical prognostic parameters (Sikora et al., 1987; Erisman et al., 1988a; Erisman et al.,
1988b).
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1.4. Chromosomal instability in colorectal cancer
Most human cancer cells are aneuploid, and the appearance of aneuploidy in early
stage tumours suggests that the altered DNA content, and its underlying causes, play an
important role in the development and progression of human cancers. Non-random
patterns of acquired chromosome changes have been detected in all tumour types that have
been investigated in any great detail (Mitelman et al., 1997). Hematolymphoid
malignancies demonstrate a recurrent theme of balanced structural aberrations leading to
deregulation of oncogenes or to the creation of hybrid genes (Rabbitts, 1994). In contrast,
available data indicate that the development of solid tumours is more dependent on
combination of deletions and amplifications of multiple chromosome segments (Mertens et
al., 1997). It should be noted that much less cytogenetic information has been gathered for
carcinomas partly due to technical difficulties in obtaining good metaphases for analysis
from neoplastic epithelial cells and partly due to the karyotypic complexity (Mertens et al.,
1997).
1.4.1 Chromosomal changes in primary colorectal cancers
Colorectal cancers display a wide range of chromosomal changes both structural
and numerical. Cytogenetic analysis of short-term cultures from primary tumours and cell
lines (Reichmann et al., 1981; Muleris et al., 1988; Muleris et al., 1990; Yaseen et al.,
1990; Konstantinova et al., 1991; Bardi et al., 1993a; Bardi et al., 1995; Mertens et al.,
1997; Eshleman et al., 1998) and, recently, comparative genomic hybridisation (CGH)
performed on DNA directly extracted from tumour tissue (Ried et al., 1996; DeAngelis et
al., 1999; Georgiades et al., 1999), have identified the most common clonal changes in
colorectal cancers to be loss of chromosomes 17p and 18. Other common chromosome
losses include lp, 4, 5q, 6q, 8p, lOq, 14, 15, 21, 22 and Y. Gain of chromosomes 7, 8q,
and 20 are widely reported followed in incidence by gain of lq, 5p, 9, 12q, 13q, and 16.
Structural abnormalities in the form of deletions, amplifications, insertions, inversions and
translocations are common, although no specific structural abnormality was detected by
classical cytogenetic analysis in colon cancer and balanced rearrangements are reported to
be rare (Bardi et al., 1995; Dutrillaux, 1995). There is a striking progressive increase in
chromosomal number and structural rearrangement in the transition from proximal to distal
large bowel (Reichmann et al., 1982; Muleris et al., 1990; Bardi et al., 1995). There have
been some attempts in the literature to subclassify colorectal cancers according to their
cytogenetic profiles. This is discussed later (see 1.4.6).
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1.4.2 Chromosomal abnormalities in colorectal adenomas
Clonal cytogenetic changes have been recorded in up to 65% of all colorectal
adenomas. Some of these show only numerical changes, most commonly gain of
chromosome 7. Loss of 14 and 18 and to a lesser extent gain of 20 and 13 were also
recorded. Other adenomas show both numerical and structural rearrangements, the most
often involved chromosome is chromosome 1, with loss of lp with a breakpoint at lp32-
36. Loss of 8p, gain of 8q and 13q and loss of 17p are also reported. Adenomas with
structural chromosomal abnormalities are generally larger and had a higher degree of
dysplasia (Bomme et al., 1994; Dutrillaux, 1995; Bomme et al., 1996; Ried et al., 1996).
Loss of genetic information from lp36 is suggested to be an early, seemingly primary,
premalignant event in intestinal tumorigenesis that may occur at induction of the
hyperproliferation stage (Bardi et al., 1993b; Bomme et al., 1998), although this is debated
(Reichmann et al., 1984).
1.4.3. Chromosomal and other genetic lesions and metastasis
Cytogenetic similarities between primary and secondary cancers were found in
almost all cases studied, indicating that many of the chromosomal aberrations presumably
occurred before tumour spread took place. Compared with the primaries, the metastases
appeared to exhibit decreased clonal heterogeneity but, concurrently, an increase in the
karyotypic complexity of individual clones. Among the aberrations recurrently found in
metastatic lesions, in order of frequency, are del(l)(p34), i(17)(ql0), -18, -Y, -21, +7 and
+20, all of which have been seen repeatedly in series of primary colorectal carcinomas, and
del(10)(q22) and add(16)(pl3), which so far have not been associated with primary
tumours and which may play a particular pathogenetic role in the metastatic process (Bardi
et al., 1997). Loss of the p53 and DCC on 17p and 18q appear to be essential to
metastasis. Loss of regions of 13q (including the Rb-1 locus) and 14q occur more
frequently in liver metastases when compared to the corresponding primary tumours.
These changes are also more frequent in late stage primary carcinomas compared to earlier
stages (Ookawa et al., 1993). Loss of heterozygosity of the gene nm-23, located on
chromosome 17q21, supposed to be associated with metastatic progression is not found in
all studies (Ookawa et al., 1993). The gene encoding motility-related protein (MRP/CD9),
implicated in cancer cell motility and metastasis, is highly expressed in primary cancers,
compared with the low levels of expression in metastases (Cajot et al., 1997).
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1.4.4. Common chromosomal losses suggesting tumour suppressor genes in colorectal
cancer
1.4.4.1 lp loss
As mentioned above partial deletion of chromosome lp occurs in up to half of all
colorectal cancers and is associated with poor prognosis. Some studies suggested that it is
a primary change appearing very early at the hyperplastic stage (Bomme et al.,
1996),while other studies found lp loss to be a later event (Reichmann et al., 1984; Leister
et al., 1990). Detailed deletion mapping, using loss of heterozygosity (LOH) studies,
suggests that at least three separate loci may be involved (Praml et al., 1995a; Praml et al.,
1995b), though no tumour suppressor genes have yet been unequivocally identified.
Introduction of lp36 into colon cancer cells suppresses tumorigenicity (Tanaka et al.,
1993), and this region contains a candidate tumour suppressor, p73, which encodes a
protein with homology to p53 that can activate p53 target genes and interact with p53
(Kaghad et al., 1997).
1.4.4.2 8p loss
Loss of material on chromosome 8p also occurs in about half of all sporadic
colorectal carcinomas (Cunningham et al., 1993) and may be associated with the change
from adenoma to carcinoma (Cunningham & Dunlop, 1994; Cunningham et al., 1994).
There is strong evidence to suggest that this region of the genome harbours at least two
colorectal tumour suppressor genes (Cunningham et al., 1993), though no such gene has
yet been convincingly identified. A recently identified candidate gene is KILLER/DR5, a
tumour necrosis factor (TNF)-receptor related protein which may be involved in p53-
dependent apoptosis (see above). Partial gene screening of the remaining allele in
colorectal cancers has not yet identified mutations (Wu et al., 1997).
1.4.4.3 5q loss and MCC
Loss of heterozygosity studies which led to the eventual identification of the
tumour suppressor gene APC, initially suggested another candidate gene, MCC (mutated in
colorectal cancer), located within lOOkb of APC, as being frequently lost in colorectal
cancer as part of the 5q deletion event (Solomon et al., 1987; Vogelstein et al., 1988). The
gene product of MCC shows sequence homology to a murine G protein receptor important
in signal transduction. Mutations in the gene were detected in several sporadic cancers,
leading to speculation that it may play an important role in colorectal cancer development
(Kinzler et al., 1991a; Kinzler et al., 1991b). However, no further mutations have been
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reported and MCC seems to have no role in colorectal carcinogenesis (Curtis et al., 1994;
Cripps et al., 1995).
1.4.5 Gene amplification
In mammalian cells, the ability to amplify genes is restricted to genetically unstable
transformed or tumorigenic cells (Otto et al., 1989; Tlsty, 1990) and is a recessive trait
(Tlsty et al., 1992). Cytologically, amplified sequences may be present
intra-chromosomally, as homogenously-staining regions (HSRs) or extra-chromosomally,
in the form of double minutes (DMs) (Tlsty & Adams, 1990). Both DMs and HSRs are
rare in primary bowel cancers, although presence of DMs has been demonstrated in vitro in
one study (Bruderlein et al., 1990) and metastases of colorectal cancers have been reported
to contain DMs (Reichmann et al., 1981).
In mammalian cells, sequences that contain amplified genes are not simple repeats
and often appear at new chromosomal locations, suggesting that their generation involves
several steps (Stark et al., 1989; Stark, 1993). Several models for gene amplification have
been proposed. The unequal exchange model and the re-replication model (Stark & Wahl,
1984)—with multiple initiations of replication—have not been observed in mammalian
cells (Windle & Wahl, 1992). A third model suggested that DNA breakage can induce the
breakage-fusion-bridge cycle, leading to chromosomal instability and gene amplification
(Stark, 1993). Hypoxia, which occurs when tumours outgrow their vascular supply, has
been demonstrated to facilitate gene amplification (Rice et al., 1986), and this has been
postulated to be due to the induction of endonuclease activity, which may create fragile
sites and potentiate break-related genomic instability (Stoler et al., 1992; Coquelle et al.,
1997; Coquelle et al., 1998).
1.4.6 Cytogenetic classifications of colorectal cancers
1.4.6.1 Dutrillaux's model
This model suggests two distinct types of abnormal karyotype, possibly indicating
the presence of separate underlying mechanisms of tumour development (Reichmann et
al., 1982; Muleris et al., 1988). These groups have been termed 'Monosomic type' (MT)
and 'Trisomic type' (TT) (Muleris et al., 1990; Dutrillaux, 1995). Based on data from
cytogenetic analysis of short term-cultured colorectal cancers, MT was reported to be
found in 70% of colorectal cancers, and is characterised by loss of chromosome 18 and
17p together with progressive structural changes with loss of chromosomal fragments thus
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creating a hypo-diploid karyotype. Endoreduplications are then suggested to occur leading
to the formation of a hypo-tetraploid clone, which is seen mixed with the hypodiploid one
in 40% of MT tumours, as shown by the presence of many duplicated markers. Structural
changes continue, reducing the chromosome number and creating a pseudo-triploid
pattern, however, there are still many duplicated markers. Examples of MT were
identified in breast cancers (including some in which endoreduplicative event was
apparent) and similar patterns were identified in colorectal cancers, particularly in the
distal colon and rectum. Later studies linked this group to the RER- cancers (Remvikos et
al., 1995) and a high frequency of abnormal p53 function (Remvikos et al., 1997).
In contrast, the TT was found in 20-25% of colorectal cancers, and shows few
structural rearrangements and whole chromosome losses, but rather tends to gain
chromosomes (+7, +13, +20, +12, +X). Polyploid clones are exceptional indicating that
endoreduplication is a rare event. TT tumours occur commonly in the rectum (Lasserre et
al., 1994). Additionally, a small proportion (around 7%) of cancers have apparently
normal karyotypes (termed NT), and are associated with significantly lower age of
diagnosis than those with abnormal karyotypes, proximal location in the bowel,
microsatellite instability and improved patient survival (Remvikos et al., 1995).
The mechanisms driving each type of karyotypic evolution are not understood, but
may reflect differences in local environment such as carcinogen content throughout the
colon, or, since endoreduplication can occur as a consequence of hypoxic conditions,
degree of angiogenesis (Loffler, 1987). Alternatively, fundamental molecular changes
associated with each karyotypic group may drive the acquisition of different chromosomal
abnormalities.
1.4.6.2 Chromosomal instability (CIN) versus microsatellite instability
RER- tumours demonstrate a high degree of karyotypic instability affecting both
chromosome number and structure. In contrast, RER+ tumours demonstrate a marked
degree of chromosomal stability with a near diploid karyotype and few structural changes
(Eshleman et al., 1998). Further studies by Lengauer et al. (1997) discovered a striking
defect in chromosome segregation in RER- cells resulting in chromosome gains or losses
in excess of 10" per chromosome per generation (equivalent to a gain or loss every 5 cell
generations), as a dominant trait (Lengauer et al., 1997). This form of chromosomal
instability (CIN) is sufficient to drive carcinogenesis in RER- colorectal cancers (Lengauer
et al., 1997). CIN is shown to be consistently associated with the loss of function of a
mitotic checkpoint, and in two cell lines CIN was associated with mutations of the mitotic
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checkpoint gene hBUBl which is responsible for normal mitotic delay upon spindle
disruption (Cahill et al., 1998). The cellular conditions that favour or permit CIN are not
yet fully understood, and it does not appear to correlate absolutely with p53 status
(Lengauer et al., 1997; Eshleman et al., 1998).
1.4.7 Mechanisms underlying chromosomal changes in cancers
1.4.7.1.The mitotic machinery as a source of numerical chromosomal instability
In human cells, an elaborate macromolecular machine, the mitotic spindle,
accomplishes faithful segregation of chromosomes during cell devision. The events of
spindle assembly and function in most human cells include depolymerization of interphase
microtubules, centrosome-mediated nucleation of new microtubules, centrosome
separation, chromosome condensation, nuclear envelope breakdown, chromosome
congression, chromosome cohesion and movement, and finally, cytokinesis. It is not
difficult to envision how defects in components of this complex machinery, such as the
molecules that control its organization and function, and the regulators that temporally
couple spindle operation to other cell cycle events, could lead to chromosome
mis-segregation (reviewed by Pihan & Doxsey, 1999). The following discussion will
concentrate on some of these components that might contribute to the generation of
aneuploidy in tumours.
1.4.7.1.1 Centrosomes
Recent studies indicate that centrosome defects may contribute to spindle
abnormalities, aneuploidy and tumour development and progression (Doxsey, 1998).
Using antibodies to pericentrin and y-tubulin, it has been shown that the vast majority of
malignant tumours including colorectal carcinomas exhibit abnormal centrosomes (Pihan
et al., 1998). Centrosome abnormalities included: supernumerary centrosomes,
a-centriolar centrosomes, and centrosomes of aberrant size and shape (Uren et al~ 1996).
All abnormal centrosomes were able to participate in the formation of structurally and
functionally aberrant mitotic spindles. Cells with abnormal centrosomes mis-segregated
chromosomes at a high rate producing aneuploid cells with dramatically different
chromosome numbers (i.e. CIN) (Uren et al., 1996). Malfunction of three cellular
processes—centrosome assembly, centrosome duplication and cytokinesis—either singly
or in combination, could produce an abnormal centrosome phenotype (Pihan et al., 1998;
Pihan & Doxsey, 1999). Centrosome-associated regulatory molecules implicated in
centrosome malfunction include the human homologue of Polo (Plk), the human
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homologue of Drosophila aurora (aurora2/Stkl5), NEK2 (Doxsey, 1998), and
cdk2-cyclin E complex (Hinchcliffe et al., 1999). Supernumerary centrosomes are
observed in p53_/" cells (Fukasawa et al., 1996) suggesting a role for p53 in regulating
centrosome duplication, but, centrosome abnormalities can also occur in cells with
wild-type p53 (reviewed by Pihan & Doxsey, 1999).
1.4.7.1.2 Chromosomes
Cellular structures and processes that remodel chromosomes and facilitate
chromosome movement could have profound effects on the fidelity of chromosome
partitioning during mitosis. These include kinetochore structure and function and
chromosome condensation and cohesion. Centromere DNA lacking kinetochore proteins
have been observed in tumour cells (Vig & Rattner, 1989; Vig & Sternes, 1991). Defects
in chromosome condensation may induce chromosome mis-segregation (reviewed by
Pihan & Doxsey, 1999). Inhibitors of topoisomerase II can induce both numerical and
structural chromosomal abnormalities by interfering with chromosome
condensation/decatenation (Cimini et al., 1997).
1.4.7.1.3 Cytokinesis
Failure of cytokinesis—the physical division of one cell into two daughter cells—
has been observed in tumours: in cells with abrogated p53 and/or p21, cells escape G2
arrest, enter mitosis, segregate chromosomes but fail to undergo cytokinesis leading to a
doubling of the DNA complement (Bunz et al., 1998). Recent data showed that p21
restored cyclin E/Cdk2 regulation and prevented endoreduplication induced by defects in
microtubule dynamics (Stewart et al., 1999). Cytokinesis failure has also been implicated
in polyploidization (Shackney et al., 1989). However, cytokinesis failure on its own—in
the absence of other cell cycle or spindle anomalies—would be expected to produce cells
with two diploid nuclei (not a single tetraploid nucleus). Cytokinesis can be affected
through its regulatory components. In S. cerevisiae CUT (cell ultimately torn) mutants
undergo premature cleavage and cut DNA randomly at any time during the cell cycle
giving rise to both structural and numerical chromosomal changes (Yanagida, 1998).
Mutations in other genes regulating cytokinesis can produce polyploid cells. However,
these molecules have not yet been linked to tumorigenesis and thus represent an important
area for future investigation (Field et al., 1999).
1.4.7.1.4 Regulatory molecules and mitotic check points
Entry into and exit from mitosis are controlled by multiple cell cycle regulatory
pathways including the p34cdc2/cyclin B kinase. A human fusion protein from Ewing's
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sarcoma (EWS/FLI1) up-regulates a ubiquitin-conjugating enzyme involved in cyclin B
destruction (Arvand et al., 1998). Moreover, the human CDC23, a component of the
anaphase-promoting complex, is a candidate tumour suppressor gene on chromosome
5q31, an area commonly deleted in haematological malignancies (Zhao et al., 1998). The
role of mitotic check point hBUBl gene has been discussed previously. More recently,
another mitotic checkpoint gene termed Chfr was shown to delay entry into metaphase in
response to mitotic stress such as that induced by microtubule depolymerizing agent
nocodazole (Scolnick & Halazonetis, 2000). Chfr was found to be inactive in 50% of
tumour cell lines examined owing to either lack of expression or by mutations (Scolnick &
Halazonetis, 2000). At least in yeast, the BIM1/EB1 gene participates in a checkpoint that
delays the exit from mitosis in response to an abnormally orientated spindle (Muhua et al.,
1998).
1.4.7.1.5 Apoptosis in mitosis
Recent studies indicate that there is a default apoptotic pathway in mitosis that
needs to be overcome for the successful completion of mitosis. This pathway appears to
involve survivin, an inhibitor of apoptosis (IAP) protein expressed in G2/M and associated
with microtubules (Li et al., 1998). Recent data showed that interference with the
expression or function of survivin causes caspase-dependent cell death in the G2/M phase
of the cell cycle, and a cell-division defect characterized by centrosome dysregulation,
multipolar mitotic spindles and multinucleated, polyploid cells (Li et al., 1999). Survivin
disruption also results in caspase-dependent cleavage of p21, suggesting that control of
apoptosis and preservation of p21 integrity within centrosomes by survivin are required for
normal mitotic progression. Other data suggest roles for survivin in controlling the later
stages of cytokinesis (Chen et al., 2000), and also in resistance to Fas-mediated cell death
(Suzuki et al., 2000). Survivin is over-expressed in many cancers and may constitute an
important mechanism whereby cancer cells progress through aberrant mitosis and fail to
undergo apoptosis (Altieri & Marchisio, 1999; Tamm et al., 2000).
High doses of anti-microtubule agents induce p53-independent apoptosis during
mitosis (Sorger et al., 1997), which is reduced after expression of mutant BUB1 (Taylor &
McKeon, 1997). Bcl-2 appears to be involved in this pathway as disruption of
microtubules leads to Bcl-2 phosphorylation and inactivation initiating apoptosis (Haldar
et al., 1997). Recent data show that Fas promotes cell cycle progression via a link to the
MEK1-ERK (mitogen-activated protein kinase-ERK kinase 1/extracellular signal-regulated
Einase) pathway, but the implication of this Fas mediated cell cycle progression is not clear
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(Shinohara et al., 2000). These data suggest that apoptosis during mitosis is a safeguard
mechanism much like those enacted in other phases of the cell cycle.
1.4.7.2 Mechanisms underlying structural chromosome rearrangements
1.4.7.2.1 DNA Double strand breaks (DSBs)
DSBs are generated by endogenously produced radicals as well as exogenous
agents such as ionizing radiation (IR), which is often used in anti-cancer therapy. Repair
of DSBs is of cardinal importance to prevent structural chromosomal rearrangements. The
deleterious effects of DSBs have triggered the evolution of multiple pathways for their
repair. Homologous recombination (HR) repair is an error-free pathway that requires
extensive regions of DNA homology. On the other hand, DNA non-homologous end
joining (NHEJ) uses extremely limited sequence homology to rejoin the juxtaposed DNA
ends. The outcomes of HR depends on the template used for repair: if it occurs between
equivalently positioned sister chromatids, it restores the original sequence, while
recombination between sequences other than equivalently-positioned sister chromatids
results in genome rearrangements including deletions, expansions and translocations, as
well as loss of heterozygosity (LOH) with subsequent expression of recessive alleles.
NHEJ often results in deletions or small insertions (reviewed by Kanaar & Hoeijmakers,
1997; Kanaar et al., 1998; Dasika et al., 1999; Jasin, 2000). Figure 1.4 illustrates both HR
and NHEJ and molecules involved in both pathways. Some components of the DSB-repair
pathways have been shown to play a role in suppressing chromosomal aberrations and
malignant transformation. Recent data show that two DSBs, each on different
chromosome, are sufficient to induce frequent recombinations resulting in balanced
translocations and genome instability in mouse ES cells (Ricardson & Jasin, 2000).
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Figure 1.4
DNA double strand break repair
In recombinational repair, a DSB is initially processed by Rad50/Mrel 1/NBS1
nuclease complex yielding a 3' single strand overhangs. Rad52 protects DNA ends and
also facilitates the formation of heteroduplex DNA which requires Rad51 and its associate
proteins. Intact DNA with sequence homology (blue) is used as template to replace the
lost genetic information at the DSB ends. Following the nucleolytic process, Holliday
junction formation, branch migration, extension, nuclease resolution of the junction, and
then ligation of the DNA complete the recombinational repair.
In Non Homologous end-joining, the Ku heterodimer binds to the DNA ends and
recruits DNA-PKcs. The Rad50/Mrell/NBS1 complexes has enzymatic and/or structural
roles on the DNA. Xrcc/LiglV joins the DNA ends. In mammalian cells, loss or addition
of nucleotides are frequently seen at the broken ends, however, the factors and mechanisms
underlying this last step are not yet identified.
The figure and information included are based on: Kanaar & Hoeijmakers, 1997;
















1.4.7.2.2 Chromosomal breakage syndromes and chromosomal fragile sites
Chromosome fragility is a hallmark of two human diseases, ataxia telangiectasia
and Nijmegen breakage syndrome. The protein products, ATM and Nibrin, of the genes
mutated in these diseases, ATM and NBS1 respectively, play an important role in DNA
repair and cell cycle arrest in response to genomic insult. DSBs induce activation of ATM
resulting in Gl/S arrest through the p53/p21 mechanism, as well as G2/M arrest through
the Chk2/Cdc25 pathway. Both ATM and Nibrin are also involved in S-phase arrest in
response to DNA damage, however the identities of the downstream effectors in this
pathway are not yet identified (Carney et al., 1998; Carney, 1999).
Chromosomal fragile sites are loci that are especially prone to forming gaps or
breaks on metaphase chromosomes when cells are cultured under conditions that inhibit
DNA replication or repair. They have been shown to display a number of characteristics
of unstable and highly recombinogenic DNA in vitro, including chromosome
rearrangements, sister chromatid exchanges and, more recently, intra-chromosomal gene
amplification. The most frequently observed common fragile sites are FRA3B at 3pl4.2,
FRA16D at 16q23, FRA6E at 6q26, FRA7H at 7q32, FRAXB at Xp22 (reviewed by Hecht
et al., 1988; Vernole et al., 1988; Sutherland et al., 1998). Apart from FRA3B at 3pl4.2,
which is frequently deleted in several solid tumours (Glover, 1998), no significant
association is found between the common fragile sites and cancer breakpoints. These data,
along with other chromosome mapping evidence that rare fragile sites are not at the
breakpoints in some cancer chromosome rearrangements, cast serious doubt on any role for
fragile sites in oncogenesis (Sutherland & Simmers, 1988). However, recent reports by
Coquelle et al (1998) showed that hypoxia-induced fragile sites are associated with gene
amplifications in tumour cells (Coquelle et al., 1997; Coquelle et al., 1998).
1.4.7.2.3 Telomeric sequences
There is evidence suggesting that telomeres - tracts of hexanucleotide repeats at
chromosomal ends that protect against degradation, rearrangement, and chromosomal
fusion events - as well as intra-chromosomal telomere-like sequences (Day et al., 1998)
are hotspots for recombination, breakage and chromosome fusion (telomeric association)
events that may initiate chromosomal instability (Morgan et al., 1998). In germ cells,
telomere length is maintained by the enzyme telomerase, but in almost all other somatic
tissues, the gene encoding this enzyme is not expressed, resulting in progressive reduction
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in telomere length with age (Hastie et al., 1990). Telomere length is substantially reduced
by about the same extent in both colorectal adenomas and colorectal carcinomas when
compared to normal colonic and blood tissue (Hastie et al., 1990; Bouffler et al., 1996;
Slijepcevic & Bryant, 1998; Sprung et al., 1999; Urquidi et al., 2000). However,
maintenance of telomere length to some degree could be a critical event in the progression
to colorectal malignancy, allowing cells to avoid the acquisition of a senescence signal
associated with substantially shortened telomeres. Expression of telomerase, though not
present in early colorectal adenomas, is detectable in colorectal carcinomas (Chadeneau et
al., 1995). Recent data from telomerase deficient, p53-heterozygous mice suggest that
telomerase deficiency in a p53 deficient background favours the development of epithelial
tumours, including large intestinal ones, that show evidence of chromosomal instability in
the form of frequent non-balanced translocations (Artandi 'et al., 2000; Hanahan, 2000).
1.4.7.2.4 DNA Methylation
DNA is methylated by a covalent modification of cytosine residues by DNA
methyl transferase. Strand breaks are associated with hypomethylation, probably because
a reduction in methylation affects chromatin structure, and protein binding ability allowing
increased access of changed regions to DNA damaging agents such as nucleases (Lewis &
Bird, 1991). Loss of chromosome condensation in this way may also lead to chromosome
non-disjunction (Schmid et al., 1984). Hypomethylation, thus may facilitate both
structural and numerical chromosomal changes, however, there is not enough data to
support this proposal in human carcinogenesis.
Extensive hypomethylation is evident within the genomes of colonic neoplasms,
occurring even in very small benign adenomas (Feinberg & Vogelstein, 1987).
Hypomethylation does not appear to be a feature of hyperplasic epithelium, and is
therefore thought to be an early event in tumour development, preceding malignancy. In
colorectal cancer, reduction in methylation occurs selectively, with some genes -
consistently hypomethylated and others variable. Thus, whilst hypomethylation would
allow increased expression of proto-oncogenes, specific areas of hypermethylation can
occur and expression of tumour suppressors could be reduced in this way (reviewed by
Feinberg & Vogelstein, 1983; Robertson & Jones, 2000). Transcriptional repression
through hypermethylation of the promotor region is indeed a common mechanism of down
regulating mismatch repair genes—in particular hMLHl—in colon cancers (Herman et al.,
1998; Wheeler et al., 1999).
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1.5 Summary
This chapter has discussed current knowledge of the development and progression
of colorectal cancers. These tumours develop through a complex series of interactions
between environmental and genetic factors. Several lines of evidence suggest that sporadic
colorectal cancers evolve along different pathways according to the type of underlying
genomic instability they possess. Two distinct pathways of genetic evolution of these
tumours have been described and both appear to share early steps of APC mutation or loss
and K-ras deregulation. RER+ tumours are characterized by microsatellite instability
which targets a group of genes with intra-exonic nucleotide repeats, one of which, Bax,
codes for a pro-apoptotic gene. RER+ tumours are also characterized by marked
karyotypic stability possibly related to the low frequency of p53 abnormalities in these
tumours. The RER- group, on the other hand, show a marked degree of structural and
numerical chromosomal instability (CIN) the basis of which is not fully understood.
Previous studies have linked the chromosomal instability to abnormal p53 function, which
is frequently observed in RER- tumours but this correlation is far from consistent. The
nature and extent of karyotypic abnormalities in colorectal cancers has not been described
in detail yet, possibly because of the marked complexity observed. Apoptosis pathways
appear to be linked to these pathways generating different types of genomic instability.
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1.6. Aims of this study
The aims of this project were to characterize more precisely: (1) the patterns of
genomic instability associated with sporadic colorectal cancers; (2) the mechanisms
underlying deregulation of key apoptotic pathways; and (3) the impact of different tumour
genotypes on treatment responsiveness in colorectal cancer cells.
(1) Genomic instability was studied in RER+ and RER- colorectal cancer cell lines,
with or without mutant p53, using Spectral Karyotyping (SKY), a recently developed FISH
based technique that has the power to identify complex chromosomal rearrangements, in
order to determine the patterns of numerical and structural chromosomal changes
associated with RER and p53 status.
(2) Deregulation of key apoptotic pathways was studied by analysis of three
apoptosis genes (Fas, Bik and Box) and one growth control gene (TGF/3RII) for mutations
in both RER+ and RER- tumours in order to establish the frequency and significance of
such genetic changes as causes of deregulation of apoptosis in colorectal cancers.
(3) Colorectal cancer cell lines with either mismatch repair or p53 abnormalities
were studied for their responsiveness to treatment in terms of clonogenic survival and
induction of apoptosis after anti-cancer cytotoxic therapy such as 5-FU, IR and the
methylating agent temozolomide. Similarly, xenografts of uncultured primary tumours
with different combinations of p53 and RER abnormalities were studied in vivo for their
responsiveness in terms of induction of apoptosis by cytotoxic therapies in order to






2.1.1. Source and origin
All cell lines used in this study were supplied by Sir Walter F. Bodmer (Cancer and
Immunogenetics Laboratory, Oxford, United Kingdom). These were obtained originally
from public sources, kind gifts or from tumours cultured at ICRF laboratories, UK. C70
was established locally at the Cancer and Immunogenetics Laboratory, Oxford, UK.
Available information on the origin, clinical history, and molecular genetic analysis of
these lines are assembled in Table 3.1.
2.1.2. General maintenance of the cell lines
The colorectal cell lines were cultured in Glasgow Minimal Essential Medium
(GMEM) with L-Glutamine, 10 - 15% (v/v) Foetal Calf Serum, and 1% (v/v)
Penicillin-Streptomycin (stock solution contains 5000 U Penicillin and 5000 ug
Streptomycin per 1 ml, GibcoBRL, UK). All cells were grown at 37°C in a humidified
atmosphere of 5% C02. The VACO cell lines were cultured in Iscove's Modified
Dulbecco's Medium* (GibcoBRL, UK). Cell lines were split no more than 1:4 at passage.
When confluent they were rinsed briefly with buffered EDTA saline (Versene, GibcoBRL,
UK) before being incubated for approximately 5 minutes at 37°C with Trypsin (0.5 mg ml"
'in buffered EDTA saline). The enzyme was inactivated by adding fresh growth medium
with serum and the cells were pelleted, re-suspended in growth medium and seeded into
tissue culture flasks, to the required density.
For frozen stocks, pellets of cells were re-suspended in freezing mix (10% v/v
DMSO, 90% cell culture medium), and placed in Nunc cryotubes. After slow freezing in a
-70°C freezer at least overnight, cells were transferred to liquid nitrogen for long-term
storage. To restart from frozen samples of cells, the cells were thawed rapidly in a 37°C
water bath, diluted in 10 ml pre-warmed growth medium (added slowly, drop by drop),
then pelleted and re-suspended in fresh medium before being seeded into tissue culture
flasks.
*
Contains 9 more amino acids in addition to the GMEM components as specified in the GibcoBRL
catalogue.
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2.2 Fluorescence in situ hybridization (FISH) techniques
2.2.1 Preparation of cell suspensions for making metaphase spreads
Cell lines were passaged into two 25 cm" flasks and cultured for 18-24 hours. One
of the flasks was incubated in Colcemid (0.05 pg ml"1) for 1-2 hours. Due to the observed
chromosomal shrinkage and distortion after adding Colcemid to some lines like C70, the
other flask was used for metaphase spread preparation directly, without Colcemid, and the
better metaphase spreads were used for hybridisation. Cultures were harvested by
trypsinization as usual but all the supernatants were added to the cells, transferred into 10
ml centrifuge tubes and spun at 500 x g for 5 minutes to pellet cells. The supernatant was
removed and the pellet re-suspended in 10 ml pre-warmed (37°C) 0.075M KC1 hypotonic
solution and incubated in a 37°C water bath for 10 minutes. 0.5 ml fixative solution (3
parts methanol: 1 part glacial acetic acid) was added and the tubes were spun again at the
same speed, the supernatant removed and the pellet tapped to loosen it. Cells were fixed
dropwise with gentle vortexing to a final volume of 10 ml with fresh ice-cold fixative
solution and ice-cooled for 1 hour. Tubes were spun again at the same speed, the fixative
solution was replaced by fresh fixative solution and ice-cooled for 10 min. Fixing and
spinning was repeated once again to obtain a white pellet, cells were resuspended in 1 ml
of fixative solution and stored at -30°C for up to one year.
2.2.2 Preparation of metaphase spreads for FISH analysis
2.2.2.1 Metaphase spread preparation by dropping
Pre-washed microscope slides were soaked in 100% ethanol at least overnight.
Stored cell suspensions (prepared in 2.2.1 above) were spun at 500 x g for 5 minutes to
pellet cells, the supernatant discarded and the cell pellet re-suspended in a few drops of
fixative solution to form a milky cell suspension. Slides were polished with a soft lint-free
cloth just before use and one drop of fixed milky cell suspension was dropped directly on
to the slide to make metaphase spreads. The position of the drop on the slide was marked
with a diamond pencil. Metaphase spread quality was checked on a phase contrast
microscope at x400 magnification. If necessary, spreading of chromosomes was facilitated
by re-dropping the cell suspension and adding a drop of adjusted fixative solution (1 part
methanol: 1 part glacial acetic acid) just before drying of the metaphase spread. If
necessary slides were pepsin-treated for 3-10 min with a pepsin solution (10 pi of 10%
pepsin in 50 ml 0.01 M HC1) at 37°C. Slides were washed rapidly in DDW (de-ionised
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distilled water) and then in lx SSC four times for 2 min each. Slides were soaked in
2xSSC pH 7.0 for 30 min at 37°C. Slides were dehydrated by incubation in ascending
grades of ethanol (70%, 90% and 100%) and air-dried.
20xSSC: 88.2 g sodium citrate, 175.3gm NaCl, pH adjusted to 7.0 using HC1 (and
different concentrations were prepared from this stock).
2.2.2.2 Metaphase spread denaturation
Slides were then placed into denaturing solution (see below) at 68°C in a fume
cabinet for 90 seconds, using a thermometer to keep a constant check on the formamide
temperature. This was always carried out in Coplin jars, adding no more than 2 slides at a
time to each jar. Slides were then plunged immediately into ice-cold 70% ethanol and left
for 5 minutes before dehydrating through the ethanol series as before, air dried, and then
kept at 37°C ready for hybridization. The required probe solution was placed onto the
middle of the chromosome spread and the coverslip was placed and sealed with rubber
solution, care was taken during this last step not to create air bubbles. Slides were placed
in a humidified chamber at 37°C for the required time.
Deionised formamide: 500 ml formamide added to 25g ion-exchange resin beads, stirred
for 45 minutes, then filtered through a paper filter. Stored at -20°C. Denaturing solution:
35 ml deionised formamide, 5 ml 20xSSC, 10 ml water, pH adjusted to 7.0 using HC1.
2.2.3 Spectral Karyotyping (SKY)
2.2.3.1 The SKYprobe
The SKYim probe kit (Applied Spectral Imaging, Migdal Ha'Emek, Israel) was
used for the 24-colour FISH, according to the manufacturer's instructions. The
chromosomes in this probe set were labelled with combinations of up to five
fluorochromes or haptens, (Table 2.1a&lb). The fluorochromes used in the SKYIM kit are
Rhodamine-dUTP, Texas Red-dUTP, Biotin-dUTP (detected with Avidin-Cy5),
FITC-dUTP, and Digoxygenin-dUTP (detected with anti-digoxygenin-Cy5.5). A unique
florescent emission spectrum for each chromosome is obtained by the labelling of each
chromosome with a different combination of these fluorochromes/haptens (Table 2.1 a &
b). This process involves up to 4 DOP-PCR reactions for each chromosome, one reaction
for each fluorochrome or hapten incorporated. Once all of the component DOP-PCR
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reactions for each chromosome are completed, all of the reaction products are pooled in the
to produce the SKY™ probe kit. For example, in the SKY™ kit the spectrum for
chromosome 1 is made up of Texas Red, Biotin-Cy5 and FITC, therefore three separate
DOP-PCR reactions are performed labelling chromosome 1 specific DNA with each of
these fluorochromes/haptens. The products from these reactions are then combined, along
with those for all of the other chromosomes, into the final probe mixture. The DOP-PCR
reactions were performed by Applied Spectral Imaging (Migdal Ha'Emek, Israel) on flow
cytometric-sorted human chromosomes and the probe was supplied commercially with
other components of the SKY™ kit ready for use.
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Table 2.1a: Chromosome labelling scheme for the SKY™ kit
Chromosome Probes3 Chromosome Probes3 Chromosome Probes3
1 BCD 9 ADE 17 C
2 E 10 CE 18 ABD
3 ACDE 11 ACD 19 AC
4 CD 12 BE 20 A
5 ABDE 13 AD 21 DE
6 BCDE 14 B 22 ABCE
7 BC 15 ABC X AE
8 D 16 BD Y CDE
J The fluorescent probes are denoted as follows: A, Rodamine-dUTP; B, Texas Red-dUTP; C, Biotin-dUTP
(detected with Avidin-Cy5); D, FITC-dUTP; E, Digoxygenin-dUTP (detected with anti-digoxygenin-Cy5.5).
Table 2.1b: Characteristics of the flurochromes
Rodamine Texas Red Cy5 FITC Cy5.5 DAPI
Excitation X (nm) 550 596 650 495 675 355
Emission X (nm 570 620 670 525 694 450
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2.2.3.2 SKYprobe Hybridization technique
24-colour chromosome painting was performed by the 'Spectral Karyotyping'
(SKY) technique, essentially as described (Schrock et ai, 1996) and as detailed in the
SKY™ product instruction manual. Contents of the SKY paint mixture (vial no.l) were
vortexed briefly and 10 |al were taken for each slide and denatured by incubation at 75°C
for 8 min then the vial was incubated at 37°C at least for 60 min. 10 u-1 of SKY probe
mixture were added to the denatured chromosome preparation on the slide (as described
above in 2.2.2.2) and 18x18 mm2 glass coverslip was placed over the probe mix and the
edges were sealed with rubber cement, care was taken during this last step not to create air
bubbles. Slides were place in a humidified chamber at 37°C for 2.5-3 days. Slides were
removed from the humidified chamber and the rubber was carefully removed and slides
were transferred to Coplin jar containing washing solution! (50% formamide in 2xSSC),
slides were washed 3 times at 45°C for 5 min each wash in a water bath, then three washes
in washing solution II (lxSSC) at 42°C for 5 min each, then slides were washed in washing
solution III (4xSSC/ 0.1% Tween 20) at 42°C for 5 min. Slides were tilted to allow fluid
to drain and then 80 p.1 of buffer 1 (vial no. 3) were applied to the slide, covered by plastic
coverslip and incubated at 37°C for 45 min. Slides were washed 3 times in washing
solution 3 at 42°C for 5 min each wash in a water bath. 80 p.1 of buffer 2 (vial no 4) were
applied to the slide and this was covered by plastic coverslip and incubated at 37°C for 45
min and then slides were washed 3 times in washing solution 3 at 42°C for 5 min each
wash in a water bath, air dried and then 20 pi of the DAPI (4,6-diamino-2-
phenylindole)/antifade solution (vial no. 5) were applied, coverslips were placed on top
and slides kept in the dark ready to be examined.
2.2.3.2 SKY Image analysis
Metaphase spreads hybridized with the SKY probe were assessed by fluorescence
microscopy and images were captured and analysed using a Spectracube SD200 mounted
on a Nikon E800 microscope and SKY software (Applied Spectral Imaging, Migdal
Ha'Emek, Israel). In this system, the 5 fluorochromes were excited simultaneously by a
triple band-pass filter (SKY-1; Chroma Technologies, Brattleboro, VT) and the spectra of
the emitted light were obtained, pixel-by-pixel, with an interferometer and cooled CCD
camera. The resulting spectra were matched to reference spectra to determine, pixel by
pixel, the identity of each chromosome or fragment of chromosome present. Data were
presented as two false-colour images of the chromosomes: the first was a simulation of the
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fluorescent colours observed, translated into the range of wavelengths visible to the human
eye (spectral image); whereas the second was a classification (Pseudo-colour) image in
which each pixel was assigned a colour representing the chromosome identified to be
present at that point. In addition, DAPI fluorescence image was captured separately and
after reversing and enhancing the image, it was displayed beside the coloured images to
provide DAPI banding information.
2.2.4 Single-dye chromosome painting for confirmation of SKY findings
2.2.4.1 Probes for Single-dye chromosome painting
Probes for conventional single-dye chromosome painting were kind gifts from
Professor M.A. Ferguson-Smith and Dr Willem Rens (Department of Clinical Veterinary
Medicine, Cambridge, UK.). Experiments were designed to test a maximum of 3
chromosomes—each labelled with a single dye—in a single experiment. For such
experiments, probe labelling was as follows: Cy3 (direct fluorescence), biotin was detected
by sequential incubation with Cy5-labelled Avidin (Amersham International PLC, UK.),
biotinylated anti-Avidin antibody, and Cy5-avidin; FITC (incorporated as dUTP
derivative) was directly detected or amplified with rabbit anti-FITC (Dako, U.K.), then
FITC-labelled goat anti-rabbit antibody (Jackson Immunoresearch, West Grove, PA).
Probes were mixed for each hybridization experiment as, lul (lOOng) of each probe with 1
pi (lpg) of human Cot-1 DNA, made up to a total of 15 pi with hybridisation buffer and
denatured at 70°C for 10 min then pre-annealing by incubation at 37°C for 1 h.
Hybridisation buffer: 50% (v/v) deionised formamide, 10% (w/v) dextran sulphate,
2xSSC, lx Denhardt's solution [50x Denhardt's solution contains5 g of Ficoll (Type 400,
Pharmacia), 5 g of polyvinylpyrrolidone, 5 g of bovine serum albuimin and DDW to
500ml], 21mM sodium dihydrophosphate and 29mM disodium orthophosphate. -
2.2.4.2 Single-dye chromosome painting procedures and analysis
Metaphase spread preparation on slides were denatured and dehydrated as
described above. Pre-annealed probes were hybridised to preparations on the slides
overnight at 37°C. After two 5 min washes in 50% formamide / 2xSSC at 45°C, three 5
min washes in 2xSSC at 42°C, one wash in 4xSSC / 1% Tween 20, slides were incubated
with the first antibody detection layer for 30 min, then three 5 min washes in 4xSSC / 1%
Tween 20, then slides were incubated with the second antibody layer (if required) for 30
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min, then three 5 min washes in 4xSSC / 1% Tween 20, then slides were washed three 5
min washes in 4xSSC /1% Tween 20. Slides were counterstained with DAPI, and
mounted in Prolong Antifade (Molecular Probes, U.K.), viewed using a Zeiss Axioplan
fluorescence microscope, and images were captured and analysed using Smart Capture /
IPLab Spectrum software (Digital Scientific, Cambridge, U.K.).
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2.3 Tissue specimens.
Fresh tumour samples were collected from patients with colorectal carcinoma
undergoing surgery in the Royal Infirmary of Edinburgh NHS Trust before November 1997.
Age, sex, clinical details and other information on the material used for gene analysis and
treatment responsiveness studies are supplied in the relevant chapters. Specimens were
immediately removed from the operating theatre and delivered on ice to the Department of
Pathology at the University of Edinburgh. Blocks of fresh tissue (approximately 10x5x5
mm) were taken from each colorectal cancer and one from normal mucosa at a point distant
from the lesion. Each block of tissue collected from the tumour was subsequently divided
into three separate pieces. One portion was placed in 1.5 ml capacity screw-capped vial,
snap frozen in liquid nitrogen and stored at -70°C awaiting DNA extraction. The middle
portion was fixed in periodate-lysine-paraformaldehyde-dichromate (PLPD), paraffin-
processed and sections were stained with haematoxylin and eosin, following standard
methodology, for histological assessment. Sections from paraffin blocks were also used for
immunohistochemical detection of stabilised p53 protein. The third portion of each of the
tissue blocks from the tumours was first washed in PBS and then either placed in a vial with
antibiotic medium (Glasgow Modified Eagle's Medium (GMEM) supplemented with 1%
v/v, penicillin/streptomycin, 10% Fetal Calf Serum) and immediately taken for implantation
in SCID mice. In cases when the implantation could not be performed immediately, samples
were placed in freezing medium [10% dimethyl sulphoxide (DMSO) in GMEM] for slow
freezing and stored at -80°C until animals were available for establishing xenografts.
2.3.1 Establishment of colorectal cancer xenografts in SCID mice.
All experiments on animals were carried out under project license number 01624
held by Professor Andrew H. Wyllie at Edinburgh University in 1997-1998. Xenografts
were established by implantation of two pieces approximately 2x2x2 mm through a small
dorsal incision in mice with severe combined immunodeficiency syndrome (SCID), aged 12-
16 weeks. Animals were maintained in sterile conditions and provided with sterile food and
water. All experimental procedures were undertaken aseptically inside a laminar flow
facility. These mice are deficient in both B and T lymphocyte functions due to an inability to
correctly rearrange the immunoglobulin and T-cell receptor genes by site-specific [V(D)J]
recombination (Bosma et al., 1983; Custer et al., 1985) and thus do not reject implanted
foreign tissue. They do, however retain non-specific macrophage-mediated immune
responses, useful for removal of bacterial contamination from implanted tumours.
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2.4 Polymerase Chain Reactions (PCR)
2.4.1 Extraction of DNA from frozen tissues
DNA was extracted from frozen tissue according to the method of Goelz et al.,
(Goelz et al., 1985). Frozen tissue was chopped into small pieces in 0.5 ml TE-9 SDS and
0.5 mg ml"1 proteinase K and incubated for 48 hours at 48°C, mixing occasionally. An
equal volume of water-saturated phenol was added, mixed and centrifuged at 10000 x g for
2 minutes. The top layer was removed and an equal volume of PC-9 added to it, mixed
and spun again. The top layer was removed and an equal volume of 24:1 chloroform:
isoamyl alcohol was added, mixed and spun. The top layer was once again removed and
0.5 volume 7.5 M ammonium acetate and 2x volume ethaqol added, mixed and left
overnight at -20°C. This was centrifuged at 4°C and 10000 x g for 20 minutes, the
supernatant drained and the pellet vacuum dried. The DNA was resuspended in 250 pi TE,
dissolved at 4°C for 3 hours and an OD reading taken at 260nm. Concentration was
adjusted to 1 mg ml"1.
TE-9 SDS: 500 mMTris pH8, 20 mM EDTA, 10 mM NaCl, 1% SDS (sodium dodecyl
sulphate)
PC-9: 50 ml water-saturated phenol, 50 ml chloroform.
TE: 10 mM Tris, 1 mM EDTA.
2.4.2 Polymerase Chain Reactions
Reactions were carried out in 0.5 ml thin-walled Eppendorf s tubes. PCR was
carried out for 35 cycles, each consisting of denaturation for 30 seconds at 94°C, annealing
for 30 seconds at a temperature (Ta) calculated according to the primer composition,
extension for 30 seconds at 72°C, followed by a final extension step for 10 minutes at
72°C. Reactions consisted of 50 pi volume containing 100 ng genomic DNA, 10-25 pmols
of each primer, 200 pM of each dNTP (Advanced Biotechnologies Ltd), 1-4 mM MgCl2,
1.25 U of thermostable DNA polymerase and a final concentration of 1 x buffer consisting
of 20 mM Tris-HCl (pH 8.4), 50 mM KC1 and 0.05% non ionic detergent (Taq DNA
polymerase, Life Technologies, UK). Dimethyl sulphoxide (DMSO) at 10% (5 pi per 50
pi reaction) was added for some PCR assays (details are supplied in Table 4.1 and 4.2).
The PCR hot start method was used by mixing up all the PCR components except the Taq
DNA polymerase enzyme, then adding the enzyme at an initial stage of heating and
(UJ
holding the PCR mixes at 94°C, then the thermal cycles were allowed to proceed as
required. The products were analysed by electrophoresis on 2% agarose gels for detection
of the amplified DNA product.
2.4.3 Agarose gel electrophoresis
Agarose gels were prepared by adding 3 g electrophoresis-grade agarose to 150 ml
lx Tris-borate-EDTA buffer (TBE) and heating to boiling point in a microwave oven, with
regular mixing, to dissolve the agarose. The gel was stirred and allowed to cool to
approximately 55°C before adding 20 ng ml"1 ethidium bromide and pouring into a
12x16cm gel mould with a 20-well comb. For checking PCR products, 8 pi product was
added to 2 pi loading dye before loading. Products were rqn against 500 ng of a suitable
molecular weight marker, usually Ladder Mix (Fermentas Ltd) or 1-kb ladder (Life
Technologies Ltd) were used. Electrophoresis was carried out at 125 V in lxTBE buffer
for variable lengths of time; for most purposes, migration of the bromophenol blue dye
approximately 5 cm through the gel was sufficient. Gels were visualised and
photographed using a UV illumination box.
IOxTBE: 107.8 g Tris (0.89M), 55 g Boric acid (0.89M), 7.44 g Na2EDTA (0.02M) in
1000 ml DDW pH adjusted to 8.3.
Loading dye: 30% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol FF.
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2.5 Analysis of microsatellite instability
2.5.1 Microsatellite loci
The following microsatellite markers were used for analysis of microsatellite
instability: D2S119, D2S123, D3S1293, D8S282, D13S160, D15S132, D17S849, D18S58,
TGF(3R-II, BAT26, BAT40, and L-myc. At least five loci were examined in each patient.
The primers and conditions are described in (Table 2.2).








D2S119 2 55 214-232 CTTGGGGAACAGAGGTCATT
GAGAATCCCTCAATTTCTTTGGA
D2S123 2 58 210-240 AAACAGGATGCCTGCCTTTA
GGACTTTCCACCTATGGGAC
D3S1293 2 50 116-144 ACTCACAGAGCCTTCACA
CATGGAAATAGAACAGGGT
D8S282 1.5 50 260-274 GGGCACAGGCATGTGT
GGCTGCATTCTGAAAGGTTA
D13S160 1.5 55 229-241 CGGGTGATCTAAGGCTTCTA
GGCAGAGATATGAGGCAAAA
D15S132 1 55 69-83 CTGATAATAAAACCAGGAAGACAC
TATTGGCCTGAAGTGGTG
D17S849 1 50 144-174 CAATTCTGTTCTAAGATTATTTTGG
CTCTGGCTGAGGAGGC
D18S58, 1.5 60 -110 CTCTTTCTCTGACTCTGACC
GACTTTCTAAGTTCTTGCCAG
TGFPR-II, 3 58 267 CCTCGCTTCCAATGAATCTC
TTGGCACAGATCTCAGGTCC
BAT26, 1.5 58 80-100 TGACTACTTTTGACTTCAGCC
AACCATTCAACATTTTTAACCC
BAT40, 1.5 58 80-100 ATTAACTTCCTACACCACAAC
GTAGAGCAAGACCACCTTG
L-myc 1.5 53 140-209 TGGCGAGACTCCATCAAAG
CTTTTTAAGCTGCAACAATTTC
(Bubb et al., 1996; Huang et al., 1996; Dietmaier et al., 1997)
2.5.2 Radio-labelling and denaturation of the PCR products
The PCR products were radioactively labelled through primer end-labelling with
33
[y- "P]ATP using T4 polynucleotide kinase. The radio-labelled products were
electrophoretically separated in denaturing 6% polyacrylamide gel and subjected to
autoradiography for detection of band shifts.
Oligonucleotide primer sequences were diluted with sterile distilled water before
use, giving a final concentration of 10 ng (il1. The strand primer in each reaction was 5'
end-labelled with [y-33P]ATP using T4 polynucleotide kinase. Labelling was performed
prior to each PCR reaction. lOng of oligonucleotide (10 ng pi1) was added to 2jli1 of 5x
buffer, 6.2jll1 of sterile distilled water, 0.3pl of [y-?,P]ATP (equivalent to 3 p.Ci) and
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placed on ice. 0.53 jllI (5 U) of T4 polynucleotide kinase was then added giving a total
volume of 10 pi and the reaction placed in a water bath at 37°C for one hour. This amount
was sufficient for up to 10 PCR reactions.
Polymerase chain reactions were carried out as usual for any microsatellite locus,
except that prior to amplification an additional 1 pi labelled primer was added to each
reaction. After amplification, 5 pi stop solution was added to 5 pi PCR product, the
mixture boiled for 3 minutes and cooled quickly on ice in preparation for loading onto a
gel.
2.5.3 Gel preparation and running conditions
A 6% denaturing polyacrylamide gel was used in vertical sequencing gel apparatus
with 0.5xTBE buffer. Gels were prepared in 35 cm x 50 cm vertical DNA sequencing
electrophoresis plates. Plates were thoroughly cleaned with 'Decon' detergent, rinsed with
water and finally wiped with 70% alcohol. One plate was siliconised by wiping with 3 ml
Gel Slick, air drying and removing excess with water. Plates were assembled with 0.4 mm
spacers and combs. Sixty microlitres of TEMED and 60pl 25% ammonium persulphate
(APS) were added to 60 ml stock acrylamide immediately prior to pouring and the gel was
allowed to polymerise for 1 hour. The gel was pre-run for an hour in 0.5xTBE at 70 W to
reach 55°C. 5 p.1 of combined PCR product and stop solution denatured as described
above were added to the wells after rinsing with TBE to disperse urea. The gel was then
run at 70 W for 3-6 hours or until the xylene cyanol marker dye approached the end of the
electrophoresis plate. It was then fixed for 10 minutes in a solution of 10% methanol and
10% acetic acid, transferred to Whatman No 17 paper and dried on a vacuum gel drier.
Autoradiography was carried out for 1-3 days and autoradiographs were assessed visually
for microsatellite instability.
5X T4 polynucleotide kinase buffer: 350mM Tris-HCl pH 7.6, 50mM MgCl2; 500mM
KC1, 5mM 2-mercaptoethanol.
Stop solution: 95% formamide, lOmM EDTA pH8, 0.1% bromophenol blue, 0.1% xylene
cyanol FF.
Acrylamide solution: 75ml 19:1 acrylamide:bis acrylamide 'Instagel' (Severn Biotech
Ltd), 250g 500ml urea (7M), 50ml lOx TBE, 175ml DDW stored protected from light at
4°C.
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2.6 Mutation screening methods
2.6.1 Single strand conformation polymorphism (SSCP) analysis
35x50 cm glass plates were used. To 60 ml 0.5xMDE gel solution, 240 pi 10%
ammonium persulphate and 24 pi TEMED were added, the solution mixed and poured
immediately. The gel was allowed to set for 1 hour before use. Five microlitres of PCR
product were denatured for 5 minutes at 50°C in 1 pi denaturing solution then chilled on
ice. Three microlitres of the stop solution (95% formamide, 10 mM EDTA pH 8, 0.01%
bromophenol blue, 0.01% xylene cyanol) were added and the samples loaded quickly onto
0.75 mm thick MDE gel (Flowgen, UK) containing 5-10% glycerol, after rinsing the wells
with lxTBE. and DNA strands were electrophoretically separated at 20°C at 6 W constant
power overnight or 25 W for 4-6 hours. Running time varied according to fragment size;
good fragment separation was achieved when samples were run such that the xylene
cyanol marker dye had migrated between 20 and 60 cm through the gel. Electrophoresis
buffer was lxTBE.
0.5xMDE gel solution: 15 ml MDE gel, 3 ml glycerol, 6 ml lOx TBE, 36 ml DDW.
Denaturing solution: 0.5 M sodium hydroxide, 10 mM EDTA.
2.6.2 Heteroduplex analysis
A lxMDE gel containing 3.12 M urea was prepared by addition of 240 pi 10%
ammonium persulphate and 24pl TEMED to 60ml gel mix. The gel was poured and
allowed to set for 1 hour before use. PCR products for heteroduplex analysis (White et al.,
1992) were heated to 95°C to denature double-stranded DNA and then cooled slowly to
37°C over 30 minutes, allowing reannealing of single strands. 4 pi of samples in 2 pi
loading buffer (30% glycerol, 0.25% bromophenol blue, 0.25 xylene cyanol FF) was
electrophoresed on the MDE gel and run at 0.71-0.80 kV for 16 hours. This slow running
of the gel ensured that it remained cool. 0.5 pg of a molecular weight marker, Marker V
(Boehringer Mannheim Ltd), and a control sample known to separate into heteroduplex
and homoduplex bands were also loaded. Both glass plates were pre-treated as above, and
the resulting bands were visualised using the silver staining method as for SSCP.
lxMDE gel mix: 30 ml MDE, 3.6ml lOxTBE, 9 g urea, DDW to 60ml.
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2.6.3 Silver staining of mutation screening gels
Gels were stained according to the methods of Bassam et al. (Bassam et al., 1991),
as detailed in Promega's DNA Silver Staining System protocol with some modifications to
avoid detachment of the gel from the plate during the staining process. 35x50 cm glass
plates for vertical gel electrophoresis were used with 0.75 mm spacers and square or
shark's tooth combs. Both glass plates were pre-treated: the first was wiped with 3ml Gel
Slick, allowed to dry for 5 minutes then wiped with 70% ethanol. The second was treated
with 20 gl gamma-methacryloxypropyl-trimethoxysilane in 5ml distilled water (pH 3.5
with acetic acid) in order to attach the gel to the plate for staining in situ and dried for ten
minutes before wiping four times with 95% ethanol. Silver staining of gels was carried out
in a shallow glass dish on a gently shaking platform, carefully pouring off used solutions.
Ultrapure water was used throughout.
The glass plates were separated and the gel soaked for 10 minutes in 10% ethanol
followed by 10 minutes in 1% nitric acid. It was then rinsed for 5 minutes in UDDW and
placed in staining solution for 20 minutes. After rinsing for 10 seconds with UDDW, 1/3
of the pre-cooled developer solution was poured on the gel and left in until a brown
precipitate appeared, then this developer was replaced with the remaining 2/3 of the fresh
cooled developer. When bands appeared, the reaction was stopped by replacing the
developer with 0.1 M citric acid for 10 minutes, the gel rinsed in UDDW for a further 5
minutes and then interpreted and photographed on a light box. For re-use, plates were
soaked in 5 M sodium hydroxide for one hour and cleaned with detergent and 70%
ethanol. Spent silver nitrate was treated with sodium chloride to precipitate the silver
before disposal.
Staining solution: 2.04 g silver nitrate in 1 litre UDDW
Developer solution: 160 g sodium carbonate (decahydrate), 1 ml 37% formaldehyde, in 2
litres UDDW.
Stop solution: 19.2 g citric acid in 1 litre UDDW
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2.7 Sequencing reactions
2.7.1 Sequencing using Sequenase Version 2.0 kit
Sequencing of Fas and Bik gene PCR products was carried out according to the
protocol provided with the Sequenase Version 2.0 kit (Amersham International pic).
2.7.1.1 Preparation of PCR products
Double-stranded DNA was denatured by incubating at 37°C for 30 minutes in 0.1
volume denaturing solution. This was neutralised with 0.1 volume 3 M sodium acetate, pH
4.5-5.5, and precipitated with 4x volume ethanol. After 15 minutes at -70°C, the DNA was
centrifuged at 4°C for 15 minutes, washed with 4x volume 70% ethanol, centrifuged again
and vacuum dried. The pellet was resuspended in 7 pi DDW, and to it was added 50 pg of
appropriate primer in lpl volume and 2 pi Sequenase buffer. This was mixed and heated to
65°C for 2 minutes then allowed to cool to <35°C in a water bath over 15-30 minutes. It
was then spun briefly and placed on ice. To it was added 1 pi 0.1 M DTT, 2pl labelling
mix (diluted 1/5 in DDW) 3.2 U Sequenase in 2pl dilution buffer and 5 pCi 35SdATP. 2.5
pi of each termination mix was warmed to 37°C and 3.5 pi of the the above DNA solution
added and mixed thoroughly. After 5 minutes the reaction was stopped by adding 4 pi stop
solution and the reactions stored at -20°C for up to one week before use.
Denaturing solution: 2M NaOH, 2mM EDTA.
Dilution buffer: 10 mM Tris.HCl pH 7.5, 5 mM dithiothreitol, 0.5 mg ml"1 BSA.
5 x Sequenase buffer: 200 mM Tris-HCl pH 7.5, 100 mM MgCl2, 250 mM NaCl.
Stop solution: see 2.14.
2.7.1.2 Sequencing gel electrophoresis and autoradiography
Sequencing was carried out on BRL S2 sequencing apparatus using 0.4 mm spacers
and sharks-tooth combs. Plates were cleaned with cream cleaner, washed thoroughly and
wiped with 70% ethanol. One plate was treated with gel slick as in section 2.5.3. 60 ml
gel stock solution was polymerised by adding 60 pi 25% ammonium persulphate and 60 pi
TEMED immediately before pouring. The gel was allowed to polymerise horizontally for
1 hour with inverted combs and then pre-run without combs, after rinsing thoroughly with
lxTBE, at 90W for 30-60 minutes in lxTBE until it reached 50°C. Combs were then
replaced to form wells, which were again rinsed thoroughly. Samples were heated to 75°C
for 3 min prior to loading and run at 70 W until the bromophenol blue marker reached the
bottom of the gel. The gel was fixed twice in 10% acetic acid 10% methanol for 5 minutes
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and transferred onto 3 mm paper. It was dried for 2 hours on vacuum gel dryer and
exposed to autoradiography film overnight.
Labelling mix (dGTP): 7.5pM dGTP, 7.5pM dTTP, 7.5pM dCTP.
Termination mix: 50mM NaCl, 80pM each dNTP, 8pM of one of ddGTP, ddATP, ddTTP
or ddCTP.
Acrylamide solution: see 2.5.3.
2.7.2 Cycle sequencing of PCR products
Direct sequencing of PCR products was carried out for Box and TGF/3R1I gene
PCR products using the ThermoSequenase radio-labelled terminator cycle sequencing kit
(Amersham International pic). This is a method of cycle sequencing which utilises radio-
labelled ddNTP terminators in conjunction with a thermostable DNA polymerase to
produce high quality sequence which is largely free of background.
2.7.2.1 Pretreatment ofPCR DNA samples
Before sequencing reactions can be carried out, PCR-generated DNA must be
pretreated with exonuclease I and shrimp alkaline phosphatase (SAP) to remove single-
stranded oligonucleotides, single-stranded PCR-generated DNA and free dNTPs. To do
this, 1 pi each enzyme (10 U exonuclease I and 2 U SAP) was added to 5 pi PCR product
and incubated at 37°C for 15 minutes. The enzymes were then inactivated by heating to
80°C for 15 minutes. Additionally, an aliquot of untreated DNA sample was quantitated
by agarose gel electrophoresis against a quantitative marker.
2.7.2.2 Sequencing reactions
2 pi dGTP termination master mix was mixed with 0.5pl of [a-^^P]ddNTP to
produce a termination mix for each ddNTP. A reaction mixture was made for each test
DNA sample by mixing 50 ng (25 fmol) treated DNA with 0.5 pmol sequence-specific
primer (forward-strand primer) and 2 pi reaction buffer in a final volume of 20 pi. 4.5 pi
reaction mixture was transferred to each termination tube, mixed and overlaid with one
drop of paraffin oil. The tubes were placed on a thermal cycling block and subjected to 30
cycles of 95°C for 30s, 55°C for 30s and 72°C for 1 minute. 4 pi stop solution was added
to each tube and the samples heated to 70°C for 2 minutes before loading 3 pi per lane onto
a denaturing polyacrylamide gel.
Reaction buffer: 260 mM Tris HC1, pH9.5, 65 mM MgCl2.
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dGTP termination master mix: 7.5 pM dGTP, 7.5 jrM dATP, 7.5 p,M dTTP, 7.5 jxM dCTP.
2.7.2.3 Gel electrophoresis
Gel electrophoresis and autoradiography were carried out as in 2.7.1.2, except that
glycerol-tolerant buffer was substituted for TBE buffer.
20x glycerol tolerant buffer: 216 g Tris base, 72 g taurine, 4g Na2EDTA 2H2O, made to
1 litre with DDW.
2.7.2.4 Elimination ofsequencing band compressions using dITP
Where sequencing band compressions (observed as uneven band spacing) caused
difficulties in reading a sequence, reactions were repeated substituting dITP termination
master mix (supplied with the ThermoSequenase kit) for dGTP. Reactions were carried
out as above, except that the termination (extension) temperature was reduced from 72°C
to 60°C and the time at this temperature increased to 5 minutes.
dITP termination master mix: 7.5 pM dITP, 7.5 pM dATP, 7.5 pM dTTP, 7.5 pM dCTP.
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2.8 Immunocytochemical detection of stabilised p53
The p53 protein accumulation status of the samples was established by
immunohistochemistry using antibody DO-7, which recognises an amino terminal epitope
and is capable of reacting with both wild type and mutant p53 (Vojtesek et al., 1992).
Sections were prepared in the Department of Pathology, University of Edinburgh, by
cutting 3 pm sections from tissue stored in periodate-lysine-paraformaldehyde-dichromate
(PLPD) and embedded in paraffin wax. Sections were placed onto poly L-lysine (PLL)-
treated microscope slides. Matching normal mucosae were stained with each tumour.
Unstained sections from known p53 positive and negative colorectal carcinomas were also
included as controls for each staining batch. Samples were deparaffinised by placing in
xylene for 10 minutes, absolute ethanol for 1 minute, 90% ethanol for 1 minute and 70%
ethanol for 1 minute and then rinsed in water. Endogenous peroxidase activity was
blocked by treatment in 3% hydrogen peroxide for 15 minutes. This was followed by
washing for 5 minutes in DDW and 5 minutes in phosphate buffered saline (PBS). Slides
were then wiped to remove excess fluid and marked around the area of the section with a
wax pen to retain solutions. 100 pi normal rabbit serum (NRS) diluted 1/5 in PBS was
added and left for 20 minutes. This was then drained and the slides incubated overnight at
4°C in a 1/100 dilution of Do-7 antibody (Vojtesek et al., 1992) in 1/5 NRS/PBS solution.
After overnight incubation, the sections were washed twice for 5 minutes in PBS
before applying the secondary antibody. Biotinylated rabbit anti-mouse immunoglobulins
(Dako Ltd) were diluted 1/400 in the above NRS/PBS solution and 100 pi added to the
sections and incubated for 30 minutes at room temperature. Meanwhile, an
avidin/biotinylated horseradish peroxidase (HRP) complex (ABC kit, Dako Ltd) was made
up by adding 1 drop of avidin and 1 drop of biotinylated horseradish peroxidase to 5 ml
PBS and allowing 30 minutes for the reagents to conjugate. After incubation, the slides
were washed twice in PBS for 5 minutes and 100 pi ABC complex was added. Slides
were incubated for 30 minutes at room temperature then again given two 5-minute washes
in PBS. They were then incubated for 3 minutes in diaminobenzidine (DAB) solution at
room temperature to allow formation of brown colouration through oxidation of DAB by
HRP, washed for 5 minutes in DDW and counterstained for 6 seconds in haematoxylin.
They were washed until the water was clear and dehydrated through 1 minute in 70%
ethanol, 1 minute in 90% ethanol, and 1 minute in absolute ethanol and 10 minutes in
xylene. Slides were mounted with DPX mountant and examined under lOOx total
magnification on a light microscope. Cases were scored positive if any nuclei stained
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positively and the extent of staining, which varied considerably, was noted. Although
strength of staining also varied, this was not taken into account as it could vary between
experiments.
PLPD: 0.1 M lysine, 0.1 M periodate, 2% paraformaldehyde made to 50 ml with
Sprensen's phosphate buffer (0.05 M, pH 7.4). 5% potassium dichromate in 50 ml DDW
added immediately before use
PBS: 8 g NaCl, 0.2 g KC1, 1.44 g Na2HP04 0.24 g KH2P04 to 1 litre DDW pH7.4.
DAB solution: 5 mg DAB, 4.8 ml DAB buffer, 100 pi hydrogen peroxide solution (1/30,
[v/v], 30% hydrogen peroxide stock/DDW).
DAB buffer: 24 ml 0.2 M Tris, 38 ml 0. IN HC1, 0.068lg imidazole, DDW to 100 ml, pH
adjusted to 7.6.
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2.9 clonogenic survival assay
The plating efficiency for each cell line was determined first by incubating 1.5 x
102, 2 x 102, 3 x 102 and 5 x 102 cells in 25-cm2 flasks in triplicate experiments. Cell
concentrations, which gave 100-150 colonies after 12 days, were chosen. These were 1.5 x
102 Cells for HT29 and 3 x 102 for LoVo. Cells were trypsinised, using standard
protocols, and the trypsin neutralised with two volumes of cell culture medium. An aliquot
of cell suspension was removed and the cell density counted using a haemocytometer. The
suspension was also examined to ensure it contained only single cells and not clumps.
Cells were plated out, in triplicate flasks, at the required densities. Cells were allowed to
reach the log phase over night.
5-FU was dissolved in PBS and temozolomide was dissolved in 10% DMSO/PBS
and then added to fresh media to give the required concentrations of each drug. Cells were
then exposed to the required concentrations of 5-FU for one hour at 37°C, or different
doses of ionizing radiation and then washed and fed by fresh media. Because of the short
half-life of temozolomide, cells were exposed continuously to the drug over 12 days.
Media were replaced with fresh media containing temozolomide each 2-3 days to ensure
that cells were exposed to active drug. Controls were exposed to the drug vehicles and to
the same procedures of washing and replacing the media as the treated flasks. Cells were
irradiated using X-ray source (Siemens Stabilipan II 300 kv orthovoltage unit) at 0.80 Gy
min"1 and controls were exposed to the same procedures of transport but were not
irradiated. After 12 days, the medium was removed from the plates and the cells washed
in PBS, then methanohPBS (1:1), then fixed in 100% methanol for 10 minutes. Plates
were then stained in filtered 50% Giemsa-50% methanol (v/v) for 30 minutes, washed
gently with tap water, dried, and the numbers of colonies counted.
2.10 Acridine Orange staining for counting apoptosis
Acridine orange is a metachromatic fluorochrome that differentially stains double-
stranded versus denatured DNA. The dye is an intercalating agent that, on excitation with
UVC light, emits green light when bound to double-stranded DNA and red light when
bound to denatured DNA or RNA. The nucleus of a stained cell thus appears green under
UVC light, whilst the cytoplasm stains red. This staining allows the examination of
nuclear morphology and hence the sensitive detection of cells which have undergone
apoptosis.
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At selected time points (1, 2, 3.5 days) after irradiation or drug treatment, cells
were trypsinised and centrifuged at 600 x g for 5 min, together with the medium and PBS
from the pre-trypsinisation wash. The supernatant was then discarded, cells resuspended
in PBS and two volumes of ice cold fixative (90% ethanol, 10% formaldehyde) added and
the cells were left to fix for 1-3 hours before counting. Cell suspensions were counted
immediately or stored at 4°C until counting. Before counting, cells were centrifuged at
220 x g for 10 minutes at 4°C, re-suspended in 5 ml PBS, spun again and finally
re-suspended in 50 to 1000 pi of PBS (depending on cell density). 10 pi of cell suspension
was dropped onto a clean glass slide, and an equal volume of Acridine Orange solution (5
pg ml"1, Sigma) dropped onto a coverslip. The coverslip was carefully lowered onto the
slide, and the number of cells scored for apoptosis, on the grounds of nuclear morphology,
under a fluorescence microscope (Zeiss, Axiovert S100T.V, UK). Nuclear changes
characteristic of apoptosis included chromatin condensation nuclear shrinkage and nuclear
fragmentaion. Apoptosis was counted in a minimum of 300 cells, each 100 cells, from a
different field on the slide.
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Chapter 3
Genomic Instability Patterns in Sporadic
Colorectal Cancers
3.1. Introduction:
Genomic instability is a feature of most malignant tumours. It implies either
increased rate of genomic changes, or an increased tolerance to genomic changes, or both.
This genomic instability appears to take different forms in different individual tumours,
and leads to different characteristic patterns of abnormality in the genome. Non-random
patterns of acquired chromosomal changes have been detected in all tumour types that
have been investigated in any great detail (Mitelman et al.,.1997), and there is already
some evidence that the pattern of chromosomal change reflects the kind of genomic
instability in the tumour (Eshleman et al., 1998). The best understood form of genomic
instability - microsatellite instability - generates repeated errors in the fidelity of
replication of microsatellite sequences resulting from loss of function of the nucleotide
mismatch repair pathway. However, the majority of RER+ tumour cell lines have few if
any chromosomal rearrangements or numerical changes (Eshleman et al., 1998). Other,
RER-, carcinomas have stable microsatellites, but frequently show chromosomal instability
(CIN) (Lengauer et al., 1997; Eshleman et al., 1998). As in RER+ tumours, there is clear
evidence that the errors responsible for the CIN+ phenotype are repeated many times, at
different locations within the genome, during the development of the tumours (Lengauer et
al., 1997). The defects that cause chromosomal instability are not yet well established, but
are likely to be various, since a range of defects can lead to chromosomal changes in model
systems, including defects in double-strand break repair and in centrosomes (see Chapter 1
1.4.7). Deficiency of p53 appears to be not sufficient, but may be permissive (Carder et
al., 1993; Carder et al., 1995). Two RER-, CIN+ colorectal carcinoma cell lines have
mutations in hBUB-1, a mammalian gene whose yeast homologue is essential for normal
chromosome disjunction, but these mutations appear to be uncommon (Cahill et al., 1998).
It should be noted that much less cytogenetic information has been gathered for
carcinomas, compared with haemato-lymphoid malignancies for example, partly due to
technical difficulties in obtaining good metaphases from neoplastic epithelial cells and
partly due to the karyotypic complexity and variability making conventional Giemsa (G)
banded karyotypes difficult to interpret (Mertens et al., 1997). It seems likely that
different patterns of karyotypic changes will be discernable when karyotypes are analysed
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in more detail, reflecting different types of chromosomal instability or tolerance of
different types of chromosome damage. In other words, there are probably multiple CIN
phenotypes. Indeed, not all RER+ colorectal tumours are near-diploid, and there is a
substantial subset of RER- human colorectal cancers in which there is little evidence for
instability in chromosome numbers (Georgiades et al., 1999). Clear definition of the
different patterns of genomic instability in colorectal tumours may give clues to the nature
of these undiscovered defects. It may also prove predictive of response to therapy, since
consistent patterns of genomic instability are likely to reflect selective defects in cellular
ability to recognise and respond to errors or damage of specific types. In particular,
nucleotide mismatch and DNA strand breaks, genomic abnormalities that appear
repeatedly in human cancers, each trigger apoptosis when they are induced in normal cells
(Clarke et al., 1994; Toft et al., 1999). Such specific defects in apoptosis pathways could
explain emerging correlations between patterns of genomic instability and tumour
resistance to particular therapeutic agents (Bunz et al., 1999). Perhaps related to this is the
observation that RER status is one of the strongest factors predictive of long-term survival
for patients with colorectal carcinoma (Bubb et al., 1996).
Here, chromosomal changes in a series of 17, well-characterized, colorectal cancer
cell lines were studied comprehensively using Spectral Karyotyping (SKY) (Schrock et al.,
1996). SKY is a recently developed fluorescent in situ hybridization (FISH)-based
technique that has the power to identify complex chromosomal rearrangements (Macville
et al., 1997; Rao et al., 1997; Ried et al., 1997; Ried, 1998). Tumour cell lines were
selected to represent RER+ and RER- groups and within each of these p53 wild type and
mutants were selected. SKY findings were confirmed, in some cases, by conventional
single-dye chromosome paint FISH, and cytogenetics.
65
3.2. Materials and Methods:
The 17 human colorectal carcinoma cell lines (Table 3.1) were selected from a set
of over 50,collected from many different sources, to represent different combinations of
molecular and genomic abnormalities within sporadic colorectal cancers. SKY was as
described (Schrock et al., 1996) (see Chapter 2 for details). Briefly, an electronically
inverted DAPI image (Figure 3.1 B & 3.2 A) is used for banding of the metaphase
chromosomes. The so-called 'spectral image' is obtained from the same metaphase
(Figures 3.1 C and 3.2. B) after hybridisation to the SKY paint and spectral imaging of the
fluorescent signals on a fluorescence microscope using a spectrometer (Spectracube,
Applied Spectral Imaging). The SKY software analyses the spectrum of each pixel of the
image, determines which dyes are present and hence which chromosome is being detected .
Each pixel of the image is then presented in a false-coloured way using a 'classification or
pseudo-colour' to show which chromosome spectrum best matches the spectrum recorded
as in Figure 3.1 D and 3.2 C. At least 10 good metaphases were analysed initially for each
cell line, this was increased up to a total of 24 metaphase spreads for those lines displaying
marked clonal heterogeneity.
The identities of most translocated fragments were verified by conventional
chromosome painting using a single fluorescent dye for each chromosome, because SKY
occasionally misidentifies small fragments of chromosomes due to overlap between
adjacent fluorescent signals. Such errors are, however, almost invariably predictable.
Representative karyotypes (Table 3.2) were assembled as follows: all rearranged
chromosomes present in at least two metaphases were listed, and the number of copies of
each chromosome was that present in the majority of metaphases, except where noted.
(Detailed descriptions of the technical aspects of the methods are included in Chapter 2)
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Table 3.1 Clinico-pat tologica and molecular features of cell lines
RER-1'2 Age Sex Site Diff Du.S. p53 APC2 P-cat1
C70 691 F1 sig2 mod2 B2 wt mu wt
HT29J 44 F col well-mod mu4"6 mu wt
LIM18637 74 F Rt col poor B wt
SW1417* 53 F col mod C wt mu wt
SW403* 51 F col mod C mu mu wt
SW480* 50 M col mod B 4,6,7mu mu wt
SW620* 50 M LN met D mu" mu wt
SW837" 53 M rectum poor C
y
mu mu wt
VAC04A10 59 M rectum mod D wt ipu wt
RER+
DLDl" M col poor C mu6 mu wt
GP2D12 F col poor B wt12 mu wt
HCT116u M col wt4"7 wt mu
LS174T14 58 F colon well B wt4,6 wt mu
VAC05IU 78 F caecum poor C mu' mu wt
LoVo'" 56 M LN met D wt4'7'16 mu wt
HCA7" 58 F Hep fix mod-muc B mu wt wt
LS41118 32 M caecum poor B wt mut wt
Original references describing cell line establishment are supplied after the name of each line. p53,
APC, and /3-catenin data either were obtained from work done by Sir Walter F. Bodmer's group or
collaborators some of which are published in references 1 and 2. C70 was established in Sir Walter
Bodmer laboratory and there is no publication describing its establishment. Additional references
for the p53 status are supplied. Diff, differentiation; Du.S., Dukes' stage; wt, wild type (used to
denote absence of abnormalities at the level of the available information); mu, mutant; sig,
sigmoid colon; Rt, right colon; LN met, lymph node metastasis; Hep flex, hepatic flexure; mod,
moderately differentiated adenocarcinoma; well-mod, well to moderately differentiated
adenocarcinoma; poor, poorly differentiated adenocarcinoma; mod-muc, moderately -
differentiated adenocarcinoma with mucinous differentiation. Gaps in the table indicates absence
of information. RER status determined by BAT26 or BAT25 and further r confirmed by D15S58
microsatellite loci.
1, (Wheeler et al., 1999); 2, (Rowan et al., 2000); 3, (Fogh & Trempe, 1975); 4, (Cottu et al.,
1996); 5, (O'Connor et al., 1997); 6, (Yoshikawa et al., 1999); 7, (Whitehead et al., 1987); 8,
(Leibovitz et al., 1976); 9, (Eshleman et al., 1998); 10, (McBain et al., 1984); 11, (Tibbetts et al.,
1977); 12, (Solic et al., 1995); 13, (Brattain et al., 1981); 14, (Rutzky et al., 1980); 15, (Drewinko
et al., 1976); 16, (Soulie et al., 1999); 17, (Kirkland, 1985); 18, (Suardet et al., 1992).
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3.3. Results and Discussion
3.3.1. Karyotypes of the cell line
The representative summary karyotypes of the cell lines are described in Table 3.2.
Representative metaphases analysed by SKY are shown in Figure 3.1 - 3.18. Detailed
karyotypes of each of the constituent metaphases of each line are described in Appendix 2.
Some of the initial SKY classifications were incorrect in detail, due to overlap of
adjacent fluorescent colours, as illustrated in Fig 3.1 C70-E, F, G, and Fig 3.2 HT29-E, F
but their correct composition, was determined by conventional FISH , using single
fluorescent dyes for each chromosome is shown in Table 3.2. Single-dye chromosome
painting was used to confirm the identity of all translocated fragments in C70, HT29,
SW403, SW480, DLD1, HCT116, VAC05, and all potentially misidentified translocations
in the other lines. These confirmation experiments are described in detail in the legends
for Figure 3.1-3.18. The karyotypes ranged from entirely normal to highly aneuploid and
multiple chromosomal rearrangements. One line (LS174T) deviated from diploid only in
having 3 numerical changes (-X, +7, +15); four others (DLD1, GP2d, HCT116, VAC05)
deviated from diploid by having 2-4 rearranged chromosomes and 0-1 numerical changes.
LoVo showed 3 trisomies and 3 structural rearrangements. The remaining lines were to
varying degrees aneuploid, and/or structurally rearranged with modal chromosome
numbers in the range 38 to 127 and with between 8-21 rearranged chromosomes.
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Table 3.2
Karyotypes of the colorectal carcinoma cell lines
RER- cell lines
C70: 115-130 (mode 127), XXXXX, 1x4, der(l)t(l;5)(pl2;pl3)x2, 2x1, del(2)(p21),
del(2)(?)* x4, 3x6, 4x2, der(4)del(4)(q31q35)t(4;18)(?pl5;?)x2, 5x4, 6x3, 7x9, 8x5, 9x5,
10x4, der( 10)t(3; 10)(?;q23-24), 11x3, del(ll)(?q23), dup(l l)(?)x3, 12x6,
der( 12;22)t( 12;22)(?p 13;p 1 l)t(12;22)(?q24;ql 1), 13x6, dup(13)(?)+ x2, 14x4, 15x6, 16x3,
der(16)t(10;16)(q23-24;q24)x2, 17x2, der(17)t(6;17)(?q23;q24-25)x2, 18x4, 19x4,
der(19)t(19;22)(?pl3. l;?ql 1.2)x2, 20x9, 21x2, der(17;21)(ql0;ql0)x2, 22x3[12]/idem,
+der(8)t(5;8)[2]
HT29: 69-73 (mode 70), XX, del(X)(?p21), 1x3, 2x3, der(2)t(l;2)(q32;qll-13), 3x3, 4x2,
del(4)(?q31), 5x3, der(5)t(5;6)(pl0;7), 6x2, 7x4, 8x2, hsr(8)(p22-23), 9x2,
der(6;9)(pl0;ql0), 10x3, 11x4, 12x3, 13x1, i(13)(ql0), 14x2, 15x4, 16x3, 17x2,
der(17;19)(qlO;?plO), 18x2, del(18)(ql2), 19x3, 20x3, del(20), 21x2, 22x3,
der(22)t(17;22)(?;ql2)[13]/idem, 11x3, der(9;ll)[2]/idem, -11, +der(ll;13), -13,
+der(13)t(7;13)(?;ql0), -16, +der(lI;16)(ql0;?pl0)[3]
LIM1863: 66-82 (mode 80), XXXX, 1x3, 2x3, 3x3, der(2;3;8)t(2;3)t(3;8), 4x3, 5x3, 6x2,
7x4, 8x2, del(8)(p?)x3, der(8;17), 9x3, 10x3, 11x3, der(l;ll), 12x3, der(12)t(ll;12),
13x0, i(13)(ql0)x4, der(9;13), 14x3, 15x4, 16x3, 17x0, der(17)t(X;17)x2, 18x3, 19x3,
20x7, 21x2, 22x2[10]/idem, -der(17)t(X;17), +der(17)t(3;17)[2]
SW1417: 66-71 (mode 70), XX, lxl, del(l)(?)x2, 2x3, 3x4, 4x2, 5x1, del(5)(?)x2,
der(5)t(5;17), der(5)t(5;20), 6x2, del(6)(q?), 7x1, dup(7)(q?), der(7)t(l;7)t(l;8)x2, 8x1,
der(8)t(l;8), 9x1, del(9)(?)x2, 10x2, 11x4, 12x3, 13x2, 14x3, 15x1, i(15)(ql0), 16x3,
17x2, 18x1, del(18)(?), dup(18)(?), 19x1, der(19)t(9;19)x2, 20x2, dup(20)(?)x2, 21x2,
22x4[13]/idem, -2, +del(2)(?), +der(2)t(2;3), +del(10)(?)[2]/idem, der(2)t(2;20), -3,
+del(3)(?), +der(5;18), -12, +del(12)(q?), -17, +der(17)t(16;17)[3]
SW403: 60-65 (mode 64), XXX, 1x2, del(l), 2x3, 3x3, 4x2, 5x3, 6x2, 7x4, 8x1,
dup(8)(?), i(8)(ql0), der(2;8), 9x3, 10x3, 11x3, 12x2, der(12)t(12;15), 13x1,
dup(13)(q?)x2, 14x2, 15x2, 16x2, 17x1, del(17)(?), der(17)t(17;22), 18x1, dup(18)(q?),
der(18;22), 19x3, 20x4, der(20)t(X;20), 21x3, 22x1, der(22)t(7;22)[9]/66, idem, ~
+del(18)(?)[3]/idem, -22, +der(22)t(18;22) [2]
SW480-clone-l: 52~59(mode 58), XX, YxO, lxl, derQ^ljO)*, 2x2, der(2)t(2;12), 3x2,
del(3)(?), 4x2, 5x1, der(5)t(5;20)*, 6x2, 7x2, der(7)t(7;13), der(7)t(7;14), 8x1, der(8;19),
9x1, der(8;9), der(9)t(l;9)*, 10x1, der(10)t(10;12)(3;12), 11x3, 12x1, del(12)(?), 13x3,
14x2, 15x2, 16x2, 17x2, del(17)(q?), 18x1, del(18)(q?), 19x1, der(5;8;19)t(5;19)t(8;19),
20x2, der(20)t(5;20)t, 21x3, 22x2[9]
SW480-clone-2: 88-97 (mode 90), XX, YxO, 1x4, 2x3, del(2)(?), der(2)t(2;12),
der(2)t(2;18), 3x3, 4x3, 5x2, der(5;12), der(5)t(5;20)tx2, 6x3, 7x3, der(7)t(l;7),
der(7)t(7;14)x2, 8x4, 9x3, 10x2, der(10;12)x2, der(10)t(10; 15), 11x3, der(ll)t(ll;15)x2,
12x2, del(12)(?), der(12)t(12;14)t, 13x5, 14x1, der(14)t(12;14)*x2, 15x3, 16x3, 17x4,
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18x1, del(18)(q?)x3, 19x2, der(5;8; 19)t(5; 19)t(8, 19)x4, 20x4, der(20)t(5;20)tx3, 21x5,
22x4[13]
SW620: 45-49 (mode 48), XX, YxO, 1x2, 2x1, der(2)t(2;12), 3x1, del(3), 4x1, del(4),
5x1, der(5)t(5;20)*, 6x1, der(6)t(6;7)t, 7x2, del(7), der(7)t(6;7)t, 8x0, der(8)t(8; 13),
der(8)t(8;17), 9x2, 10x1, der(10)t(10; 13), 11x3, 12x2, 13x1, 14x2, 15x2, 16x1,
der( 16)dup( 16)t(3; 16)t(6; 16), 17x2, 18x1, der(5;18), 19x2, 20x2, der(20)t(5;20)*, 21x2,
22x2[ll]/46~47, idem, -X, +der(X;18), -der(5;18), +del(5)[3]
SW837: 38-40 (mode 38), der(X)t(X;5), YxO, 1x0, del(l)(?), der(l)t(l;8)x2, 2x2, 3x1,
der(3)t(3;l 1), 4x2, 5x2, 6x1, del(6)(?), 7x1, der(7)t(7;19), 8x1, der(8)t(8;17), 9x2, 10x2,
llxl, der(ll)t(l;ll), 12x2, 13x0, der(13;15), 14x2, 15x1, 16x2, 17x1, 18x1, 19x1, 20x2,
21x2, 22x2[7]/idem, +1, -der(l)t(l;8), -2, + der(2)t(2;17), -der(7)t(7;19), +der(7)t(2;7), -
16, +der(16)t(16;20)t, -20, +der(20)t(16;20)t [5]
VAC04A: 61-65 (mode 62), XX, YxO, 1x2, i(l)(qlO), 2x3, 3x2, der(3)t(3;10)(ql0;ql0),
4x2, 5x3, 6x2, 7x4, 8x2, i(8)(ql0)x2, der(8;20)(ql0;?)x2, 9x3, 10x2, 11x3, 12x3, 13x2,
der(13)dup(13)(q?)t(13;15)x2, 14x4, 15x1, 16x2, 17x2, der(10;17), 18x2, 19x2, 20x2,
21x2, 22x2[5]/idem, -der(10;17), +der(4;17)[4]/idem, -X, +der(X)t(X;2)[3]/idem, -9,
+del(9)(q?)[2]/idem, -20, +dup(20)(?)[2]
Typical RER+ cell lines
DLD1: 43-46 (mode 46), XY, dup(2)(pl3p23), der(6)t(6;ll)[14]/ idem, -1, +dup(l)(p?)[4]
GP2d: 45-47 (mode 46), XX, del(3)(?), del(5)(q?), der(6)t(3;6), dup(10)(q?)[12]
HCT116: 43-45 (mode 45), X, YxO, der(10)dup(10)(q?)t(10;16), der(16)t(8;16),
der(18)t(17;18)[18]
LS174T: 46-47 (mode 47), X, +7, +15[14]
YAC05: 43-47 (mode 46), XX[12]/idem, +del(7)(?)[2]/idem, -21, +del(21)(p?)[4]
Atypical RER+ cell lines
LoVo: 48-50 (mode 49), XY, der(2)t(2;12)*, +5, +7, +der(12)t(2;12)*, i(15)(ql0)[12]
HCA7: 42~43(mode 43), der(X)t(X;4)(p22;q25-26)t, lxl, der(l)del(q)t(l;16)(pl3;pl 1.2)*,
2x1, der(2)t(2; 11 )(q 14-21 ;q21 )*, 3x0, del(3)(pl3p21), der(3)t(l;3)(?p36;q27-29)*, 4x1,
der(4)t(X;4)(p22;q25-26)t, 5x2, 6x0, der(6)t(6;7)(q21-22;q31)t, der(6)t(6;18)(ql3-
15;qll.2)*, 7x1,
der(7)t(6;7)(q21 -22;q31 )*, 8x2, 9x1, der(9)t(9;21)(pl2-13;ql 1.2), 10x2, llxl,
der( 11 )t(2; 11 )(q 14-21 ;q21 )*, 12x1, dup(12)(q?), 13x1, 14x1, der(14)t(14;14)(pl 1.2;ql3-
21), 15x1, del(15)(?ql2ql5), 16x1, der( 16)t( 1; 16)(p 13;p 11.2)t( 1 ;3)(p36;q27-29)*, 17x2,
18x1,
der(18)t(6;18)(ql3-15;qll.2)t, 19x2, 20x2, 21x1, 22x2[ 14]/40-45, idem, +2,
-der(2)t(2;ll)(ql4-21;q21), -der(3)t(l;3)(?p36;q27-29), +der(3;14), +6, -der(6)t(6;7)(q21-
22;q31), +7, -der(7)t(6;7)(q21-22;q31), -10, +der(10)t(3;10), +11,
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-der(ll)t(2; 1 l)(ql4-21 ;q21), +14, -der(14)t(14;14)(pll.2;ql3-21),
-der(16)t(l;16)(pl3;pl 1.2)t(l;3)(p36;q27-29), +der(16)t(l;16)(pl3;pll.2)* [7]/ 48, idem,
+der(4)t(X;4)(p22;q25-26)*, +der(7)t(6;7)(q21-22;q31)t, -del(15)(?ql2ql5), +der(15;20),
+der(16)t(l;16)(pl3;pll.2)t, +17, +17, -20, +22[3]
LS411: 70-76 (mode 73), X, der(X)dup(X)t(X;5), YxO, 1x3, del(l), 2x3, 3x3, del(3), 4x3,
5x3, del(5), 6x2, 7x2, dup(7), der(7)dup(7)t(7;12), 8x3, der(8;22), 9x3, del(9), 10x3,
11x3, 12x3, del(12), 13x2, i(13)(ql0), 14x1, i(14)(ql0), 15x3, 16x3, 17x3, del(17), 18x2,
del(18), 19x3, dup(19)(p?), 20x3, 21x1, der(12;21), 22x2, der(6;22)[8]/idem, -del(l),
+del(6), +der(10, 17), -dup(19)[3]/idem, -del(l),
-der(6;22), +dup(6), +der(6)t(5;6), +del( 11 )(q?)[3]
Footnote to Table 3.2:
Representative summary karyotypes of the cell lines as obtained by SKY analysis
and confirmed by single-dye chromosome painting. For the simple diploid lines, DLD1,
GP2d, HCT116, LoVo, LS174T, and VAC05, karyotypes are described according to the
standard ISCN (International System for Human Cytogenetic Nomenclature) (Mitelman,
1995), as deviations from diploid. The more complex karyotypes are presented more
explicitly as: range of chromosomes per metaphase, (mode), content of normal sex
chromosomes, listing of all chromosomes with copy numbers, [number of metaphases with
the given composition]. Additional clones are separated by /. Isochromosomes, deletions
and duplications are reported where they were evident from size changes; and confirmed
by the DAPI image. Breakpoints given for C70, HT29 and HCA7 were judged by
cytogenetic banding analysis of the DAPI image following SKY (cytogenetic identification
of such breakpoints was according to the advice of an expert cytogenticist [Mrs Patricia
Gorman]).
*deletion of 2p at different points with possibility of dup(2)(q?), tentatively
identified as der(13;13)(ql0;ql0)del(ql4q34)t(13;13)(?ql4;?q34), Apparently balanced
translocation.
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Figures 3.1 - 3.18: Karyotypes of the cell lines determined by SKY with confirmation
by single-dye chromosome painting FISH
Illustration of how karyotypes were produced are supplied with C70 and HT29
(Figure 3.1 B, C, D & 3.2 A, B, C) as explained in the text (see 3.2). SKY classified
(pseudo-colour) images of representative metaphases for each of the 17 cell lines are
presented in Figure 3.1- 3.18: C70-a, HT29-d, LIM1863, SW1417, SW403, SW480-clone-
1, SW480-clone-2, SW620, SW837, VAC04A, DLD1, GP2d, HCT116, LS174T, VAC05,
LoVo, HCA7, LS411. These are typical metaphases that may not show all the numerical
or structural changes to chromosomes described in Table 3.2. The HCA7 metaphase
shown represents the most complex clone. The metaphases for C70, SW1417, and SW837
show rearranged chromosomes unique to that metaphase, t(l;2), der(ll)t(X;ll), and
der(5)t(2;5) respectively, and accordingly these are not recorded in Table 3.2. The
chromosomes are shown in classification colours, i.e. each pixel is assigned a colour
representing the chromosome that the software has identified from the fluorescence at that
position. Satellites at chromosomes 13, 14, 15, 21, 22 as well as pericentromeric
heterochromatin (e.g. at chromosome 1) hybridise non-specifically so they are often
miscoloured. Illustrative examples of the single-dye chromosome painting FISH are
shown. Fig 3.1 C70 E shows a whole C70 metaphase hybridised to chromosome 10 green
paint and chromosome 16 red paint showing the rearranged chromosome der(16)t(10;16).
Figure 3.2 HT29 F shows use of chromosome 10 green paint and chromosome 22 red paint
to prove that the chromosome 10 strip, which appears in the translocation derivative
der(22)t(17;22) in Fig 3.1 HT29 D, is just misclassification due to overlap. Fig 3.1 C70 F
shows rearranged chromosome der(17)t(6;17), also shown in Fig 3.1 A, in which the right
image displays SKY identification of this marker showing that overlap of the fluorescence
at the junction between the fragments of chromosomes 6 and 17 creates the fluorescence
spectrum of chromosome 10 such that an artefactual thin stripe of chromosome 10 is
mistakenly assigned to this region by the software. In contrast, left image shows
hybridization with chromosomes 6 paint (red), and 17 paint (green) whereas chromosome
10 paint did not hybridize (not shown). Fig 3.1 C70-G shows C70 rearranged chromosome
der(4)t(4;18) also shown in Fig 3.1 A in which the left image hows the translocation as it
was originally identified as t(l;4) by the software as the fragment of 18 is very small and
its fluorescent signal blends with the adjacent chromosome 4 fluorescence such that the
SKY soft ware mistakenly assigned a fragment of chromosome 1 to this region. In
contrast, right image shows the correct identification of this very small chromosome
fragment using the single-dye chromosome FISH with chromosome 4 green paint and 18
red paint thus establishing it as t(4; 18), whereas chromosome 1 paint did not hybridize.
The same interpretation applies to Fig 2 HT29-E showing the rearranged chromosome
der(2)t(l;2) with the left image showing the overlap at the peri-centromeric region creating
two artefactual strips of chromosome 6 and 10 whereas the right image shows correct
hybridization with chromosome 1 green paint and chromosome 2 red paint whereas
chromosome 6 and 10 paints did not hybridize.
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3.3.2. SKY karyotypes are consistent with previously published cytogenetic karyotypes
The karyotypes of thirteen of these cell lines have previously been analysed by
cytogenetic banding. The SKY karyotypes obtained here are generally consistent with
previously published cytogenetic reports. The matching was high for the simpler
karyotypes. In one instance the difference was clearly due to difference acquired through
further in vitro passaging (LoVo), while in other cases it was due to the SKY revealing the
origin of cytogenetically unidentifiable chromosome pieces. In almost all cases of
chromosomal rearrangements SKY added more information about the nature of the
rearranged chromosomes.
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Table 3.3: Comparison of the SKY profiles with the published cytogenetic reports on
the same lines
Cell line Publication(s) Degree of Matching
HT29 (Yaseen et al., 1990) B (4y,5n,6ui)
LIM1863 (Whitehead et al., 1987) A (5y, On, lui)
SW403 (Chen et al., 1982) B (4y, 5n, 2ui)
SW480 (both clone 1 and 2) (Tomita et al., 1992) A (2 clones identified,
1 ly,ln,l lui)
(Yaseen et al., 1990) B (2 clones not identified,
6y,3n,2ui),
(Chen et al., 1982) C (2 clones not identified,
6y,15n,3ui)
SW620 (Gagos et al., 1995);
(Gagos et al., 1996)
A (7y,3n,3ui)
SW837 (Chen et al., 1982) A (7y, 3n, lui)
DLD1 (Chen et al., 1995) B (ly, On, lui)
GP2D (Solic et al., 1995) B (2y, 2ui)
LS174T (Rutzky et al., 1980) A (normal karyotype)
VAC05 (McBain et al., 1984) A (the almost normal karyotype
with 2 rare markers described)
LoVo (Drewinko et al., 1976) A (2y, On, lui)
(Chen et al., 1982) A (2y, described other rare sets
of markers in addition)





Not described in any of them
(Perry et al., 1999) Just showed pictures without
description of the markers
LS411 (Suardet et al., 1992) A (6y, In, 2ui)
One of three matching bands (A, highly matching; B, moderately matching, C, poorly matching) is assigned
for each publication. For some of these cell lines there is more than one cytogenetic report available, with a
total of 20 cytogenetic reports on 13 cell lines. 11 fall into band A, 5 fall into band B, and 1 falls into band
C. Three cytogenetic attempts to characterise HCA7 by conventional cytogenetics all failed to describe the
balanced translocation profile in this line.
y: marker described partially or completely correctly by cytogenetics, n: marker described completely
incorrectly by cytogenetics, ui: unidentified markers described by cytogenetics which may match one of the
markers fully identified by SKY. The matching bands (A, B, or C) are assigned as follows: band A refers to
lines with greater than one third of the total markers being y and no more than one third of the total markers
being n; band B indicates lines with less than or equal to one third of the total markers being y and less than
or equal to one third of the total markers being n with up to one third being ui; and band C indicates lines
with more than one third of the total markers being n.
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3.3.3 Patterns of chromosomal changes in the cell lines are similar to those of uncultured
tumours as determined by CGH
Samples of all of the 17 colorectal cancer cell lines of similar, or very close, passage
number to those used for SKY analysis were supplied to Dr Kanade Katsura, a colleague in
the same laboratory, for CGH analysis. The CGH profiles of these lines (kindly supplied
by Dr Kanade Katsura) were very similar to those obtained from uncultured primary
colorectal tumours (Figure 3.19). CGH data were compared with published surveys of
primary uncultured material (Ried et al., 1996; DeAngelis et al., 1998; Meijer et al., 1998;
AlMulla et al., 1999; Korn et al., 1999), and RER- tumours and first-pass xenografts of
colorectal cancers (Georgiades et al., 1999; Curtis et al., 2000). Common changes were
very similar, the lines showing frequencies of gain or loss one to two times that in the
primary uncultured material. The only exception was that chromosome 6, particularly 6q,
was lost in 8/9 RER- cell lines, but very rarely lost in primary uncultured material, and
therefore this may be a change selected in culture. The RER+ lines showed few
chromosomal changes detected by CGH the only recurring one being gain of chromosome
7, detected in 3 out of 8 lines. The outstanding feature is the cluster of frequently changed
chromosome arms that are common to the lines and primary tumours: 7+ ,8p-, 8q+, 13+,
17p-, 18-, 20+ (Figure 3.19).
Agreement between the SKY-determined karyotype and chromosomal changes
detected by CGH was good, as expected (Ghadimi et al., 1999; Macville et al., 1999;
Ghadimi et al., 2000). Where chromosomes were unrearranged, the SKY-determined
karyotype independently confirmed the CGH estimate of copy number. For many of the
translocations, the CGH copy number changes complemented the SKY data by suggesting
which parts of the chromosomes were involved in the translocations (Ghadimi et al., 1999;
Macville et al., 1999; Ghadimi et al., 2000). For example, the cell lines with relatively
simple karyotypes, HCT116 had three translocations involving chromosomes 8, 10,16,17
and 18. CGH (Figure 3.20) showed gains of parts of the long arms of 8, 10, 16 and 17, and
no losses identifying these as extra fragments incorporated into the translocations.
Similarly, as already reported by (Ghadimi et al., 2000), DLD1 showed an enlarged
chromosome 2 and a t(6; 11) translocation, and CGH (Figure 3.21) showed regions of
increase, at approximately 2pl3-21 and llpl5. In some metaphases there was also an
enlarged chromosome 1 seen by SKY, and an increase close to lpter was detected by
CGH. In GP2d (Fig. 3.22), CGH showed local loss around the APC locus on chromosome
5, corresponding to the short chromosome 5 in the SKY-determined karyotype, while
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chromosome 3 shows no CGH changes, suggesting that the del(3) and t(3;6) translocation
are balanced. As expected, the balanced translocations in HCA7 was not detected as gains
or losses by CGH (Figure 3.23). Some translocation breakpoints deduced this way were in




Comparison of CGH data between cell lines and (A) primary uncultured tumours including
both RER- and RER+ tumours; and (B) selected RER- tumour xenografts. CGH data are
expressed as percentage of tumours, xenografts or lines showing either gain or loss at a
chromosome arm. Two comparisons have been made. In A, pooled data from studies of
primary uncultured tumours, unselected for RER status (Ried et al., 1996; DeAngelis et
al., 1998; Meijer et al., 1998; AlMulla et al., 1999; Korn et al., 1999), are compared with
data from this study, combining the RER+ and RER- cell lines in the ratio 2:8 to mimic
unselected primary uncultured tumours. In B, data from RER- tumours and first-pass
xenografts (Georgiades et al., 1999; Curtis et al., 2000) obtained in one of our laboratories
using the same CGH criteria as for the cell lines, are compared with the CGH data from the
RER- cell lines. Numbers of changes in RER+ tumours were too small for any meaningful
comparison to be made.
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3.3.4. Comparison of RER+ with RER- karyotypes
Striking differences between the RER+ and RER- tumour cell line karyotypes were
found in terms of both structural and numerical chromosomal changes, as well as
metaphase to metaphase heterogeneity.
3.3.4.1 RER- tumour cell lines
The RER- cell lines (Table 3.2) all had very abnormal karyotypes. They were
usually near triploid or polyploid, always with evidence of double strand breaks in the
form of multiple unbalanced translocations, deletions, duplications, and iso-chromosome
formation. All RER- cell lines had numerous (8 to 21 each) structural chromosome
rearrangements, suggesting tolerance of breakage or inappropriate recombination. The
overwhelming majority of translocations were unbalanced,,as noted before for common
carcinomas (Dutrillaux, 1995; Davidson et al., 2000) and they were also diverse in site.
All chromosomes, except the Y chromosome, were translocated at least occasionally, and
they were translocated to a wide range of partners. No particular translocation, however,
was present in a substantial proportion of the lines: the most frequent was t(8; 17), present
in only three of the lines, but even these may have different breakpoints. t(8; 17) was also
found in some breast carcinoma cell lines; (Davidson et al., 2000).
Almost all the cell lines of RER- tumours had very abnormal modal chromosome
numbers. SW837 had a sub-diploid mode of 38; five cell lines (HT29, LIM1863, SW1417,
SW403, VAC04A) had modes in the range 62-80; SW480 had two clones with modes of
58 and 90; and C70 was near hexaploid (mode 127). Only SW620 had a near-diploid
mode of 48, but it had many structural rearrangements. The chromosomal abnormalities
were scored numerically as indices to allow comparison between cell lines (Table 3.4),
measuring structural chromosomal changes as a break index (BI) and the numerical
chromosomal changes from diploid as a numerical aneuploidy index (NI)—both indices
were versions of those described by Eshleman (1998) (Eshleman et al., 1998).
There was marked metaphase-to-metaphase heterogeneity both for normal and
rearranged chromosomes, suggesting ongoing instability in most of the RER- tumour cell
lines. In this work, it was not possible to distinguish instability from lack of selection
against occasional variants because the lines were not cloned. 8/9 RER- lines had more
than one cytogenetic clone (i.e. two or more identical metaphases) (Table 3.2), and
abnormal chromosomes were commonly observed that were unique to one metaphase
(according to cytogenetic convention they are not recorded in Table 3.2, but they are
described in Appendix 2). The metaphase-to-metaphase heterogeneity was analysed
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quantitatively using two further indices: (1) a numerical heterogeneity index (NHI)
modified from (Lengauer et ah, 1997); and (2) a structural heterogeneity index (SHI) (see
Table 3.4 footnote for more details). The ongoing pronounced inter-metaphase
heterogeneity strongly suggests that errors in chromosome segregation continue to be
repeated during growth, as shown previously (Lengauer et al., 1997). The multiple
examples of abnormal chromosomes that were detected in no more than one metaphase
suggest that this instability is not restricted to non-disjunction, but includes structural
changes that involve chromosome breakage and recombination events. The survival of
colorectal cancer cells with this phenotype implies defective coupling between DNA
breaks and apoptosis.
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Table 3.4: Chromosomal instability indices (NI: numeric index, BI: break index,
NHI: numerical heterogeneity index, SH
RER- Mode NI BI NHI SHI
C70 127 79 14 33 40
HT29 70 27 15 19 30
LIM1863 80 33 9 11 0
SW1417 70 22 22 13 120
SW403 64 21 14 20 10
SW480 58&90 49 24 43 ND
SW620 48 8 15 10 30
SW837 38 7 13 16 40
VAC04A 62 20 10 14 30
Mean 19.4 15 19.9 40
RER+ (typical)
DLD1 46 0 3 1 0
GP2D 46 0 4 1 0
HCT116 45 1 3 1 0
LS174T 47 3 0 1 0
VAC05 46 0 2 5 0
Mean 0.8 2.4 1.8 0
RER+(Atypical)
LoVo 49 3 3 2 0
HCA7 43 2 21 17 50
LS411 73 29 21 15 90
structural heterogeneity index)
The numerical index (NI) of chromosomal changes (aneuploidy index), was calculated for each
line, using a metaphase with modal chromosome number, by assigning one point for each gain of a
whole normal chromosome from diploid, and for each loss that was not replaced by a translocation,
[modified from (Eshleman et al., 1998)]. The break index (BI) was calculated as the total number
of structurally abnormal chromosomes, clonally present (found in 2 or more metaphases), in each
line. Duplicate abnormal chromosomes were counted only once. The numerical heterogeneity
index (NHI) for a cell line was calculated by calculating the percentage of metaphases whose
content of a particular chromosome deviated from the mode for all chromosomes in 12-24
metaphases and averaged. Since each structurally distinct chromosome was examined, the values
tend to be higher than those obtained for centromere number (Lengauer et al., 1997). The
structural heterogeneity index (SHI) was devised here and was calculated as the total number of
structurally abnormal chromosomes found in only one metaphase, divided by the number of
metaphases examined and then expressed as a percentage.
N.B. SW480 has two clones, mode 58 and 90 with NI respectively 13 and 49, but the indices were
calculated for this line as one line disregarding the constituent clones to allow comparison with
other lines. ND: the SHI was not determined for SW480 because the technical complexity
involved in distinguishing the two different clones precluded an accurate e assessment of SHI.
High metaphase heterogeneity in VAC05 is mainly due to the presence in some metaphases of
deleted 7 and 21. The high numerical index for C70 appears to be due to an endoreduplication
event, but the index does not indicate this directly.
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3.3.4.2. RER+ tumours
The majority of the RER+ lines had striking karyotypic stability; they had fewer
abnormal karyotypes than the RER- lines, both by structural and numerical criteria. Five
of eight RER+ lines were nearly or exactly (VAC05) diploid, with a maximum of four
detectable chromosomal changes (including gains or losses of whole chromosomes,
deletions and translocations). A sixth, LoVo, had only three numerical and three structural
changes. The translocations, although fewer, appeared as varied in site as in the RER-
lines. However, two RER+ lines, HCA7 and LS411, were strikingly different, with
multiple abnormalities, much more like the RER- group.
3.3.4.3 The indices show a clear separation oftypical RER+ and RER- tumours,
The indices showed a clear separation of typical RER+ and RER- tumour cell lines,
with no overlap between the groups, providing the two atypical lines, HCA7 and
LS41 lwere exclude from the RER+ group. The break indices ranged respectively from 0
to 4 and 8 to 24; the numerical aneuploidy index ranged from 0 to 3 and 7 to 79; the
numerical heterogeneity index ranged from 1 to 5 and 10 to 43, and the structural
heterogeneity indices were uniformly zero in the typical RER+ group but ranged from 0 to
120 in the RER- group.
3.3.5. Atypical RER+ lines
LS411 and HCA7 demonstrated two novel patterns of genomic instability. Both
stood apart from other RER+ lines as 'atypical RER+' lines.
3.3.5.1. LS411: an RER+ line displaying a pattern similar to the RER- group
LS411 displayed all the chromosomal instability features of the RER- group, as
shown by the indices in Table 3.4, while also exhibiting the classic RER+ phenotype,
including microsatellite instability and hMLHl gene mutation and promotor
hypermethylation (Wheeler et al., 1999). This RER+ status of LS411 was reconfirmed on
the same stock that has been karyotyped. Furthermore, LS411 was biologically like other
RER+ tumours—a poorly differentiated adenocarcinoma in the caecum from a young (32-
year-old) patient, who was alive 5 years after surgery (Suardet et al., 1992). The SKY
karyotype was recognisably similar to that originally reported using cytogenetics (Suardet
et al., 1992), and the cell stock used in this work was the same as that used by Wheeler et
al (Wheeler et al., 1999), so it is highly unlikely that an error of sample identification
occurred. Possible explanations of the LS411 phenotype would be (a) that there can be
selection for both kinds of genomic instability during the development of colorectal
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malignancy, or (b) that a tumour with chromosomal instability was treated with a cytotoxic
drug such as cisplatin that selects for survival of tumour cells with mismatch repair
deficiency (Aebi et al., 1996; Drummond et al., 1996; Fink et al., 1997; Fink et al.,
1998b). The latter explanation seems less likely given the available clinical data.
3.3.5.2. Atypical RER+ cell lines predisposed to balanced translocations: HCA7 and
LoVo
HCA7 showed a striking, previously undiscribed phenotype: it demonstrated
multiple, apparently balanced, reciprocal translocations. This was unexpected in
carcinomas, as the great majority of translocations were unbalanced and so result in loss or
gain of whole segments of chromosomes, as reported in classical banding studies (Bardi et
al., 1995; Dutrillaux, 1995), and confirmed by FISH (Ghadimi et al., 1999; Davidson et
al., 2000; Ghadimi et al., 2000). In the present study, the translocations in the other lines
were almost all non-reciprocal: out of approximately 160 identified by SKY not more than
four contained the same two chromosomes and so could have been reciprocal, although a
few reciprocal events could have been missed if the translocated fragment was too small
(Elghezal et al., 1999; Fan et al., 2000).
HCA7 is also distinctive in showing a high metaphase-to-metaphase heterogeneity
(NHI of 17 and SHI of 50) and break index (21), but limited numerical changes from
diploid (NI of 2), that is it appears to be an unstable karyotype that has acquired a large
number of structural changes but nevertheless has managed to retain an almost diploid
number of chromosomes, though this is in large part merely a reflection, in the numerical
score, of the tendency to balanced translocations.
Twenty-one rearranged chromosomes were found in HCA7 that were present in 2
or more metaphases, of which 12 are the partners of 6 balanced translocations. Three
related clones were identified in HCA7 in this work. The predominant clone contained all
the 6 balanced translocations, and what appeared to be the stem clone contained 3 of them.
Interstitial deletions, duplications, or a few unbalanced translocations accounted for 9/21
abnormal chromosomes, but only 3 out of these 9 are common to all three clones.
Previous cytogenetic analyses failed to uncover these balanced translocations (Kirkland,
1985; Kirkland & Bailey, 1986; Perry et al., 1999). This cell line has previously been
reported to have multiple, biologically and karyotypically different sub-clones (Marsh et
al., 1993).
LoVo may also belong in this group that preferentially acquires balanced
translocations, although its indices are typical for RER+ lines. It had only one balanced
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translocation in the passage we examined, but there is evidence of a tendency to balanced
translocations, since cytogenetic banding analysis of another sample by Soulie et al (1999)
showed two additional balanced translocations, which must have been acquired on
passage, with no unbalanced rearrangements.
3.3.6. SW480, SW620 and clonal heterogeneity
The lines SW480 and SW620 were derived respectively from a primary tumour of
the colon and lymph node metastasis from it. SW480 comprises two very different clones,
which have different culture behaviour, morphology and in vivo aggressiveness as well as
different karyotypes (Tomita et al., 1992). The karyotypes of these two lines are displayed
as deviations from the normal diploid karyotype in table 3.5.
The three clones illustrate how the parent tumour might have evolved. All three
clones are clearly derived from a common clone, containing what is presumably a
reciprocal t(5;20), and a non-reciprocal t(2; 12) (absent from the particular clone-2
metaphase in Figure 3.7), but have evolved separately almost beyond recognition. SW480-
clone-1 and clone-2, but not SW620, have a t(7; 14) while SW620 has a reciprocal t(6;7)
suggesting that these cells share the break point at chromosome 7q but join up with
different chromosomes in the process of translocation. The two clones of SW480, but not
SW620, have a complex translocation t(5;8; 19) which is not represented at all in SW620
even by the presence of breaks at the same points in these chromosomes.
Comparison of the karyotypes of SW480 (from the primary tumour) with SW620
(the metastasis) does not suggest any candidates for association with the process of
metasasis. Although, as noted by others (Gagos et al., 1995; Bardi et al., 1997; Melcher et
al., 2000), new breaks and gains involving chromosome 13 and 16 (Table 3.5) wer found.
However, another metastatic tumour, LoVo, does not show such changes, but rather shows
t(2; 12) in common with SW620 and its primary (SW480).
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Table 3.5
Deviation from normal diploid karyotype in SW480 and SW620
chr SW480: clone-1 SW480: clone-2 SW620
1 -l,+der(l)t(l;9)* +1.+1
2 +der(2)t(2;12) +2,+del(2)(?),+der(2)t(2; 18) -2,+der(2)t(2;12)
/ der(2)t(2;12)
3 +del(3) +3 -3,+del(3)
4 +4 -4,+del(4)
5 -5,+der(5)t(5;20)* +der(5)t(5;20)*x2, -5,+der(5)t(5;20)*
+der(5; 12)t(5; 12)
6 +6 -6,+der(6)t(6;7)*
7 +der(7)t(7; 14),+der(7)t(7; 13) +7,+der(7)t(7; 14)x2 +del(7),+der(7)t(6;7)*




10 -10,+ der( 10)t( 10; 12)(3; 12) +der( 10; 12)t( 10; 12)x2, -10,+der( 10)t( 10; 13)
11 +11 +11 ,+der(11 )t(11; 15)x2 +11
12 -12,+del(12) +del(12)(?),
13 +13 +13,+13,+13 -13
14 -14,+der( 14)t( 12; 14)x2
15 +15
16 +16 -16,+
der( 16)dup( 16)t(3; 16)t(6; 16)
17 +17,+17, -17
18 -18,+del( 18)(q?)x2 -18,+del( 18)(q?)x3 -18,+der(5; 18)t(5; 18)
19 -19,+der( 19)t(5; 19)t(8,19) +der(19)t(5;19)t(8,19)x4




Y -Y -Y -Y
Total 58 90 48
Recorded here are the modal chromosome copy number and structural alterations obtained by the
analysis of 12-24 metaphases. Empty spaces indicate that no chromosomal aberrations were found
Markers with a modal number of 0 are not recorded here. *: apparently reciprocal translocations.
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3.3.7 Overall patterns of cell lines are like those of fresh surgical materials
These molecular and cytogenetic analyses add to the evidence that cell lines are
acceptable models of the genomic abnormalities of authentic colorectal cancers. CGH is
equally applicable to cell lines and uncultured cancers, and the cell lines show the typical
gains and losses seen in uncultured cancers, as noted by others (Ghadimi et al., 2000). The
gains and losses seen in uncultured material were often present at higher frequency in the
cell lines. This is likely to be partly due to the masking of changes in surgical material by
contaminating normal cells (such as stromal connective tissue, blood vessels and
lymphocytes, ect), and may also reflect a relative lack of cell lines representing the subset
of RER-tumours that have few imbalances (Georgiades et al., 1999). The
SKY-determined karyotypes of these cell lines also broadly showed the abnormalities
described in classical cytogenetic studies on uncultured colorectal tumours (Bardi et al.,
1995; Dutrillaux, 1995), for example a high frequency of loss or rearrangement of
chromosomes 17 and 18; rearrangement of 1 and 8; and gains of 7, 13 and 20. The cell
lines appear more rearranged, but this is in part because classical cytogenetic studies
sometimes miss or can not interpret correctly certain chromosomal abnormalities
(Adeyinka et al., 2000) and primary cultures may select cells that do not fully represent the
malignant tumour (Mertens et al., 1992). Thus, the colorectal cancer cell lines appear to
carry the genetic changes found in authentic colorectal cancers; are reasonably
representative of these tumours; and any additional changes they have acquired in vitro are
not extensive enough to obscure the changes acquired in vivo before culturing. Similar
conclusions have been drawn for other tumours, including breast tumour cell lines
(Kallioniemi et al., 1994; Davidson et al., 2000).
3.3.8. Multiple patterns of abnormalities of the karyotype
The initial hypothesis under investigation was that there are different forms of
chromosomal instability, generated by different kinds of genomic instability present in
colorectal cancers. This is well established from comparison of RER+ and RER-
colorectal cancers but it is likely, as suggested already (Lengauer et al., 1997), that this
may only be an association: tumours that are RER+ are less likely to have all the defects in
genomic housekeeping that lead to the more extreme karyotypic changes, but there is no
obligatory relationship between RER status and pattern of chromosomal rearrangements.
The data obtained in this thesis are consistent with this. While the data confirm that RER-
tumour cell lines tend to have very abnormal karyotypes and RER+ lines tend to have
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near-normal karyotypes, this appears to be only a negative association between defects in
mismatch repair (RER+) and other causes of chromosomal instability. Two RER+ lines
had major chromosomal rearrangements: LS411 is derived from a classical RER+
right-sided colorectal carcinoma but shows a range of structural and numerical
abnormalities, and metaphase-to-metaphase heterogeneity, that are very similar to those
found in members of the RER- group. HCA7 also has a large number of structural
rearrangements, but has fewer numerical changes and has many balanced translocations.
Several different patterns of abnormal of karyotype pattern are suggested by the
data obtained in this work, which may correspond to different defects in genomic
housekeeping. Some of them have been previously described in the cytogenetic literature
(Bardi et al., 1995; Dutrillaux, 1995). First, there is the near-normal diploid cell line,
VAC05. Second, there are tumour cell lines that show predominantly or exclusively gains
of whole chromosomes: LS174T has gained chromosomes 7 and 15, and lost a
presumably inactive X. Third, there are three RER+ lines—DLD1, HCT116 and GP2d—
that have no net numerical changes (apart from loss of the Y chromosome in HCT116) but
have a few structural changes. Several of the structural changes, indeed all in DLD1 and
HCT116, lead to the acquisition of additional chromosome fragments. These lines are all
RER+, but CGH data on freshly excised colorectal carcinomas suggest that there may be
RER- tumours that have similarly near-diploid karyotypes (Georgiades et al., 1999).
The more obviously abnormal karyotypes seem to fall into four patterns. The most
striking and novel phenotype is exemplified by HCA7: an apparent strong tendency to
acquire balanced reciprocal translocations, in sharp contrast to the overwhelming majority
of chromosomal translocations that have been described in solid tumours. Its phenotype is
also intermediate between RER+ and RER- tumours in that it shows: many structural
chromosomal changes but almost diploid karyotype. LoVo appears to show this same
pattern of balanced translocations with near-diploid karyotype.
The majority of the cell lines with very abnormal karyotypes—HT29, LIM1863,
SW1417, SW403,VACO4A (all RER-), and LS411 (RER+) are surprisingly similar in
overall tendency to acquire large numbers of numerical and structural chromosomal
abnormalities, provided the precise chromosomes involved are not considered: they have
near-triploid karyotypes with 9-22 rearranged chromosomes, and most chromosomes are
present in 3 copies. This pattern of extensive chromosomal instabilities with near-triploid
karyotypes (multiple trisomies) seems to be the most common amongst colorectal
carcinomas. Two further phenotypes were observed, though whether they are samples of a
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continuous spectrum or truly distinct categories remains to be seen. SW837 has many
unbalanced structural changes and shows considerable metaphase-to-metaphase variation,
yet has retained almost diploid numbers. This suggests that it may not tolerate or generate
extensive numerical changes in the way that other lines do. Finally, C70 appears to have
an extreme tendency to gain whole chromosomes, with up to 9 copies of certain
chromosomes, although this is in part because it appears to have reduplicated its entire
complement of chromosomes—which appears to have been similar to the commonly seen
near-triploid pattern—at least once.
3.3.9. Evolution of abnormal karyotypes
Most of these colorectal cancer cell lines karyotypes are consistent with evolution
by a process of a steady gain of chromosomes, with or without endoreduplication,
consistent with the previously described CIN phenotype (Lengauer et al., 1997). This
process of steady gain of chromosomes appears to occur with-or without accompanying
chromosomal translocation. LS174T has simply gained whole chromosomes 7 and 15.
HCT116 and DLD1 clearly show gains of chromosome fragments present as fragments
making up the translocated chromosomes, and there are no chromosomal losses.
Surprisingly few, if any, of the lines studied here show the patterns described by
Dutrillaux and co-workers (see Chapter 1, Introduction: 1.4.6.1). Only SW837 may show
monosomic type (MT) karyotype, and one (C70), or possibly two (SW480-clone-2) show
several duplicated markers, as expected for a line that have undergone endoreduplication.
However, C70 may have endoreduplicated its entire chromosome complement from a
super-diploid rather than sub-diploid state as has been suggested for a typical trisomic type
(TT) karyotype. Several of the substantially super-diploid, RER- lines show no sign of
endoreduplication, which would usually leave a signature in the form of several duplicated
abnormalities, as in C70. Rather they appear to have evolved by accumulation of
chromosomes, and C70 resembles such a line that has accumulated chromosomes and then
duplicated its entire chromosome complement to become a super-tetraploid. On the other
hand, many of the lines studied here, including almost all of the RER- lines, could be
considered to show a TT-like pattern: presence of translocations accompanied by gains of
chromosomes. Occasional abnormal chromosomes are duplicated, but if the lines gain
whole chromosomes this is to be expected. Therefore the overwhelming majority of these
lines appear to have karyotypically developed by gradual accumulation of additional
chromosomes usually accompanied by some chromosomal translocation events, while
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there is an absence of the chromosome loss-followed-by-endoreduplication pattern
common in breast cancers.
3.3.10. Mechanisms underlying chromosomal changes
3.3.10.1. p53 status
In contrast to RER status, mutation in p53 did not appear to correlate with the
patterns of karyotypic abnormality in these lines (Table 3.1). It is possible that the p53
mutation analysis does not detect all p53 abnormalities and conversely, absence of p53
mutations does not prove that the cells have wild type p53. However, there are data in the
published literature on some of these lines that confirm their p53 status using other
techniques such as the p53 yeast functional assay (see table 3.1 for references). Two out of
five lines in the typical RER+ category (DLD1, VAC05) carried mutations in p53 but their
karyotypes did not show noticeably more numerical or structural chromosomal changes
than cell lines with apparently wild-type p53 within the RER+ group. Similar data were
recorded previously (Eshleman et al., 1998). On the other hand there is a group of four
out of nine RER- cell lines that have no p53 mutations (C70, LIM1863, SW1417,
VAC04A) all of which show all forms of numerical and structural chromosomal
instability. The atypical RER+ line, LS411 is also p53 non-mutant. This suggests that loss
of p53 function by itself does not determine the pattern of chromosomal instability. It
appears that loss of p53 is not necessary for generation of chromosomal instability, but the
lines with no detectable p53 mutations may have an unknown equivalent abnormality such
as the mdm2 aberrations. It has been shown however that transfecting a mutant p53
expressing construct into LoVo altered the pattern of chromosomal changes found in
clones selected for gene amplification from this line from numerical to structural
chromosomal instability. While the original LoVo with its wild type p53 showed gain of
whole chromosome 2, transfecting mutant p53 into this cell line was associated with
chromosomal structural rearrangements leading to gain of chromosome 2 material (Soulie
et al., 1999). Overall, abnormalities of the p53 by itself appear to be neither necessary nor
sufficient for chromosomal instability although they may be permissive.
3.3.10.2. The predisposition to balanced translocation may be a consequence ofthe
RER+ phenotype.
The predisposition to balanced translocation observed in HCA7 and LoVo was
found only in RER+ tumour cell lines and therefore may be a consequence of the RER+
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phenotype. One possible explanation for a predisposition to balanced translocations would
be that when these lines suffer double strand breaks, a homeologous (in contrast to
homologous) recombination repair process is triggered with a similar but not identical
DNA sequence on another chromosome. RER+ cells are defective in mismatch repair, and
such cells are known to be more prone to recombination repair between imperfectly
matching, homeologous sequences (de Wind et al., 1995; Schimenti, 1999). Some
translocations would be unbalanced if one product of the translocation does not contain a
centromere (Jasin, 2000). An underlying cause generating high levels of chromosomal
double strand breaks would be required as well (Ricardson & Jasin, 2000). It may be
possible that DNA single strand breaks during DNA replication may generate balanced
translocations as well. The high tendency to translocation in RER- cells is likely to occur




In summary, this study has identified, in detail, patterns of chromosomal instability
in a group of well-established colorectal cancer cell lines. It has emerged that distinct
chromosomal instability patterns characterize these tumours. Whilst the majority,
near-triploid (or multiple-trisomic) type is usually RER-, occasional RER+ lines show the
same pattern. This is to be expected if the underlying defects are selected for during
tumour evolution, since more than one defect of genomic instability may be selected. SKY
has also revealed the existence of a new type of instability that has a striking tendency to
acquire balanced translocations in contrast to the common patterns previously described in
solid tumours. The relationship of chromosomal instability to the mismatch repair
deficiency and/or p53 status has been investigated. RER status correlates with, but does
not determine, the pattern of chromosomal rearrangements. p53 abnormality itself is
neither necessary nor sufficient for chromosomal instability, although it may be
permissive. Other possible mechanisms underlying these karyotypic patterns have been
discussed. These instabilities appear to give rise to repeated and ongoing genomic
alterations, albeit constrained in type, presumably reflecting deficient pathways for
recognition and removal of the altered cells by apoptosis. Therefore, it will be of interest
to examine the relationships between drug resistance and sensitivity profiles and these
different patterns of genomic instability. In addition, the comprehensive karyotypic
information provided here on these colorectal cancer cell lines should serve further






Many proteins with an established role in carcinogenesis and cancer progression
feature in apoptosis pathways. Thus p53, pRb, c-Myc and members of the Bcl-2 and Ras
protein families, as well as many viral oncoproteins such as LMP-1 and E1B 19K are all
potent regulators of apoptosis (reviewed by Arends et al., 1993; Hale et al., 1996; Wyllie,
1997). The hypothesis has therefore arisen that loss or reduction of susceptibility to
apoptosis may be a significant factor in carcinogenesis and tumour progression (Arends &
Wyllie, 1991; Evan et al., 1992). Data from genetically manipulated animals show that
oncosuppressor deficiency may abrogate the apoptosis of cells that have sustained DNA
damage, thus permitting survival and proliferation of cells bearing mutations (Griffiths et
al., 1997). Furthermore, there is increasing evidence to support a role of apoptosis in
maintaining genomic stability. Recent studies indicate that there is a default apoptotic
pathway in mitosis that needs to be overcome for the process to be completed (Li et al.,
1998; Altieri & Marchisio, 1999; Li et al., 1999). Apoptosis is widely observed in
tumours, however, indicating that changes to the susceptibility to induce apoptosis - if
important in carcinogenesis - must be restricted to particular pathways. Clear
identification of these pathways in human tumours becomes an important aim, as it would
help define the molecular basis not only of carcinogenesis, but also of tumour resistance to
various therapeutic measures.
The Fas receptor is a key molecule in the induction of apoptosis (Itoh et al., 1991;
Oehm et al., 1992). Active Fas receptor appears to be necessary for apoptosis initiated by
wide variety of stimuli including c-Myc protein expression (Hueber et al., 1997) and
exposure to DNA-damaging chemotherapeutic agents (Muller et al., 1997). Recent data
showed that Survivin confers resistance to Fas-mediated cell death (Suzuki et al., 2000),
thus linking resistance to Fas-mediated apoptosis to disturbances in cell cycle and mitotic
spindle, possibly by leading to survival and proliferation of genetically unstable cells
(Suzuki et al., 2000).
Fas protein is constitutively expressed in normal colorectal epithelium and most
colorectal adenomas, but in only a minority of carcinomas (Moller et al., 1994). During
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colorectal malignant transformation, it appears that the constitutive Fas-positive phenotype
can change to an inducible INF-y/TNF-a-sensitive Fas-positive phenotype or to stable,
clonal deficiency in Fas expression (Moller et al., 1994). The mechanism responsible for
these changes has not been established, however, so a series of RER+ and RER- colorectal
cancers were analysed for Fas gene mutations.
Recently, clonally expanded, inactivating mutations in Bax have been observed in
RER+ colorectal cancers, together with evidence for under-expression of the Bax protein
in these tumours (Rampino et al., 1997; Ouyang et al., 1998; Yagi et al., 1998; Yamamoto
et al., 1998). This provides some circumstantial evidence for the hypothesis that the
founder cells of cancers may arise, at least in part, through selective loss of a critical death
pathway. Alternative explanations for the Bax mutations exist, however. These mutations
are restricted to tumours with MMR deficiency, and usually occur in a tract of eight
consecutive deoxyguanosines [(G)8] in the third coding exon (Rampino et al., 1997).
Since this is a classical target site for nucleotide mismatch, it is possible that mutations
within [(G)8] simply reflect the well-recognised effect of MMR deficiency on mutation
incidence in tandem repeat microsatellite sequences. The same argument applies as well to
mutations of the [(A) 10] tract described in TGFfiRII during colorectal carcinogensis
(Myeroff et al., 1995; Parsons et al., 1995), and to Bik, another potent death-inducing
protein of the Bcl-2 family (Boyd et al., 1995; Han et al., 1996). The significance of Bik
expression in colorectal carcinogenesis has not been explored hitherto.
Therefore, the genes encoding Bik as well as Fas proteins were studied in a series
of RER+ and RER- primary colorectal carcinomas, in an attempt to determine the
frequency of occurrence of mutations in these apoptosis promoting genes in the process of
human colorectal carcinogenesis. Furthermore, Bax and TGFfiRII mutations were studied
in a series of RER+ colorectal cancers, each tumour sampled at multiple sites. The basis
for such heterogeneity studies is that genetic changes that are critical for carcinogenesis are
likely to be shared by all cells in the expanding tumour and should therefore be detectable
at all sites throughout the tumour. In contrast, changes that reflect the genomic instability
of malignant cells, but are not essential for the transition to malignancy, might be expected
to occur in some but not all of the divergent subclones within a given cancer.
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4.2.Materials and Methods
4.2.1 Fas and Bik mutation analysis
All of the samples of DNA extracted from a range of sporadic colorectal cancers
were tested for microsatellite instability at a number of loci ranging from 5-11 (D2S119,
D2S123, D3S1293, D8S282, D13S160, D15S132, D17S849, D18S58, TGFpR-II, BAT26,
BAT40) (see Chapter 2 for details). The BAT26 was always included because it is known
to be highly unstable and is claimed to be highly informative for establishment of RER
status (Hoang et al., 1997; Stone et al., 2000). A minimum of 5 microsatellite loci was
examined in each case and cases were classified as RER+ if they showed instability at one
or more microsatellite loci. Following this analysis of RER status 12 RER+ and 12 RER-
colorectal cancers were selected for Fas and Bik mutation analysis. Ten out of the 12
RER+ cases demonstrated shifts at two or more microsatellite loci and 2 out of the 12
RER+ cases demonstrated shifts at only one locus. Primers were constructed from the
intronic or non-coding regions surrounding all of the nine exons of the Fas gene to allow
analysis of exonic and, where possible, splice site sequences (Table 4.1). Splice junction
and intronic sequences were retrieved from the GenBank database (accession numbers
X81335-X81342). DNA from both tumour and normal tissue samples of each case were
used for polymerase chain reaction (PCR) amplification of all the Fas gene exons. Exon 9
was amplified in two overlapping fragments (91 & 911). The PCR products amplified by
these primers ranged in size from 108 to 282 base pairs (Table 4.1).
The Bik gene was examined less comprehensively, focusing on a potential target
site for mismatch repair deficiency mutations: an interrupted trinucleotide repeat tract of
11 CTG [(CTG)2 GCG (CTG)5 GCG (CTG)3 CCG CTG] occupying positions 409-450
included within the coding gene sequence (GenBank database accession number U34584).
The PCR primers and amplification conditions are listed in Table 4.2.
The PCR products were tested for mutations using single strand conformation
polymorphism (SSCP) analysis. Heteroduplex analysis was performed on the Fas exon 5
PCR products for all 24 cases, as these samples showed a banding pattern that proved
difficult to resolve by SSCP. Whenever tumours showed aberrantly migrating bands by
SSCP or heteroduplex analysis, then their corresponding tumour and normal DNA were
directly sequenced using a modified dideoxy chain termination method (sequenase version
2.0).
The p53 protein accumulation status of the samples was established by
immunohistochemistry using antibody DO-7 at a dilution 1:100.
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Table 4.1: Fas (Apo-l/CD95) gene PCR primers and conditions
Exon Primers (5'-3') primer Ta Mg ion DM PL

























56°C 1.5 mM 5 pi 144






55°C 1.5 mM - 169











55°C 2 mM - 282
Note: Ta=temperature of annealing, DMSO=dimethyle sulphoxide, P L=product length.








GGGTCCTGGGTGTCCTGCGAACAGG 12.5 pM 63 °C 2 mM 5 pi 121
CGCCTGAGCCGCCGGGGGCTCACTT 12.5 pM
TGPRII [(A)10] tract
CCTCGCTTCCAATGAATCTC 12.5 pM 58°C 3 mM 5 pi 267
TTGGCACAGATCTCAGGTCC 12.5 pM
Box [(G)8] tract
ATCCAGGATCGAGCAGGGCG 20 pM 55°C 1.5 mM 5 pi 94
ACTCGCTCAGCTTCTTGGTG 20 pM
Note: Ta=temperature of annealing, DMSO=dimethyle sulphoxide, P L=product length.
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4.2.2 Box and TGFBRII mutation analysis
Sixty tumours, sampled at multiple sites, were originally screened for microsatellite
instability and only RER+ cases were analysed for Box and TGF/3RII gene mutations. All
the samples were tested at five microsatellite loci including the highly unstable BAT-26
locus. The other 4 loci included TGF(3RII, L-myc, D2S123, and D13S160 (see Chapter 2
for details).
Twelve RER+ cases with a total of 45 different tumour sites and the matched
normal tissue constituted the material for Box and TGF/3R1I gene mutational analysis. The
[(A) 10] repeat in exon 3 of TGF(3 RII was PCR-amplified using the primers and conditions
described in Table 2.2, then the PCR products were analysed for mutations using SSCP. A
DNA segment of 94-base pairs encompassing the [(G)8] tract in Box was PCR-amplified
using the primers and conditions described in Table 2.2. The PCR products were
•3-3
radioactively labelled through primer end-labelling with [y- P]ATP using T4
polynucleotide kinase (see chapter 2 for details). The radio-labelled products were
electrophoretically separated in denaturing 6% polyacrylamide gel and subjected to
autoradiography for detection of band shifts. At the same time, all the original PCR
products were directly sequenced with Thermosequenase radiolabeled terminator cycle
sequencing kits (Amersham Life Science).
Tumours were always analysed for mutations along with their matching normal
mucosae to supply negative controls. This was useful in excluding polymorphisms
observed particularly in the Fas gene exon 2. Known mutant sequences of similar




4.3.1.Fas and Bik mutation analysis
4.3.1.1.Clinico-pathological data and RER status
The 24 cases selected for this study were classified into 2 groups according to their
RER status. The RER+ group included 10 cases that showed microsatellite instability at a
number of loci ranging from 2-6 (Figure 4.1, Table 4.3). In this group 9/10 tumours were
right sided, 9/10 showed poor or mucinous differentiation, and 4/10 were positive for p53
accumulation determined by immunohistochemistry. In a further 2 tumours (nos. 11 & 12,
one left- and one right-sided cancer) only one of the 5 interrogated microsatellite loci
exhibited instability. Both were positive for p53 accumulation as determined
immunohistochemically, and one included areas of mucinous differentiation. The RER-
group (Table 4.4) included 12 cases, which did not show mutations at any of the 5-11
microsatellite loci examined. Only 3/12 were right sided, 3/12 showed mucinous or poor
differentiation and 9/12 were p53 positive immunohistochemically.
4.3.1. 2. No mutations in Fas or Bik
On searching the coding sequence of the Fas gene for nucleotide repeat tracts
several were found. There is a [(T)7] tract in exon 4 occupying positions 397-403, an
[(A)6] tract in exon 9 occupying positions 895-900 and a [(T)5] tract in exon 3 occupying
positions 288-292 in the coding gene sequence (obtained from the GenBank database
accession no. M67454). In addition, there are shorter nucleotide repeat tracts scattered
throughout the Fas gene. The Bik gene contains a potential target site for microsatellite
mutator phenotype induced mutations, an interrupted trinucleotide repeat tract of 11 CTG
[(CTG)2 GCG (CTG)5 GCG (CTG)3 CCG CTG] occupying positions 409-450 inclusive
in the coding sequence (obtained from the GenBank database accession number U34584).
PCR-SSCP was selected as a primary screening method because it can detect all types of
mutations with a sensitivity of 80%-90% including those associated with the mutator
phenotype at microsatellites.
There was no evidence of mutation in any of the 24 cancer or normal mucosa
samples examined either in all the Fas gene exons, or in the target repeat sequence in the
Bik gene (representative examples are shown in Figure 4.1).
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4.3.2. Heterogeneity studies for Box and TGFBR1I mutations
4.3.2. l.RER characterisation
Twelve out of 60 patients (20%) demonstrated microsatellite instability (Table 4.3).
In some cases (nos. 17, 27, 52, 53 and 55) individual tumour sites from the same
carcinoma demonstrated different sets of mutations at the five microsatellite loci tested. In
some tumours, biopsies from different sites each exhibited different mutations at the same
microsatellite locus (Figure 4.2). However, in no case was microsatellite instability
present at one tumour site, and completely absent at all tested loci in others. Hence it was
possible to classify all sampled sites of all tumours as RER+, although in 2 tumours (nos.
18 & 22) the instability was evident in only one of the five tested loci.
4.3.2.2.Bax shows two patterns ofmutations, but TGFflRFI shows a single pattern
Mutation in the Bax [(G)8] mononucleotide repeat tract occurred in six out of 12
(50%) RER+ tumours: in five, this involved loss of a repeated nucleotide and in one a gain.
Four showed a homogenous pattern, with identical changes in [(G)8] detected in all sites
sampled from each carcinoma (Figure 4.2 and Table 4.5). In the other two cases,
however, [(G)8] Bax mutations were present in some but absent in other sites from the
same cancers. Thus, case number 17 showed mutation in tumour sites A and B, but not C
and case number 25 showed mutations in A, B and D but not C (Figure 4.2 and Table 4.5).
In both these cases, the tumour site in which Bax [(G)8] was unchanged showed
unequivocal evidence of instability at most of the other tested microsatellite loci. It should
be emphasized that all samples from individual cases were taken from single tumours (not
from multiple tumours).
In contrast, TGFfRII mutations were found in 9/12 cases (75%) and in each of




Clinical and pathological data and p53 status of the RER+ cancers for Fas and Bik
mutation analysis
no age sex site in large Dukes' histology p53 shifted death genes
intestine stage stain loci mutations
1 67 F sigmoid (Lt) B adenocarcinoma + 2/6 no mut
2 63 F transverse (Rt) B mixed (ad/muc) - 6/7 no mut
3 69 M caecum (Rt) B mixed (ad/muc) - 5/5 no mut
4 74 F ascending (Rt) C mixed (ad/muc) - 5/7 no mut
5 64 F ascending (Rt) B mixed (ad/muc) - 5/5 no mut
6 66 F ascending (Rt) C mixed (ad/muc) + 3/5 no mut
7 69 F ascending (Rt) B poorly dif. + 3/11 no mut
8 49 F caecum (Rt) C mixed (ad/muc) - 3/6 no mut
9 49 F ascending (Rt) B mixed (ad/muc) - 5/5 no mut
10 75 F ascending (Rt) B poorly dif. + 5/5 no mut
11 49 M rectum (Lt) B adenocarcinoma + 1/5 no mut
12 75 M caecum (Rt) B mixed (ad/muc) + 1/5 no mut
Note: shifted loci refers to the number of microsatellite loci showing "shifted" or extra
bands (as a proportion of the total tested for that case) compared to adjacent normal
mucosa.





Clinical and pathological data and p53 status of the RER- cancers for Fas and Bik
mutation analysis










13 57 M sigmoid (Lt) C adenocarcinoma - 0/8 no mut
14 82 F sigmoid (Lt) C adenocarcinoma + 0/5 no mut
15 70 F descending (Lt) D adenocarcinoma + 0/8 no mut
16 73 F caecum (Rt) B adenocarcinoma + 0/5 no mut
17 59 F rectum (Lt) C adenocarcinoma + 0/5 no mut
18 40 F caecum (Rt) C adenocarcinoma + 0/11 no mut
19 67 F rectum (Lt) C poorly dif. - 0/11 no mut
20 57 M sigmoid (Lt) C adenocarcinoma + 0/7 no mut
21 72 F ascending (Rt) C adenocarcinoma + 0/5 no mut
22 75 F sigmoid (Lt) A adenocarcinoma - 0/5 no mut
23 86 F ascending (Rt) C mixed (ad/muc) + 0/5 no mut
24 66 M rectum (Lt) D mixed (ad/muc) + 0/5 no mut
Note: shifted loci refers to the number of microsatellite loci showing "shifted" or extra
bands (as a proportion of the total tested for that case) compared to adjacent normal
mucosa.





Mismatch repair deficient carcinomas analysed for RER and Bax status
no age sex site histology sample
site
RER status
BAT-26 L-Myc TGF(3RII D13S160 D2S123
Bax mutation
17 81 F cae mucoid A + + + - + +(loss)
B + + + - + +(loss)
C - + + - + -
18 67 F sig ac md A + - - - - -
B + - - - - -
C + - - - - -
19 70 M asc ac pd A + + + - + +(loss)
B + + + - + +(loss)
C + + + - + +(loss)
22 43 F cae ac/mu A + - - - - +(loss)
B + - - - - +(loss)
25 65 F cae ac/mu A + + + + - +(loss)
B + + + + - +(loss)
C + + + + - -
D + + + - +(loss)
27 88 F asc ac/mu A + + + - + -
B + + + + + -
C + + + + + -
D + + + + + -
E + + + + + -
F + + + + + -
G - + + - + -
28 75 F cae ac/mu A + + + + - -
B + + + + - -
38 64 M asc ac md A + + + - + +(loss)
B + + + - + +(loss)
C + + + - + +(loss)
D + + + - + +(loss)
47 60 M asc ac pd A + - + + + -
B + - + + + -
C + - + + + -
D + - + + + -
52 76 M cae ac pd A + + + + - -
B + + + + - -
C + + + + + -
D + + + + + -
53 77 F asc ac pd A + + - - - -
B + + - + - -
C + + - - + -
D + + - - - -
55 70 F asc ac pd A + + + + - +(gain)
B + + + - - +(gain)
C + + + + - +(gain)
D + + + - - +(gain)
cae=caecum, asc=ascending colon, sig=sigmoid colon, mucoid=mucoid carcinoma, ac
md=moderately differentiated adenocarcinoma, ac pd=poorly differentiated
adenocarcinoma, ac/mu=mixed adenocarcinoma glandular/mucoid pattern,
+(loss)=deletion of one G from the [(G)8] tract, +(gain)=insertion of one G in the [(G)8]
tract.
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Figure 4.1 Fas and Bik-1 mutation analysis
A Denaturing polyacrylamide gel showing RER characterization at the BAT26
microsatellite locus: samples 1 and 2 show band shift in the tumour lane (T) compared to
the normal consistent with derivation from RER+ cancers, whereas sample 13 does not
show any band shifts and is derived from a RER- cancer.
B SSCP for Fas exon 91 for samples 1 and 2 from RER+ tumours , showing no band
shifts in the tumour (T) compared to the normal (N) lanes.
C SSCP for Bik for samples 1 and 2 from RER+ tumours, showing no band shifts in
the tumour (T) compared to the normal (N) lanes.
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Figure 4.2 Bax mutation analysis
A The band shift pattern of case no. 27 at the BAT-26 (left) and L-myc (right)
microsatellite loci (N=normal mucosa; A-G=7 different tumour sites from the same
carcinoma).
Figure 2
B Bax gene analysis of case no. 55 showing the band shift pattern on a
polyacrylamide gel demonstrating one nucleotide insertion in the [(G)8] tract from all
tumour sites (A-D), compared to normal mucosa (N).
C Sequence analysis of case 17(B&C) and 25(B&C). In both cases, site C does not








4.4.1. Absence of Fas and Bik mutation in colorectal cancers
This study identified no mutations in two death pathway genes in 24 colorectal
cancers that included 12 RER+ and 12 RER- cancers. The first gene, Fas was explored
completely for evidence of mutations throughout the coding sequence in all nine exons.
The Fas gene possesses many mononucleotide repeat sequences within its open reading
frame, considered to be potential targets for MMR-deficiency mutations. Other studies
have shown that mononucleotide repeat sequences of similar length are susceptible to
mutation arising from mismatch repair deficiency (Greenblatt et al., 1996). Longer
mononucleotide tandem repeats (e.g. extending to more than 10 base pairs) are rare in
coding regions of genes (Parsons et al., 1995; Simms et al^ 1997).
The mutation screening method (PCR-SSCP) used is known to detect
approximately 80-90% of mutations when applied to single strand DNA between 150-250
nucleotides in length (Humphries et al., 1997). The PCR products generated here ranged
in size from 108 to 282 base pairs (bp) (Table 4.1). For 3 of the Fas exon PCR assays, the
PCR product length was shorter than 150 bp or longer than 250 bp, and in these assays the
PCR was designed in this way to avoid false positive results which may arise due to
amplifying intronic sequences flanking very short exons such as exon 8 (25 bp) or long
exons such as exon 9 (1664 bp in total, 331 bp from the first codon of exon 9 to the stop
codon). Hence, it is improbable that mutations in any of the exons in Fas or in the tandem
repeat region identified in Bik are frequent in human colorectal cancers, even when this
bears the mutation-susceptible RER+ phenotype. This contrasts with the high incidence of
mutation in RER+ colorectal cancers in other genes, notably TGFj5-R.II (up to 90%)
(Parsons et al., 1995), and Bax (50%) (Rampino et al., 1997). Recent studies have shown
that the low levels or absence of Fas protein expression in colorectal cancer can not be
explained on the basis of gene deletion or rearrangement (Butler et al., 1998). The data
produced in this thesis demonstrate that Fas gene exonic mutations are also not the
explanation. The question therefore arises: what is the mechanism of reduction of Fas
protein expression following colorectal malignant transformation? Possible speculative
answers include transcriptional, translational or post-translational changes affecting
functional Fas protein levels.
Fas pathway alterations have been implicated in some forms of human
carcinogenesis. Three novel Fas mutations were detected in the Canal-Smith Syndrome,
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an inherited lymphoproliferative disorder associated with autoimmunity. Two patients
followed into adulthood developed neoplasms (e.g. breast adenoma, thyroid adenoma and
basal cell carcinoma) and one died of hepatocellular carcinoma (Drappa et ah, 1996).
These data imply a role for Fas mutations in the evolution of these tumours. A recent
study has implicated decreased sensitivity to anti-FAS antibody in the evolution of a group
of poorly differentiated colorectal carcinoma (Meterissian et ah, 1997). In contrast, only 2
poorly differentiated RER+ cancers were studied here. Furthermore, there is evidence that
deficiency of the Fas-mediated apoptosis pathway without Fas gene mutations can occur in
many situations. T-cell lines from patients with autoimmune/lymphoproliferative disease
were relatively resistant to apoptosis induced by monoclonal antibody to Fas, while
sequencing of the Fas gene from the same patients did not identify any causal mutations
(Dianzani et al., 1997). Possible explanation for such situation include: expression of
apoptosis inhibitors such as the IAP family (Deveraux & Reed, 1999; Suzuki et ah, 2000)
and FLICE inhibitory protein (FLIP) (Irmler et ah, 1997), as well as, expression of decoy
receptors, DcRl and DcR2 (Ashkenazi & Dixit, 1999), or secretion of soluble FasL that
binds Fas but does not transmit death signals (Nagao et ah, 1999). Recent data support a
new role for Fas in driving cell cycle progression (Hiroi et ah, 1999; Shinohara et ah,
2000). Fas stimulation in HepG2, hepatoma cell line, induces survivin translocation into
the nucleus. Survivin then interacts with the cell cycle regulator Cdk4, leading to
Cdk2/Cyclin E activation and pRb phosphorylation thus signaling cell cycle progression.
As a result of Survivin/Cdk4 complex formation, p21 is released from its complex with
Cdk4 and interacts with mitochondrial procaspase 3 to suppress Fas-mediated apoptosis
(Suzuki et ah, 2000). What triggers this pathway including the negative feed back loop via
which Fas suppresses its own apoptotic activity after induction of cell cycle progression
remains to be clarified, however.
The role of p53 protein in coupling DNA damage to apoptosis is well established
(see Chapter 1 - 1.2.3.2). Fas-mediated apoptosis has been shown to be linked to
p53-dependent apoptosis of human carcinoma cells including colon carcinoma (Muller et
ah, 1997; Mueller et ah, 1999). An obvious alternative mechanism for Fas
down-regulation would be depressed transcription secondary to reduced availability of
wild type p53, since the first intron of Fas includes a p53 responsive element (Mueller et
ah, 1998). Of our 24 cases, 15 showed clear abnormality in p53, exhibited by
immunohistochemical stabilisation affecting a high proportion of the nuclei. Although Fas
down regulation has the capacity to reduce cellular responses to lethal stimuli, it is
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significant that mutational inactivation of the gene is not observed in cancer tissues in
which mutational events in other genes are common and clonally expanded. We conclude
that mutational inactivation of the Fas gene is unlikely to be a critical event in colorectal
carcinogenesis.
The situation is quite different in the case of the Bik gene, as little is known about
its tissue expression, biological activity, and its potential role in carcinogenesis. However,
compared with the high mutation rate for the Bax gene in RER+ colorectal cancers, it can
only be concluded that mutations affecting the CTG tandem repeat element of the Bik gene
are not important in the development of sporadic RER+ colorectal cancers.
4.4.2 Patterns of Bax and TGFBRIImutations in sporadic c'olorectal cancers
It is clear that deficiency in mismatch repair permits the generation of large
numbers of mutations throughout the genome, mainly in microsatellite loci and repetitive
polynucleotide tracts. In sporadic colorectal tumours, the microsatellite instability is
generally found in carcinomas but rather little in adenomas, whereas both adenomas and
carcinomas from HNPCC patients may show a high proportion of such instability
(Thibodeau et al., 1993; Jacoby et al., 1995; Bubb et ah, 1996; Samowitz & Slattery, 1997;
Grady et al., 1998). These observations strongly suggest that microsatellite instability is
acquired at the adenoma-carcinoma interface in the evolution of sporadic tumours, but can
appear at an earlier stage in patients who carry germline mutations in MMR genes.
Previous studies have shown clonal expansion of shifts of different amplitude at the same
microsatellite locus sampled from different sites in the same tumour (Chung et al., 1997),
as observed in the present work also. This indicates that a proportion of these
microsatellite mutations are acquired as clonal variants throughout the process of tumour
formation and expansion and reflect but do not cause the evolution of such tumours. In
contrast, mutations at some genetic loci have been found with great consistency in RER+
tumours. An outstanding example is transforming growth factor beta-type 2 receptor
(TGF(3RII), which is mutated in upwards of 90% of all tested RER+ colorectal cancers
(Markowitz et al., 1995; Myeroff et al., 1995; Parsons et al., 1995). In this series, more
than 75% of RER+ cancers showed a mutation in the one site within the TGF(3RII gene
which was tested. Together with independent evidence that TGF(3 exerts a suppressive
effect on colorectal epithelial growth (Wrana et al., 1994; Polyak, 1996), these
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observations have been interpreted as indicative of a causal role for TGFPRII inactivation
in colorectal carcinogenesis.
Frame-shift mutations have been detected in the [(G)8] tract of exon 3 of the Box
gene in 48% of 63 RER+ sporadic colorectal cancers in a total of 2 separate studies
(Rampino et al., 1997; Ouyang et al., 1998), and in a similar proportion of RER+
colorectal cancers from HNPCC patients (Yagi et al., 1998; Yamamoto et al., 1998). The
results obtained here are entirely concordant with these data: Bax mutations were detected
in six out of 12 (50%) RER+ carcinomas. Two patterns for Bax mutations were identified
in this work. In four of the six tumours bearing Bax mutations, identical alterations in the
[(G)8] tract were found in all sites sampled within each cancer, supporting the hypothesis
that Bax mutation was present in the founder malignant clone. This pattern is also
consistent with that described for Bax mutations in gastric cancers (Chung et al., 1997).
However, in two of six cases, a second pattern was demonstrated in which Bax mutation is
not shared by all the tumour sites of the same cancer. In both these cases, the tumour site
in which Bax [(G)8] was unchanged showed unequivocal evidence of instability at most of
the other tested microsatellite loci. Therefore, sampling errors and inadequate
representation of the malignant tissue in the sample are unlikely causes of the observed
heterogeneity. There is a possibility that the apparently unaltered [(G)8] tract found in
subclones of these tumours represents a reversion, through a second mutation, of the [(G)8]
mutation present elsewhere. This possibility, albeit less likely, can in the future be tested
in appropriate cell culture models to determine the frequency of occurrence. Another and
more likely explanation, however, is that in these tumours the Bax [(G)8] mutation was not
present in the founder malignant clone but was acquired later in cancer expansion. In these
tumours, it is difficult to sustain the view that mutational inactivation of Bax could have
been a critical event early in carcinogenesis. These data therefore raise some doubt as to
the significance of loss of Bax-dependent apoptosis pathways in colorectal carcinogenesis.
Rather than indicating that failure of apoptosis exerts a critical role in carcinogenesis, some
Bax mutations in colorectal tumours may merely aid tumour progression or expansion, or




Bax gene mutations were detected in 50% of RER+ tumours, but were not always
present at all tumour sites in 2 out of 6 cases and hence have arisen either during tumour
progression rather than in the founder clone or reflect reversion mutation, the former
apparently more likely than the latter. In contrast, TGFfiRlI mutations were found in 75%
of the RER+ tumours, and were present in all the sampled sites: these mutations must have
arisen in the founder clone. No mutations were found in Fas or Bik genes in RER+ and
RER- cancers. Other causes that might account for Fas down regulation or loss of the
Fas-mediated apoptosis in colorectal carcinogensis have been discussed. However, it is
significant that mutational inactivation of the gene is not observed in cancer tissues in
which mutational events in other genes are common and clonally expanded.
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Chapter 5
Effects of Tumour Genotype on Treatment Responsiveness
in Colorectal Cancer Cells
5.1. Introduction
Because genetic alterations are in large part responsible for the generation and
biological properties of tumours, it is reasonable to hypothesise that the specific alterations
in tumours, including changes to the ability to induce apoptosis by certain stimuli,
determine or influence the tumour responsiveness to therapeutic agents. Thus, absence of
wild type p53, the most frequent founder clone defect in cancers of the colon, rectum and
other sites (Hollstein et al., 1991; Purdie et al., 1991; Cripps et al., 1994), was shown to
permit propagation of mutant cells following genotoxic damage (Griffiths et al., 1997).
Wild type p53 is a critical regulator of cellular responses to genomic damage. Subsequent
to DNA damage, p53 is functionally activated and induces G1 cell cycle arrest (Kastan et
al., 1992; Lane, 1992), and via this G1 arrest, p53 has been suggested to facilitate DNA
repair (Kastan et al., 1992; Hartwell & Kastan, 1994; Linke et al., 1997). p53 is also
essential for maintaining the G2 check point in human cells (Bunz et al., 1998). In
contrast, restoration of wild-type p53 function in p53 mutant cells can directly induce
apoptosis (Yonish-Rouach et al., 1991; Shaw et al., 1992; Polyak et al., 1997). However,
the underlying mechanisms of this p53-induced apoptosis are not fully understood (Polyak
et al., 1997; Albrechtsen et al., 1999). By enhancing DNA repair, wild-type p53 could
potentially enhance the resistance of cells to killing by agents that induce DNA damage.
Alternatively, by potentiating apoptosis, wild-type p53 can increase the sensitivity of cells
to killing by agents that induce DNA damage. Both of these effects have been supported
by findings in different cell line systems both in vitro and in vivo (Clarke et al., 1993;
Lowe et al., 1993; Slichenmyer et al., 1993; Clarke et al., 1994; Lowe et al., 1994; Bracey
et al., 1995; Malcomson et al., 1995; Hawkins et al., 1996; Pellegata et al., 1996; Yang et
al., 1996; O'Connor et al., 1997; Palazzo et al., 1997; Blandino et al., 1999).
Recent studies have shown that loss of mismatch repair is an important mechanism
of resistance to a variety of clinically important cytotoxic drugs including busulphan
(Friedman et al., 1997), carboplatin, oxaliplatin (Fink et al., 1996), cisplatin (Aebi et al.,
1996; Anthoney et al., 1996; Drummond et al., 1996; Fink et al., 1996; Toft et al., 1999),
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Doxorubicin (Drummond et al., 1996), and the alkylating agents: A-methyl-A7-nitro-iV-
nitrosoguanidine (MNNG) (Kat et al., 1993; Koi et al., 1994; Toft et al., 1999),
A-methyl-iV-nitrosourea (MNU) (Friedman et al., 1997), procarbazine (Friedman et al.,
1997) and temozolomide (Liu et al., 1996; Friedman et al., 1997; D' Atri et al., 1998; Toft
et al., 1999). This wide range of resistance is due in part to the fact that the mismatch
repair system can recognize and bind to various types of adducts in DNA as well as to
mismatches (Kat et al., 1993; Hawn et al., 1995). Rather than being a major effector in the
removal of such adducts, the main role of the mismatch repair system seems to be as a
detector of specific types of DNA damage (Fink et al., 1998a). Methylating agents form a
variety of adducts in DNA, among which 06-methylguanine is the most cytotoxic.
Although the mismatch repair system does not seem to be able to recognize the
(/-methylguanine directly (Moggs et al., 1997), it does recognize the
<96-methylguanine-thymine mispair that occurs after erroneous incorporation of a thymine
rather than a cytosine opposite the 0 -methylguanine during the next cycle of DNA
replication (Griffin et al., 1994). One hypothesis is that having recognized the mismatch,
the mismatch repair system incises the thymine-containing strand; excises the thymine and
surrounding bases creating a gap; and then fills in the gap via repair synthesis. However,
because a thymine is again incorporated opposite the persisting 06-methylguanine, the site
is once again recognized and a new round of attempted repair is triggered. This futile
cycling is envisioned as increasing the risk of a double-strand break at the time of the next
S phase that could then trigger apoptosis (Karran & Bignami, 1994). Recent data support
this link between loss of mismatch repair function and the failure to engage apoptosis in
response to methylating agents (Toft et al., 1999).
However, many of these data may be specific to the particular cell lineage or
system used in the experiment and extrapolation of these results to clinical settings is far
from straightforward. This series of experiments, therefore, set out to determine the effects
of different combinations of p53 and RER status, as can be found in sporadic colorectal
cancers, on the responsiveness to treatment, both in vitro and in vivo. Three therapeutic
agents were used for this study: 5-fluorouracil (5-FU), ionizing radiation (IR) and
temozolomide.
5-FU and its derivatives are widely used in the chemotherapy of gastrointestinal
cancers, in particular colorectal cancers (Laffer et al., 1995; Erlichman et al., 1999;
Schmoll et al., 1999). The molecular mechanisms underlying 5-FU action are still not
clear, however, two main pathways for 5-FU anti-tumour effects have been suggested.
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First, the drug is metabolised to 5-fluorodeoxyuridine monophosphate (FdUMP), which
suppresses thymidylate synthase (TS), an enzyme, which catalyses the methylation of
deoxuridylate to thymidylate. 5-FU thus interferes with an essential step in DNA synthesis
(Parker & Cheng, 1990). Subsequently, some studies linked the TS levels in tumours to
the sensitivity to 5-FU (Leichman et al., 1997; van Triest et al., 1999), however, other
studies failed to demonstrate such association (Findlay et al., 1997; Mirjolet et al., 1998).
Second, 5-FU is metabolised to fluorouridine triphosphate (FUTP) which can be
incorporated into cellular RNA and DNA, resulting in adverse effects on their structures
and functions (Parker & Cheng, 1990; Geoffroy et al., 1994). 5-FU was shown to induce
apoptosis of FM3A mouse cells in vitro (Yoshioka et al., 1987) as well as human tumour
cells in vivo (Inada et al., 1997). The apoptotic positive fraction in 5-FU treated human
cancers correlated with the overall tumour growth sensitivity to 5-FU (Inada et al., 1997).
The apoptotic response to 5-FU was suggested to be mediated via activation of the Fas
(Houghton et al., 1997) and/or Bax (Koshiji et al., 1997) apoptotic pathways.
IR causes perturbation throughout the cell cycle subsequent to DNA double strand
breaks (Maity et al., 1994). Irradiation was shown to induce apoptosis through
p53-dependent or p53-independent pathways in many cell systems (Clarke et al., 1993;
Lowe et al., 1993; Slichenmyer et al., 1993; Clarke et al., 1994; Bracey et al., 1995;
Bristow et al., 1996; Bracey et al., 1997; Held, 1997; Palazzo et al., 1997). The nature of
the p53-independent apoptotic pathways in response to IR is still not clear.
Temozolomide is a well-tolerated, orally bio-available, DNA-methylating agent
that has significant activity in metastatic malignant melanoma, brain tumours, and, in
particular, high grade astrocytomas (Stevens et al., 1987; Newlands et al., 1996; Newlands
et al., 1997). Recently, the early apoptotic response to temozolomide was shown to be
dependent on p53 in addition to mismatch repair in mouse intestinal epithelium (Toft et al.,
1999). This raises the possibility that many tumour genotypes in colorectal cancers might
not benefit from this drug.
The following series of experiments was carried out in two model systems. First,
two representative cell lines of the commonly seen patterns (p53 wild type/RER+ and p53
mutant/RER-) were tested for their responsiveness to a wide dose range of the three
therapeutic agents in vitro. Responses were detected by counting apoptotic cells after
staining with Acridine Orange and also by the clonogenic survival assay. Further to this,
fresh primary tumours representing all possible genetic patterns in colorectal carcinomas in
terms of p53 and RER status were selected. They were established as subcutaneous
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xenografts in SCID mice and tested for their apoptotic response to therapy in vivo. The
tumour xenografts were grown through several passages in vivo and displayed a
remarkable consistency of many genetic, histological, and biological features of the
tumours from which they were derived (Shorthouse et al., 1980; Lefrancois et al., 1989;
McQueen et ah, 1991; Georgiades et al., 1999). This SCID mouse human tumour model
reflects the clinical situation in that clinically active therapies are similarly active in the
SCID models (PaineMurrieta et al., 1997). The data presented in this chapter thus
provides useful information on the effects of combinations of tumour genetic alterations on
responsiveness to therapy. These data on the roles of p53 and the mismatch repair
pathway in the responses to 5-FU, IR, and temozolomide may be useful in helping to
design more effective therapeutic protocols.
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5.2. Experimental design
5.2.1. In vitro response
The two cell lines, HT29 (p53 mutant/RER-) and LoVo (p53 wild type/RER+) (see
Chapter 3 for references), were grown to obtain enough stock. Their responses to each of
the therapeutic agents were studied by two methods:
i. The clonogenic survival assay (as described in Chapter 2)
ii. Their apoptotic responses were studied after 1, 2, and 3.5 days of treatment by
Acridine Orange staining (see Chapter 2) and counting apoptosis using fluorescent
microscopy (Zeiss, Axiovert S100T.V, UK).
5.2.2. In vivo response
5.2.2.1 Selection of tumours
For the purposes of this study, four colorectal carcinomas representing all possible
combinations of p53 and RER status were selected. Primary tumours and their
corresponding xenografts were previously characterized for their p53 status as determined
by immunohistochemistry, and exon 5-8 mutation screening by PCR-SSCP analysis.
Further data on chromosome arm 17p gain /loss, as determined by CGH, were also
available. However, As stated previously, there is a minor possibility that these methods
may not detect all p53 abnormalities and, conversely, absence of detectable abnormalities
at this level of analysis might not prove that the cells have wild type p53. RER status was
determined by testing for microsatellite instability at 5 microsatellite loci as described in
Chapter 4 (4.2.2). Ploidy was determined by flow cytometry and analysis of chromosomal
gains and losses was done by CGH (Table 5.1). The tumour genotype profiles of the four
xenografts are as follow: ANSC (p53 wild type/RER-), CABA (p53 mutant/RER+), JOTH
(p53 wild type/RER+), and HEKI (p53 mutant/RER-). It should be noted that mutations
were not directly demonstrated in CABA and HEKI and the word 'mutant' is used here to
denote the abnormalities observed by immunohistochemistry and CGH (Table 5.1). The
word 'mutant' is retained here for consistency in discussing these patterns, which also
include the HT29 cell line that shows unequivocal evidence of p53 mutation (Table 3.1).
However, because matching normal mucosae were immunohistochemically negative in
these cases (CABA and HEKI), it is most unlikely that causes other than p53 mutations
could account for the observed protein stabilization. Previous studies have shown that
immunocytochemically-detected stabilization of p53 correlates with p53 mutation in
colorectal carcinomas (Cripps et al., 1994; Cottu et al., 1996).
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Table 5.1
Profiles of the four tumour xenografts
ANSC CABA JOTH HEKI
Patient age 81 60 70 81
Sex M F F F
Site of primary Sig Asc Asc Asc
Histology Md/ac Pd/c Pd/c Md/ad
Dukes' stage B C C C
p53 IHC - + - +
p53 SSCP NAD ND NAD ND
17p CGH NAD loss NAD loss
RER - + + -
Ploidy aneuploid diploid diploid aneuploid
P53 IHC, detection of stabilized p53 by immunohistochemistry; p53 SSCP, p53 exon 5-8
mutation analysis using PCR-SSCP; 17p CGH, detection of 17p loss by comparative
genomic hybridisation; RER, replication error phenotype; Sig, sigmoid colon; Asc,
ascending colon; Md/ac, moderately differentiated adenocarcinoma; Pd/c, poorly
differentiated carcinoma; NAD, no abnormality detected; ND, not done.
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5.2.2.2 Therapeutic doses
SCID mice (Bosma et al., 1983; Custer et al., 1985) are known to bear several
defects including DNA double strand break repair deficiency; hence these mice are
hypersensitive to the effects of IR (Biedermann et al., 1991; Disney et al., 1992; Chang et
al., 1993; Kirchgessner et al., 1995), and probably other drugs. Therefore, an initial
experiment was performed to determine the sub-lethal doses of the therapeutic agents {i.e.
the maximum dose of each agents that SCID mice can tolerate and survive for 10 days).
Duplicate SCID mice, not harbouring tumours, were exposed to a range of doses for each
therapeutic agent and monitored for their response. Animals were killed if they were
suffering or if they survived for 10 days. To minimize unnecessary animal suffering, this
experiment was performed at consecutive steps starting by the highest dose in the
treatment ranges suggested in the literature (Biedermann et al., 1991; Blumenthal et al.,
1994). The highest dose for each therapeutic agent, which was tolerated for 10 days, was
chosen.
5.2.2.3 Preparation of mice and treatment application
Tumours were allowed to grow subcutaneously until an externally visible tumour
diameter of about 1cm was reached, or when signs of poor health of the mouse were
apparent, for typical durations of 28-56 days. Mice were then killed and tumours were cut
into small pieces (2x2 mm), which were re-grown in a group of 8 female SCID mice all
at the same time, as described in Chapter 2. Tumours were allowed to grow until an
externally visible tumour diameter of about 0.5 cm was reached. This time varied between
tumours from 3 to 8 weeks. The 8 mice were subdivided into two groups of fours. One
group of 4 mice were treated with either 5-FU, y-irradiation, or temozolomide. The other
group of 4 SCID mice was used to provide controls by leaving them unexposed to
y-irradiation or injecting them by vehicle not containing the drug in case of 5-FU and
temozolomide. A total of 96 female SCID mice were used for this experiment (8 mice per
therapeutic agent per tumour xenograft). This figure (96) does not include mice used to
establish and maintain these tumours xenografts. All treatments were applied as a single
shot of the sub-lethal dose. 5-FU was dissolved in PBS and mice received a single dose of
80 mg kg"1 body weight by intra-peritoneal (i.p.) injection. Temozolomide was dissolved
in 10% DMSO in PBS and mice received a single i.p. dose of 80 mg kg"1. Mice were
exposed to 5 Gy total body IR from a I37Cs source at 0.27 Gy min"1.
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5.2.2.4 Detection of treatment responses
At each of four time points (0.75, 3.5, 7 and 10 days), two animals were killed: one
from the treated and one from the control groups, tumours were harvested and fixed for
haematoxylin and eosin staining. Treatment responses were estimated by counting
apoptosis in five high power fields (HPFs) (x400 total magnification). The fields were
chosen around the circumference of the tumour where viable tumour cells were abundant.
The necrotic tumour centre and the margins of the necrotic areas were avoided. Apoptotic
cells inside glandular lumina were not counted. Mitoses were counted in the same 5 HPFs.
Semi-quantitative estimates of the overall extent of necrosis were made at low power (x50)
using a scale of 10%, 20%, 30%, 40%, 50% and so on. Xenograft tumour diameters were
measured before killing the animals. Samples of the middle portion of the small intestine
of the mice were harvested with each tumour, and these were fixed, and sections were
stained with haematoxylin and eosin. Apoptosis in the murine small intestines were
counted in 10 crypts for both the treated and control mice. This small intestinal apoptotic
count served as a positive control for the therapeutic agents, especially relevant in the cases
of the non-responsive xenografts.
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5.3. Results
5.3.1 In vitro clonogenic and apoptotic responses of cell lines
The results of the clonogenic survival assays are plotted in graphic forms in Figure
5.1. Treatment with 5-FU induced a significantly greater reduction of clonogenic survival
of LoVo compared to HT29 at 150 pM 5-FU (p = 0.03, Student's t-test). IR induced
significant reductions in the clonogenic survival of LoVo compared to HT29 at 1,3 and 5
Gy IR (p < 0.03 for all comparisons, Student's t-test), with the most evident difference at 3
Gy. F1T29 formed 2 different colony types, small and large colonies (Figure 5.2), the small
colonies were more resistant to therapies, particularly IR at lower doses as shown in Figure
5.1 D. Significant reductions in colony number were seen for large colonies at 3 Gy (p =
0.04, Student's t-test) and 5 Gy (p = 0.02, Student's t-test), while significant reductions of
small colony numbers were seen at 5 Gy only (p < 0.01, Student's t-test) compared to the
numbers of colonies without IR treatment. Responses of both LoVo and HT29 to
temozolomide were comparable in that both lines showed slight reductions in clonogenic
survival at 8 pM and 40 pM temozolomide and almost similar decreases of clonogenic
survival at a 100 pM temozolomide.
LoVo and HT29 cell lines showed detectable apoptotic responses by Acridine
Orange staining and counting of the proportions of apoptotic cells in 100 cells by
fluorescence microscopy only after 3.5 days of treatment application (Figure 5.4, examples
of apoptotic cells are shown in Figure 5.3). There was hardly any significant apoptotic
response detected by this technique 1 or 2 days after treatment. The apoptotic responses of
LoVo and HT29 showed a striking inverse relationship with clonogenic survival assay data
(Figure 5.4 D; Correlation R2 = 0.8688, p < 0.001). Treatment with 5-FU induced
significantly more apoptotic death of LoVo compared to HT29 at 150 pM 5-FU (p =
0.0005, Student's t-test). IR induced markedly increased apoptosis of LoVo compared to
HT29 at 1 (p = 0.03, Student's t-test), 3 (p = 0.04, Student's t-test) and 5 Gy (p = 0.03,
Student's t-test), with the most evident difference at 3 Gy. Responses of both LoVo and
HT29 to temozolomide were very similar with both lines showing minimal increase in
apoptotic death at 8 uM and 40 uM temozolomide and an almost similar slow increase in
apoptotic death up to 100 uM temozolomide.
5.3.2 In vivo responses of tumour xenografts to therapeutic agents
Apoptotic and mitotic counts and the overall necrosis score for each tumour
xenograft are shown in Tables 5.2. Photomicrographs of representative areas of the
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haematoxylin and eosin stained sections are presented in Figures 5.5 - 5.8. Small
intestinal apoptosis was maximal at 0.75 day then declined rapidly afterwards. Small
intestinal apoptotic counts (Figure 5.9 D) at 0.75 day for all the controls were 2-10/ 10
crypts, but 39-63 after 0.75 day of treatment application for any of the 3 therapeutic agents,
and these differences were all statistically significant (p<0.001 for all comparisons,
Student's t-test).
The apoptotic responses of the four tumour xenografts to therapies are presented as
graphs (Figure 5.9). p53 wild type tumours, ANSC and JOTH, showed maximal apoptotic
responses to 5-FU at 3.5 and 7 days respectively, which was statistically significant (p =
0.006 for ANSC and p = 0.01 for JOTH compared to baseline apoptotic figures in controls,
Student's t-test), whereas p53 mutant tumours—CABA and HEKI—showed no significant
responses at days 3.5 or 7 or 10 (Figure 5.9 A). No correlation was observed between
RER status and responses to 5-FU. Thus, responses to 5-FU appeared to be dependent on
the presence of wild type p53.
Significant apoptotic responses to IR were observed at 3.5 days—compared to base
line levels in controls—in tumours which were wild type for p53 (JOTH), mismatch repair
(HEKI), or both p53 and mismatch repair (ANSC) (p = 0.01, 0.02 and 0.01 respectvely,
Student's t-test). The ANSC tumour xenograft showed a significant apoptotic response
earlier, at 0.75 days after IR treatment (p = 0.01, Student's t-test) than the other two
tumours. The fourth tumour (CABA, p53 mutant/RER+) showed no significant apoptotic
responses to IR between 0.75 and 10 days. Therefore, apoptotic responses to IR appeared
to be dependent on possession of either wild type p53 or alternatively proficient mismatch
repair or both.
Apoptotic responses to temozolomide were lower in amplitude than those for 5-FU
and IR and were dependent on the presence of both wild type p53 and proficient mismatch
repair together, as in the case of ANSC (p53 wild type/RER-) in which the maximum
response occurred at the first time point of 0.75 days and declined rapidly thereafter. This
apoptotic response of ANSC at 0.75 days was statistically significant compared to baseline
apoptotic levels in controls (p = 0.05, Student's t-test). The other 3 tumours showed no
significant changes in apoptotic responses to temozolomide between 0.75 and 10 days.
The mitotic counts and overall extent of necrosis (Table 5.2) spanned a wide range,
which in many cases included or overlapped the control range, or otherwise, was not
significantly different from the control values.
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5.3.3 Clinical follow up of the patients
Limited clinical follow up data were available on only two of the four tumour cases studied
in vivo. The patient with the tumour CABA (p53 mutant/RER+) presented with advanced
disease, which progressed despite chemotherapy, including 5-FU, and the patient died 9
months after diagnosis. The patient with the tumour JOTH (p53 wild type/RER+), which
was a Dukes' C tumour, received adjuvant chemotherapy, including 5-FU, and remained
alive and well three years after diagnosis. These clinical outcomes, in terms of response to
chemotherapy, appear to be consistent with the results obtained in these experiments.
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Table 5.2 Responses of xenografts to therapies
A: ANSC (p53 wild-type/RER-)
Time (days) 0.75 3.5 7 10 S.I.
Apoptosis Count / 5HPFs (X400)
Control 89 61 63 93 8
5-FU 92 228 170 103 53
Gamma Rays 205 267 195 142 51
Temozolomide 147 110 102 47 56
Necrosis (percent)
Control 50 50 50 40
5FU 40 60 50 95
Gamma Rays 40 90 60 80
Temozolamide 80 70 80 40
Mitosis Count/5HPFs (X400)
a -
Control 12 18 15 15
5FU 15 22 8 8
Gamma Rays 25 5 27 35
Temozolamide 15 18 17 13
B: CABA (p53 mutant/RER+)
Time (days) 0.75 3.5 7 10 S.I.
Apoptosis Count/5HPFs (X400)
Control 76 85 89 64 9
5-FU 71 96 88 died 53
Gamma Rays 64 101 85 84 46
Temozolomide 52 73 62 53 52
Necrosis (percent)
Control 30 30 50 40
5-FU 30 40 50 died
Gamma Rays 40 50 D 50
Temozolamide D 30 30 50
Mitosis Count/5HPFs (X400)
Control 26 22 24 18
5-FU 5 18 21 died
Gamma Rays 15 20 18 21
Temozolomide 28 16 23 25
Table 5.2 (continued)
C: JOTH (p53 wild-type/RER+)
Time (days) 0.75 3.5 7 10 S.I.
Apoptosis Count/5HPFs (X400)
Control 60 53 60 99 1
5-FU 87 241 289 138 49
Gamma Rays 61 209 157 98 53
Temozol amide 65 101 93 91 53
Necrosis (percent)
Control 35 35 45 55
5-FU 25 30 85 70
Gamma Rays 30 40 80 50
Temozolamide 30 75 50 40
Mitosis Count/5HPFs (X400)
Control 22 9 15 15
5-FU 6 10 20 17
Gamma Rays 16 43 46 22
Temozolomide 26 21 24 43
D: HEKI (p53 mutant/RER-)
Time (days) 0.75 3.5 7 10 S.I.
Apoptosis Count/5HPFs (X400)
Control 38 40 39 46 3
5-FU 69 54 47 59 63
Gamma Rays 42 98 326 died 40
Temozolomide 41 42 48 56 39
Necrosis (percent)
Control 20 30 15 50
5-FU 25 30 85 70
Gamma Rays 10 30 85 died
Temozolamide 10 15 20 15
Mitosis Count/SHPFs (X400)
Control 10 6 10 5
5-FU 6 10 20 17
Gamma Rays 6 3 7 died
Temozolomide 6 3 4 5
All the control sets from any xenograft showed the same range of values for any of the three parameters:
apoptosis, mitosis and necrosis. Therefore, only one control value showing the widest range is presented for
each xenograft. S.I., mouse small intestinal apoptotic count/10 crypts at 0.75 day; D, difficult to assess due




A 5-FU, B ionizing radiation, C temozolomide
The clonogenic assay was performed in triplicate flasks and treatment responses are shown
as mean ± S.E.M of number of surviving colonies relative to 100 colonies in controls.
When the control flasks yielded slightly less or more than the standard 100 hundred
colonies, the values from treated flask were corrected accordingly.
D Responses of the large and small HT29 colonies to ionizing radiation
Different responses (mean ± SEM)of the large and small HT29 colonies to ionizing
radiation are demonstrated. There is progressive reduction in the number of large colnies
with increasing doses of ionizing radiation. The small colonies are more resistant to the












Figure 5.1 D: HT29 response to
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Figure 5.2
Representative flasks showing the clonogenic assay for the HT29 cell line treated with
ionizing radiation. Progressive reduction in the number of the large colonies is observed
with increasing doses of ionizing radiation, but the small colonies are more resistant to




Photomicrographs showing different examples of apoptotic cells as detected by Acridine
Orange staining and UV fluorescence microscopy of the cell line LoVo after treatment
with different therapies (A - D: Control, 5-FU, IR and temozolomide respectively).
Arrows indicate normal cells and arrow-heads indicate apoptotic cells with condensed




Figure 5.4 A - C
Graphic illustrations of the proportions of apoptotic cells detected by Acridine orange
staining of the cell lines LoVo and HT29 3.5 days after treatment with different doses of
each therapeutic agent (mean ± SEM of three estimations of apoptotic count).
Figure 5.4 D
Scatter plot comparing apoptotic responses to colony number observed in the clonogenic
survival assays of cell lines LoVo and HT29 after treatment with 5-FU, ionizing radiation
or temozolomide. The trend-line (regression equation: y = -2.2565x + 110.19, p < 0.001)
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Figure 5.4 D: Scatter plot comparing apoptotic responses to
clonogenic assay data of LoVo and HT29 after treatment with
the three therapeutic agents.
Apoptosis
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Figure 5.5 ANSC, Figure 5.6 CABA, Figure 5.7 JOTH, Figure 5.8 HEKI
Photomicrographs of representative areas showing the apoptotic responses of the
xenografts to therapies in vivo. A, control; B, 5-FU; C, y-irradiation and D, temozolomide







Figure 5.9 A - C
Graphic representation of the apoptotic responses of the tumour xenografts to each
therapeutic agent: A 5-FU, B ionizing radiation (IR), C temozolomide
To allow comparison between different tumour xenografts and different therapeutic agents,
the test data (number of apoptotic cells/5 high power fields [HPFs] for each tumour
xenograft at each time point in response to treatment with 5-FU, IR and temozolomide)
were adjusted to take into account the differences between the background apoptotic levels
observed in the controls for each tumour xenograft as follows: the highest apoptotic count
observed in any one set of controls from a single tumour xenograft treated with one
therapeutic agent was converted to 100 and the test apoptotic counts/5 HPFs at each time
point from the treated xenografts were converted by the same factor so that they are
expressed as a percentage of this control. Two mice died before reaching day 10: the
CABA/5-FU-treated mouse and HEKI/IR-treated mouse.
Figure 5.9 D
Apoptotic counts in murine small intestinal epithelium
Murine small intestinal apoptotic count/10 crypts at 0.75 day after application of therapies
are shown for mice bearing the 4 tumour xenografts.
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5.4.1 Comparison of the in vivo and in vitro responsiveness to cytotoxic treatment
Both of the responses in vitro to therapeutic agents determined by counting of
apoptosis by fluorescence microscopy with Acridine Orange staining and the reduction of
clonogenic survival (Figures 5.1 & 5.4) independently demonstrated that LoVo is more
sensitive to both 5-FU and IR and that both cell lines were similarly resistant to
temozolomide (Figure 5.4 D). This correlation between apoptotic responses in vitro to
therapeutic agents and the reduction of clonogenic survival suggest that the apoptotic
responses of such tumour cells may be representative of their overall response to therapy.
Previous reports have suggested that in vivo apoptosis frequency might be, in some cases, a
better predictor of drug responsiveness than colony formation (Lamb & Friend, 1997;
Waldman et al., 1997; Bunz et al., 1999). In these experiments the apoptotic responses
obtained from the two p53/RER combinations studied in vitro were broadly similar to the
patterns of apoptotic responses obtained in vivo from tumours with the equivalent
combinations—HT29 (p53 mutant/RER-) compared to HEKI (p53 mutant/RER-) as both
showed a low or absent apoptotic responses to 5-FU, and LoVo (p53 wild type/RER+)
compared to JOTH (p53 wild type/RER+) as both showed a higher response to 5-FU. This
consistency adds weight to the validity of the data obtained in this study and indicates the
relevance of combining the results for those p53/RER combinations studied both in vivo
and in vitro.
5.4.2 Apoptotic responses to 5-FU are associated with p53 status
Responses to 5-FU in this study correlated strongly with wild-type p53 status. In
the absence of wild type p53 cells were strikingly resistant to the effects of 5-FU both in
vitro (HT29) and in vivo (CABA and HEKI tumour xenografts). The mismatch repair
status did not show any significant influence on the responses to 5-FU in the absence of
wild type p53. The data obtained here are in accord with those in normal murine intestinal
epithelium which showed that p53 deficiency leads to decreased apoptosis after treatment
with 5-FU and that the p53-dependent apoptosis after treatment with 5-FU reflected
inhibition of RNA metabolism rather than DNA metabolism (Pritchard et al., 1997;
Pritchard et al., 1998). These observations in murine intestinal epithelium together with
the data presented here in human colorectal cancer cells indicate the fundamental
importance of wild type p53 to the apoptotic response to 5-FU. It might be significant that
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5-FU effects on RNA metabolism were previously suggested to be independent of TS
(Cory et al., 1979; Ghoshal & Jacob, 1997) and clinical studies showed that the effects of
5-FU on RNA metabolism were the most important mode of action for treatment by bolus
schedules but not continuous infusion (Harstrick et al., 1998). The data obtained in this
experiment are also in strong agreement with a recent report showing that p53 disruption
rendered cells strikingly resistant to the cytotoxic effects of 5-FU both in vitro and in vivo
(Bunz et al., 1999). This report also showed that the effects of 5-FU were independent of
the cyclin dependent kinase inhibitor p21, and appeared to be the result of perturbation of
RNA metabolism rather than inhibition of TS and, subsequently, DNA metabolism.
Furthermore, the report demonstrated also that p53-dependent cell death following 5-FU
treatment was apoptotic in requiring active biosynthesis of cellular suicide proteins (Bunz
et al., 1999). Overall, these data justify further work to elucidate the molecular
mechanisms underlying the 5-FU mediated induction of p53-dependent apoptosis.
5.4.3 IR induces apoptosis via alternative pathways
Apoptotic responses and reduction of clonogenicity after IR in these experiments
were associated with presence of either wild type p53 or proficient mismatch repair or both
together, in that only the CABA xenograft tumour (p53 mutant/RER+) showed no increase
in apoptosis above base line levels. Although, it is difficult to draw conclusions regarding
the link between the amplitude of the apoptotic response and the underlying p53/RER
combination (Figure 5.9), some comments are appropriate. The in vivo experiments
demonstrated that the combined presence of wild type p53 and proficient mismatch repair
(ANSC) gave the earliest response at 0.75 day as well as the strongest response at 3.5 days
which subsequently declined; while the p53 mutant-mismatch repair proficient tumour
(F1EKI) showed a progressive increase in apoptotic response which continued up to day
seven (the mouse harbouring the tumour to be harvested at day 10 died before completion
of this experiment). This pattern suggested that absence of wild type p53 may sensitise
tumours that possess alternative pathways for responses to IR such as the mismatch repair
system. This is in accord with, and may further explain, previously published work which
has highlighted the conflicting results on the relationship between p53 status and response
to IR (Slichenmyer et al., 1993; Lowe et al., 1994; Bracey et al., 1995; Bristow et al.,
1996; Yang et al., 1996; Bunz et al., 1999). However, the lower but still increasing in
vitro apoptotic responses to IR of the HT29 cell line (p53 mutant/RER- tumour) indicate a
poorer correlation between in vitro and in vivo behaviour of p53 mutant tumour cells. The
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discrepancy between the in vivo and in vitro responses even for the same tumour has been
documented in the literature and the in vivo responses are considered to be more
informative (Lamb & Friend, 1997; Waldman et al., 1997; Bunz et al., 1999).
Furthermore, it was observed in this work that the HT29 cell line gave rise to different-
sized colonies one small and the other large. The large colonies showed progressive
reduction in frequency with increasing doses of irradiation, and at 5 Gy they disappeared
completely. The small-sized HT29 colonies were more resistant and formed all the
surviving colonies at 5 Gy. This observation raises interesting issues regarding the effects
of tumour heterogeneity on the responsiveness to treatment and further study of this
particular line may reveal the basis for such clonal heterogeneity and its influence on the
responses to treatment.
Absence of both wild type p53 and proficient mismatch repair in the same
xenograft tumour (CABA) was associated with a very poor apoptotic response to IR. This
finding suggests a critical role for the mismatch repair system in the apoptotic response to
IR in the absence of wild type p53.
5.4.4 Colorectal cancers appear to be resistant to temozolomide
Apoptotic responses and reduction of clonogenicity after temozolomide treatment
were insignificant, apart from the response of the p53 wild type/RER- tumour (ANSC).
However, this apoptotic response of ANSC was weaker, and declined faster than those
responses observed after the other two therapeutic agents. This may represent the expected
response from a single bolus dose considering the very short half-life of temozolomide
(Stevens et al., 1987; Newlands et al., 1996). The lack of other tumours of this particular
phenotype in this study, and generally in colorectal cancers, makes it difficult to judge the
significance of this early apoptotic response. The data obtained here suggest that
colorectal cancer responses to temozolomide may be dependent on the presence of wild
type p53, together with proficient mismatch repair. Previous studies have shown that DNA
methylator damage, as seen with temozolomide treatment, induces hMutSa and
hMutLa-dependent phosphorylation of p53 (Duckett et al., 1999). Recent reports in the
literature also suggest that wild type p53 potentiates the killing effects of the methylating
agents in mouse small intestine (Toft et al., 1999), and in human tumour cells (Tentori et
al., 1998; Duckett et al., 1999).
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5.5 Conclusions
It is important to bear in mind that responses to therapeutic agents are complex and
unlikely to be completely explained by a single molecular alteration in a tumour.
However, the data obtained here, combined with the available follow up information on
two of these tumours, revealed significant effects of the p53 and RER status on
responsiveness to treatments. These effects varied dramatically depending on the
therapeutic agent. The data may explain previous reports about the effects of p53 status on
the response to IR as it links it to the mismatch repair status: p53 wild type tumours are
generally responsive to IR. However, the combined loss of p53 and mismatch repair
rendered the tumours studied resistant to IR. The data also suggested a critical role for
wild type p53 in the response to 5-FU. A reasonable overall interpretation is that tumours
with mutant p53 appear to be less likely to be responsive to 5-FU and temozolomide than
tumours with wild type p53. The mismatch repair status, combined with p53, can predict
the response to temozolomide. Further experiments based on these data in appropriate cell
line systems would help to dissect the complex relationships between the p53 status and
the mismatch repair status in treatment responsiveness.
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Chapter 6
Summary, Final Discussion and Future Prospects
6.1 Summary and final discussion
This thesis has characterized patterns of genomic instability associated with
sporadic colorectal cancers. The thesis has also examined mechanisms underlying
deregulation of key apoptotic pathways and the impact of some aspects of tumour
genotype on treatment responsiveness in sporadic colorectal cancers.
6.1.1 genomic instability in colorectal cancers
Application of FISH-based techniques in this study identified subsets of colorectal
cancers characterized by patterns of chromosomal changes. RER- colorectal cancer cell
lines usually displayed extensive numerical and structural chromosomal changes with
marked intermetaphase heterogeneity. While most of the RER- lines showed a tendency to
approach a near-triploid karyotype with multiple trisomies, a minor subgroup retained a
near-diploid karyotype. Only one cell line was near-pentaploid and showed clear evidence
of endoreduplication in the form of duplication of almost all abnormal chromosomes. The
common feature of all of these subgroups of RER- cell lines was the presence of multiple
forms of chromosomal instability including numerical chromosomal instability, structural
chromosomal instability, numerical inter-metaphase heterogeneity and structural
inter-metaphase heterogeneity. These different forms of instabilities were measured by a
set of indices: numerical (aneuploidy) index, break index, numerical heterogeneity index
and structural heterogeneity index (see Chapter 3, Table 3.4). These indices showed that
some lines had a pronounced tendency to acquire particular forms of chromosomal
instability but were relatively immune to other forms. This suggests that different forms of
chromosomal instability arise through independent mechanisms and possible mechanisms
for some of these have been discussed before: abnormalities of the mitotic machinery as a
source of numerical chromosomal instability (see Chapter 1: 1.4.7.1), DNA double strand
breaks, and changes to telomeric sequences and telomerase expression as a source of
structural chromosomal instability (see Chapter 1: 1.4.7.2). However, the situation is much
less clear regarding the mechanisms underlying the heterogeneity forms of instability. One
possible explanation could be that the mechanisms responsible for numerical and structural
chromosomal instabilities are the same ones that produce ongoing intermetaphase
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heterogeneity. In that case, the heterogeneity reflects a survival advantage of the new
clone or an equal survival capability of the new clone to that of the existing clones. More
plausible explanations exist for both forms of heterogeneity, however. The marked
numerical heterogeneity is more likely to be associated with particular defects in the
mitotic check point proteins including Chfr, the BUB family and EB1 as discussed
previously (see 1.4.7.1.4). Marked structural heterogeneity may be due to an increased
rate of DNA double-strand break events, which could be due to multiple factors including
endogenous or exogenous toxins, drugs and ionizing radiations as well as genetic
alterations such as telomerase deficiency. Recent data have shown that telomere attrition
in aging telomerase-deficient, p53 mutant mice promoted the development of epithelial
cancers via the formation of complex non-reciprocal translocations (Artandi et ah, 2000).
This led to the speculation that telomerase dysfunction early in the process of
carcinogenesis may lead to tumour development via the generation of multiple structural
chromosomal changes if permitted by p53 mutations (Hanahan, 2000).
The RER+ lines examined here usually showed stability of both chromosome
number and structure. However, this turned out to be just an association, as extensive
chromosomal instability was identified in 3 out of 8 RER+ lines, one of which showed a
near-triploid pattern as commonly seen in RER- tumours. Thus, microsatellite instability
did not preclude chromosomal instability, although it may possible that in most instances
the combined effect of both instabilities may generate too much instability beyond that
which is consistent with tumour cell survival and growth.
Almost half of the cell lines studied here were chosen to have no evidence of p53
mutations. This group of cell lines demonstrated chromosomal instability suggesting that
p53 mutation by itself is not necessary for the production of chromosomal instability.
Furthermore, p53 mutations were present in some of the RER+ lines, but were not
associated with any chromosomal instability, suggesting that p53 mutations are also not
sufficient for the production of chromosomal instability. However, the evidence that has
been accumulated in the literature associating p53 abnormalities with aneuploidy could be
compatible with p53 abnormalities being permissive for some forms of chromosomal
instability, such as those chromosomally unstable tumours that were produced in
telomerase-deficient, p53 mutant mice (Artandi et al., 2000).
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SKY has also revealed the existence of a new type of instability in colorectal
cancers characterised by multiple reciprocal translocation events. Two RER+ lines were
near-diploid but showed a striking and previously unreported tendency to acquire balanced
translocations. Previous work has suggested a role for the mismatch repair system in
maintaining the fidelity of the homologous recombination repair of DNA double-strand
breaks (de Wind et al., 1995; Schimenti, 1999). Therefore, it was possible to speculate
that this predisposition to balanced translocations is a consequence of the mismatch repair
deficiency leading to subsequent failure to recognize a homeologous (in contrast to
homologous) recombination repair of DNA breaks joining imperfectly matching DNA
sequences (Jasin, 2000). Combined to this, it is also possible that this balanced
translocation phenotype may be related to particular types of DNA insults. It has been
suggested that the balanced and unbalanced translocations in therapy-related acute myeloid
leukaemia develop in different ways depending on the therapeutic agent used. Balanced
chromosomal aberrations were the result of illegitimate DNA recombinations related to the
activity of DNA-topoisomerase II (Pedersen-Bjergaard & Rowley, 1994). This may be
applicable as well to the balanced translocations observed here in the colorectal cancer
cells, as the original neoplasms were continuously exposed to various intestinal toxins
which might have played a role in their initial development (as explained in 1.1.4).
Furthermore, some toxic agents might have been used for the treatment of the two tumours
from which these lines were established. Although such data are not available, it could be
quite possible in case of the LoVo cell line as it was established from a lymph node
metastasis (Drewinko et al., 1976).
Some patterns of chromosomal instability identified here were not possible without
events that are likely to cause apoptosis, such as DNA double-strand breaks, mismatches
produced through illegitimate DNA recombinations and probably non-disjunction and
other mitotic defects responsible for numerical chromosomal alterations. These patterns of
chromosomal instabiliy also appear to give rise to repeated genomic alterations, albeit
constrained in type, presumably reflecting deficient pathways for recognition and removal
of the altered cells by apoptosis. As it has been discussed previously, several molecules
appear to link apoptotic pathways to pathways implicated in the production of some forms
of chromosomal instability. Thus, survivin, BUB1, Bcl-2 and Fas all feature in pathways
linking apoptosis to the mitotic machinery (see Introduction: 1.4.7.1.5). p53 and other
downstream apoptotic molecules such as Bax are clearly involved in pathways responsible
for removal of cells with damaged DNA, which otherwise are likely to produce different
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sorts of structural chromosomal rearrangements (see Introduction: 1.2.3). Hence, tumours
arising in this way could be more resistant to cytotoxic therapeutic agents due to loss of
key apoptotic pathways—or such therapies may even trigger genetic alteration contributing
to further neoplastic progression. No clear relationship was detected here between p53
mutations and chromosomal instability. Bax gene mutations were recently identified in 3
of the RER+ lines used here (LoVo, LS174T, HCT116) (Carethers & Pham, 2000), but 2
of these lines displayed the marked karyotypic stability typical of an RER+ karyotype.
However, the status of other candidate pro- or anti-apoptotic molecules that may play a
role in chromosomal instability, such as survivin, remains to be explored in common
cancers.
6.1.2 Apoptosis deregulation in colorectal cancers
Deregulation of key apoptotic pathways was studied by analysis of three apoptosis
genes {Fas, Bik and Bax) and one growth control gene (TGFpRII) for mutations.
Mutational inactivation of the Fas gene or mutations affecting the CTG tandem repeat
element of the Bik gene were not found and thus are unlikely to be critical events in
colorectal carcinogenesis. Thus, the basis of Fas under-expression in colorectal cancers
remains elusive. Recent work showed that p53 controls the levels of Fas expression
(Maecker et al., 2000), and this may be an explanation of why Fas receptor is
under-expressed in a majority of colorectal carcinomas. However, pre- and
post-transcriptional causes may also be responsible for Fas under-expression in colorectal
carcinomas.
Although Bax gene mutations were found in 50% of the RER+ tumours studied
here, they were not always homogeneously present at all sites of the same tumour. This
could represent reversion of the original mutation through a second mutational event at the
same site, as these tumours already have an elevated rate of mutation (100-300 fold
compared to RER- tumours), especially at these sites of repetitive nucleotide tracts.
Compared with the results from the TGF/3RII gene, Bax mutations may be interpreted as
simply a consequence of mismatch repair deficiency without a functional connotation. It is
also possible that these late occurring Bax gene mutations help tumour progression by
offering better survival advantage in terms of loss of the susceptibility to apoptosis. This
could be particularly useful for tumour metastasis or tumours exposed to therapeutic
agents. The higher incidence (75% of RER+ cancers) and the ubiquitous intra-tumoral
presence of TGFfiRII mutations found in this work indicate a significant role for such
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mutations in RER+ colorectal carcinogenesis. Furthermore, inactivating mutations were
found in TGF/3RII in 15% of RER- tumours and a further 55% of RER- cancers
demonstrated a TGF(3 signalling blockade distal to TGF(3RII, including inactivation of
SMAD4 and SMAD2 (Grady et al., 1999). These findings can be interpreted as indicative
of a significant causal role for TGF(3 pathway inactivation in colorectal carcinogenesis.
6.1.3 Effects of tumour genotype on treatment responsiveness
The combined data obtained from the in vivo and in vitro experiments in this thesis
revealed significant effects of the p53 and RER status on tumour cell responsiveness to
treatments. The data showed that wild type p53 is critical for tumour cell killing by the
three therapeutic agents used here—5-FU, ionizing radiation (IR) and temozolomide.
Wild type p53 was absolutely necessary for the 5-FU anti-tumour effects. Tumours
lacking wild type p53 used alternative independent pathways including mismatch repair in
response to IR-induced damage, and the combined loss of p53 and mismatch repair
rendered the tumours studied here resistant to IR. Responses to temozolomide were
dependent on the presence of both wild type p53 and functional mismatch repair.
Accordingly, temozolomide or similar agents are less likely to be effective in the treatment




The colorectal cancer cell lines studied here were carefully selected to represent
different combinations of p53 and RER status. The comprehensive karyotypic information
provided here on these colorectal cancer cell lines together with other information
assembled in Table 3.1 should serve further research in the field. One immediate aim
would be to test if any of these patterns are more or less sensitive to therapy. Equally
important would be to test if such treatments stimulate further chromosomal changes in
these lines. SKY could be a useful tool to characterise the chromosomal changes after
treatment with different therapies and compare it to the original SKY karyotypes. As it has
been discussed before, there is evidence that balanced translocations appear to arise
following treatment with particular therapeutic agents in haematological malignancies and
possibly in one of the colorectal cancer cell lines studied here (see 6.1.1). This possibility
raises the serious implication that cytotoxic treatments of such tumours may provoke
accumulation of more genetic abnormalities resulting in progression to a more aggressive
cancer. This possibility needs to be fully explored by testing the patterns of chromosomal
changes in the surviving cells after application of a range of therapies to cells
representative of the different patterns described here, particularly the RER+,
chromosomally stable group. It may be necessary to test the invasive and metastatic
behaviour of such tumours, which may develop via this pathway in vivo as well as in vitro.
Molecules implicated in the generation of chromosomal instability such as Chfr,
the BUB family EB1 and telomerase should be candidates for future studies to understand
the mechanisms of chromosomal instability. An attractive study would be analysis of the
role of the mismatch repair system in homologous/homeologous recombination events in
the generation of balanced translocations. Cloning of the break points involved in the
consistently present balanced translocations may reveal sequences that are, for some
reason, prone to balanced translocation events or it may reveal hybrid genes generated by
these translocations with oncogenic potential similar to those observed in
haemato-lymphoid malignancies (Rabbitts, 1994).
There are recognition sequences in the Fas promotor for a number of
transcriptional proteins including p53, c-myb and NF-KB (Behrmann et al., 1994)—the
loss of any of which may reduce or prevent Fas expression. The Fas promotor also
contains a number of CpG dinucleotides, which are targets for hypermethylation and
subsequent reduction or loss of Fas expression. Therefore, future work could include
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study of the status of the recognition sequences and of CpG hypermethylation in the Fas
promotor region in colorectal cancers.
Future work could be done to evaluate the significance of Box gene mutations in
colorectal carcinogenesis by reintroducing wild type Box into 5ar-deficient tumour cells.
Restoring wild type TGF/3RII to cell lines lacking functional TGF|3RII was found to be
potentially growth suppressive (Grady et al., 1999), and TGFfiRII gene therapy may thus
have a future role in the treatment of colorectal carcinoma tumours.
The data obtained in the thesis linking responses to 5-FU to p53 status deserve
further work to clarify the basis of such a relationship and how widespread it is in primary
or xenografted colorectal cancers. Study of larger number of tumours would be useful to
establish the correlation between 5-FU responses and wild type p53. Other factors, which
may also affect the response to 5-FU such as thymidylate synthase, could be studied in
relation to p53 status in the process of cellular responsiveness to 5-FU in a suitable cell
line system.
The accumulated evidence indicates an association between lack of functional p53
and inability or reduced capability of tumour cells to undergo apoptosis in response to
therapies. Therefore, restoration of normal p53 functions in tumours might restore the
apoptotic pathways and lead to increased responsiveness to conventional therapeutics. In
the past few years, the development of methods for the introduction of genes such as p53
into tumour cells in vivo has made gene therapy intervention a possibility for the future
(Chang et al., 2000).
The information obtained here from the series of treatment responsiveness
experiments suggest that it may be possible to subclassify colorectal tumours into groups
regarding the combined status of both p53 and mismatch repair in order to predict which
tumours are most likely to benefit from a particular therapeutic agent.
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Reagents are listed in alphabetical order against the name of their supplier(s). All suppliers
are based in the UK unless otherwise specified.
a SdATP; Amersham International pic
ABC kit; Dako Ltd
Acridine Orange: Sigma Aldrich Chemical Company
Agarose; Sigma Aldrich Chemical Company
Ammonium acetate; Fisher Scientific
Ammonium persulphate; Severn Biotech Ltd
Bench alcohol; Genta Medical
Biotin-16 dUTP; Boehringer-Mannheim Ltd
Biotinylated anti-avidin; Vector Laboratories
Biotinylated rabbit anti-mouse immunoglobulins; Dako Ltd
Blocking agent; Amersham International pic
Boric acid; Sigma Aldrich Chemical Company
Bromophenol blue; Fisher Scientific
BSA fraction V; Fisher Scientific
Calcium chloride; Fisher Scientific
Chloroform; Fisher Scientific
Colcemid; Life Technologies Ltd
Cotl DNA, human and mouse; Life Technologies Ltd
Coverslips (No.O & No.l, Chance Propper); Fisher Scientific
'Decon' detergent; Fisher Scientific
Deionised distilled water (DDW); Elga Ltd
Diaminobenzidine (DAB); Sigma Aldrich Chemical Company
Diaminoethanetetra-acetic acid (EDTA), Sigma Aldrich Chemical Company
Diaminophenolindole (DAPI); Boehringer-Mannheim Ltd
Digoxygenin-11-dUTP; Boehringer-Mannheim Ltd
Dimethyl sulfoxide (DMSO); Sigma Aldrich Chemical Company
Dithiothreitol (DTT); Sigma Aldrich Chemical Company
DNA molecular weight marker 1 kilobase DNA ladder; Life Technologies Ltd
dNTPs; Pharmacia Biotechnologies Ltd
Do7 antibody; Dako Ltd
Ethanol; Hayman Ltd
Ethidium bromide; Sigma Aldrich Chemical Company
5-Fluorouracil, Sigma Aldrich Chemical Company
Foetal Calf Serum; Life Technologies Ltd
Formaldehyde solution; Fisher Scientific
Formamide: Fisher Scientific
33
[y P]ATP; Amersham International pic
'Gel Slick1; AT Biochem
Giemsa; Sigma Aldrich Chemical Company
Glacial acetic acid; Fisher Scientific
Glasgow Minimal Essential Medium (GMEM) with L-Glutamine; Life Technologies Ltd
Glycerol; Sigma Aldrich Chemical Company
Glucose; Fisher Scientific
Hydrochloric acid; Fisher Scientific
Hydrogen peroxide; Sigma Aldrich Chemical Company
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Ion-exchange resin beads; Bio-Rad Laboratories Ltd
Imidazole; Sigma Aldrich Chemical Company
'Instagel' 40% 19:1 acrylamide:bis acrylamide solution; Severn Biotech Ltd
Iscovo's Modified Dulbecco's Medium; Life Technologies Ltd
Iso-amyl alcohol; Fisher Scientific
Kodak X-OMAT autoradiography film; Amersham International pic
L-glutamine; Life Technologies Ltd
Magnesium chloride; Sigma Aldrich Chemical Company
Magnesium Sulphate; Sigma Aldrich Chemical Company
MDE gel; AT Biochem
Methanol; Fisher Scientific
Microscope slides 'Select' (Chance Propper); Fisher Scientific
Microscope slides (pre-washed); Beriner Glass KG, UK supplier: H.V. Skan LTD.
N,N,N',N',-tetramethylethylenediamine (TEMED); Severn Biotech Ltd
Normal rabbit serum; Life Technologies Ltd
Oligonucleotides;, Cruachem and VHBio
Penicillin-Streptomycin; Life Technologies Ltd
Phosphate buffered saline (PBS); Life Technologies Ltd
Pepsin; Sigma Aldrich Chemical Company
Potassium chloride; Fisher Scientific
Prolong Antifade (mounting medium); Molecular Probes
Propidium iodide; Sigma Aldrich Chemical Company
Proteinase K; ICN Biomedicals Ltd
Sequenase version 2.0 DNA polymerase and all other sequencing reagents; Amersham
International pic
Sequencing apparatus; Bio-Rad Ltd
Silver nitrate; Fisher Scientific
SKY™ probe kit; Applied Spectral Imaging, Migdal Ha'Emek, Israel
Sodium carbonate (decahydrate); Fisher Scientific
Sodium chloride; Fisher Scientific
Sodium citrate; Fisher Scientific
Sodium dodecyl sulphate (SDS); ICN Biomedicals Ltd
Sodium hydroxide; Fisher Scientific
Sodium dihydrogen orthophosphate; Fisher Scientific
Sodium thiosulphate; Fisher Scientific
Streptavidin alkaline phosphatase; Boehringer-Mannheim Ltd
Streptavidin alkaline phosphatase anti-digoxygenin; Boehringer-Mannheim Ltd
T4 polynucleotide kinase + buffer; Life Technologies Ltd
ThermoSequenase radio labelled terminator cycle sequencing kit, including all enzymes,
termination master mixes and reaction buffer; Amersham International pic
Thermostable DNA polymerase + buffer IV; Advanced Biotechnologies Ltd
Tissue culture plasticware; Iawa Ltd
Trypsin; Life Technologies Ltd
Tris; Sigma Aldrich Chemical Company
Trisodium citrate; Sigma Aldrich Chemical Company
Tween 20 (Polyoxyethylenesorbitan monolaurate); Sigma Aldrich Chemical Company,
Fisher Scientific
Urea; Fisher Scientific
Versene; Life Technologies Ltd
Whatman paper; Whatman Ltd
Xylene; Fisher Scientific
Xylene cyanol FF; Sigma Aldrich Chemical Company
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Appendix 2
Karyotypic details of constituent metaphases of each cell line
Constituent metaphases of each cell line are described in vertical columns, and
where relevant, were grouped into clones. 'Marker' is used to denote abnormal
chromosomes, and those observed in only one metaphase are still recorded under the
category 'rare markers'. Abnormal chromosomes (markers) are described according to the
standard ISCN (International System for Human Cytogenetic Nomenclature) (Mitelman,
1995).
m (lower case): metaphase; md: mode; mn: mean; sd: standard deviation; M:
marker; chr: chromosome; meta: metaphase (used in the footnotes).
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Role of BAX mutations in mismatch repair-deficient colorectal
carcinogenesis
Wael M Abdel-Rahman1, Izabela B Georgiades1, Lucy J Curtis', Mark J Arends1 and
Andrew H Wyllie*-'
'Sir Alastair Currie CRC Laboratories, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Crewe
Road, Edinburgh EH4 2XU
BAX gene mutations occur in approximately 50% of
RER+ colorectal cancers. To determine the role of
these mutations in tumour progression we analysed
multiple different tumour sites from RER+ colorectal
cancers for BAX mutations. Sixty colorectal carcinomas
were analysed for microsatellite instability at loci BAT-
26, L-myc, TGF/5RII, D13S160 and D2S123. Twelve
out of 60 tumours (20%) were RER + . Forty-five
different tumour sites from the 12 RER+ carcinomas
were analysed for BAX mutations at the [(G)8| tract in
exon 3. Six out of 12 (50%) RER+ tumours showed
BAX mutations, four of which showed a homogenous
pattern of such mutations detected in all tumour sites. In
the other two cases, BAX mutations were present in
some but not all tumour sites sampled from the same
patient. In contrast, TGF/IR// mutations were found in
9/12 cases (75%) and in each of these were present in all
the sampled sites. Two cases showed neither BAX nor
TGFfRII mutation. These data suggest that mutations in
TGFfiRH may occur at a very early stage in tumour
progression, perhaps in the founder clone. BAX muta¬
tions, however, are clearly not necessary for formation of
the founder clone and can occur for the first time later in
tumour progression.
Keywords: BAX; colorectal cancer; RER; mismatch
repair
Introduction
The BCL2 family of proteins control an important
checkpoint prior to activation of the caspase family of
proteases in apoptosis (Brown, 1997; White, 1996). One
prominent, widely expressed member of this family is
BAX, a 21 kDa protein with the capacity to
homodimerize or heterodimerize with other members
of the BCL2 family (Oltvai et al., 1993). Whereas
BAX-BAX homodimers are potent death inducers, the
BAX-BCL2 heterodimers and BCL2-BCL2 homodi¬
mers appear to promote survival (Kroemer, 1997).
Moreover, the tumour suppressor protein p53, a major
element in the response to lethal stimuli arising from
DNA damage or hypoxia, can transactivate BAX
(Miyashita and Reed, 1995) whilst down-regulating
BCL2 (Miyashita et a/., 1994). BAX is thus a
significant effector in the initiation of apoptosis.
"■Correspondence: AH Wyllie, Department of Pathology, University
of Cambridge, Tennis Court Road, Cambridge CB2 1QP
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Recently, clonally expanded, inactivating mutations
in BAX have been observed in a proportion of
colorectal cancers, together with evidence for under-
expression of the BAX protein in these tumours
(Rampino et al., 1997; Yamamoto et al., 1998; Yagi
et al., 1998; Ouyang et al., 1998). This provides some
circumstantial evidence for the hypothesis that the
founder cells of cancers may arise through selective loss
of a death pathway and the resultant inappropriate
survival of cells that have sustained DNA damage or
other severe intracellular injury. This hypothesis carries
the significant implication that cancer cells that arise in
this way are liable to be resistant to many cytotoxic
agents to which more normal cells would be sensitive,
because of constitutional loss of a critical death
pathway. Alternative explanations for the BAX
mutations exist, however. These mutations are
restricted to tumours with mismatch repair (MMR)
deficiency, and usually occur in a tract of eight
consecutive deoxyguanosines [(G)8] in the third coding
exon (Rampino et al., 1997). Since this is a classical
target site for nucleotide mismatch (Aaltonen et al.,
1993; Thibodeau et al., 1993), it is possible that
mutations within [(G)8] simply reflect the well-
recognized effect of MMR deficiency on mutation
incidence in tandem repeat microsatellite sequences.
In this paper we seek to distinguish between these
possibilities by studying the homogeneity of BAX
mutation within colorectal cancers. We argued that
genetic changes that are critical for carcinogenesis are
likely to be shared by all cells in the expanding tumour
and should therefore be detectable at all sites
throughout the tumour. In contrast, changes that
reflect the genomic instability of malignant cells, but
are not essential for the transition to malignancy might
be expected to occur in some but not all of the
divergent subclones within the given tumour. Accord¬
ingly, in this paper we studied BAX mutations in the




Twelve out of 60 patients (20%) demonstrated
microsatellite instability (Table 1). In some cases (nos.
17, 27, 52, 53 and 55) individual tumour sites from the
same carcinoma demonstrated different sets of muta¬
tions at the five microsatellite loci tested. In some
tumours, biopsies from different sites each exhibited
different mutations at the same microsatellite locus
2140
No Age Sex Site Histology
Sample





17 81 F cae mucoid A + + + _ + + (loss)
B + + + - + + (loss)
C — + + — + —
18 67 F sig ac md A + — — - — —
B + — — — — -
C + — — — — —
19 70 M asc ac pd A + + + - + + (loss)
B + + + - + + (loss)
C + + + - + + (loss)
22 43 F cae ac/mu A + — — — — + (loss)
B + — - - — + (loss)
25 65 F cae ac/mu A + + + + — + (loss)
B + + + + - + (loss)
C + + + + — —
D + + + + — + (loss)
27 88 F asc ac/mu A + + + — + —
B + + + + + —
C + + + + + —
D + + + + + —
E + + + + + —
F + + + + + —
G — + + — + —
28 75 F cae ac/mu A + + + + — —
B + + + + — —
38 64 M asc ac md A + + + — + + (loss)
B + + + - + + (loss)
C + + + — + + (loss)
D + + + — + + (loss)
47 60 M asc ac pd A + — + + + —
B + — + + + —
C + — + + + —
D + — + + + —
52 76 M cae ac pd A + + + + — —
B + + + + — —
C + + + + + —
D + + + + + —
53 77 F asc ac pd A + + — — — —
B + + — + — —
C + + — — + —
D + + — — — —
55 70 F asc ac pd A + + + + - + (gain)
B + + + - — + (gain)
C + + + + — + (gain)
D + + + - - + (gain)
Cae
pd =
= caecum, asc = ascending colon, sig =
poorly differentiated adenocarcinoma
sigmoid colon, mucoid = mucoid carcinoma, ac md = moderately differentiated adenocarcinoma, a
, ac/mu = mixed adenocarcinoma glandular/mucoid pattern, + (loss) = deletion of one G from th
[(G)8] tract, + (gain) = insertion of one G in the [(G)8] tract
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Table 1 Mismatch repair deficient carcinomas analysed for RER and BAX status
(Figure 1). However, in no case was microsatellite
instability present at one tumour site, and completely
absent at all tested loci in others. Hence it was possible
to classify all sampled sites of all tumours as RER + ,
although in two tumours (nos. 18 and 22) the instability
was evident in only one of the five tested loci.
BAX mutation analysis
Mutation in the BAX [(G)8] mononucleotide repeat
tract occurred in six out of 12 (50%) RER+ tumours.
In five, this involved loss of a repeated nucleotide and
in one a gain. Four showed a homogenous pattern,
with identical changes in [(G)8] detected in all sites
sampled from each carcinoma (Figure 2a and Table 1).
In the other two cases, however, [(G)8] BAX mutations
were present in some but absent in other sites from the
same cancers. Thus, case number 17 showed mutation
in tumour sites A and B, but not C and case number
25 showed mutations in A, B and D but not C (Figure
2b and Table 1). In both these cases, the tumour site in
which BAX [(G)8] was unchanged showed unequivocal
evidence of instability at most of the other tested
microsatellite loci.
Discussion
It is clear that deficiency in mismatch repair permits
the generation of large numbers of mutations
throughout the genome, mainly in microsatellite loci
and repetitive polynucleotide tracts (Aaltonen et al.,
1993; Thibodeau et al., 1993). In sporadic colorectal
tumours, the microsatellite instability is generally
found in carcinomas but not adenomas, whereas both
adenomas and carcinomas from HNPCC patients may
show a high proportion of such instability (Samowitz
and Slattery, 1997; Bubb et al., 1996; Jacoby et al.,
1995; Thibodeau et al., 1993). These observations
strongly suggest that microsatellite instability is
acquired at the adenoma-carcinoma interface in the
evolution of sporadic tumours, but can appear at an
Roie of BAX mutations in colorectal carcinogenesis








Figure 1 The band shift pattern of case no. 27 at the BAT-26 (a)
and L-myc (b) microsatellite loci (N = normal mucosa; A-G = 7
different tumour sites from the same carcinoma)
earlier stage in patients who carry germline mutations
in MMR genes. Previous studies have shown clonal
expansion of shifts of different amplitude at the same
microsatellite locus sampled from different sites in the
same tumour (Chung et al., 1997), as observed in the
present work also. This indicates that a proportion of
these microsatellite mutations are acquired as clonal
variants throughout the process of tumour formation
and reflect but do not cause the evolution of such
tumours. In contrast, mutations at some genetic loci
have been found with great consistency in RER +
tumours. An outstanding example is transforming
growth factor beta-type 2 receptor (TGF/IRII), which
is mutated in upwards of 90% of all tested RER +
colorectal cancers (Markowitz et al., 1995; Parsons et
al., 1995). In this series, more than 75% of RER +
cancers showed a mutation in the one site within the
TGF/IRII gene which we tested. Together with
independent evidence that TGF/i exerts a suppressive
effect on colorectal epithelial growth (Wrana et al.,
1994), these observations have been interpreted as
indicative of a causal role for TGF/iRII inactivation in
colorectal carcinogenesis.
Frameshift mutations have been detected in the
[(G)8] tract of exon 3 of the BAX gene in 48% of 63
RER + sporadic colorectal cancers in a total of two
separate studies (Rampino et al., 1997; Ouyang et al.,
1998), and in a similar proportion of RER +
colorectal cancers from HNPCC patients (Yamamoto
et al., 1998; Yagi et al., 1998). Our own observations
are entirely concordant with these results: we detected
BAX mutations in six out of 12 (50%) RER +
carcinomas. In the presence of BAX and TGF/IRII
mutations, others have shown second allele mutations
in pure cultures of cell lines (Rampino et al., 1997;
Markowitz et al., 1995), but this is much more
difficult to demonstrate in primary tumours due to
contamination by stromal and lymphoid cells. Hence
Figure 2 (a) BAX gene analysis of case no. 55 showing the band
shift pattern on a polyacrylamide gel demonstrating one
nucleotide insertion in the [(G)8] tract from all tumour sites
(A-D), compared to normal mucosa (N). (b) Sequence analysis
of case 17 (B and C) and 25 (B and C). In both cases, site C does
not show the one nucleotide deletion in the [(G)8] tract observed
in site B (indicated by arrow)
some uncertainty remains over the functional status of
BAX in primary human tumours, even when there is
evidence for mutation in one allele. However, we
report here, we believe for the first time, two patterns
for such mutations. In four of the six tumours bearing
BAX mutations, identical alterations in the [(G)8] tract
were found in all sites sampled within each cancer,
supporting the hypothesis that BAX mutation was
present in the founder malignant clone. This pattern is
also consistent with that described for BAX mutations
in gastric cancers (Chung et al., 1997). However, in
two of six cases we demonstrated a second pattern in
which BAX mutation is not shared by all the tumour
sites of the same cancer. We can not completely
exclude the possibility that the apparently unaltered
[(G)8] tract found in subclones of these tumours
represents a reversion, through a second mutation, of
the [(G)8] mutation present elsewhere. This possibility
can in the future be tested in appropriate cell culture
models. A more obvious explanation, however, is that
in these tumours the BAX [(G)8] mutation was not
present in the founder malignant clone but was
acquired later in cancer progression. In these
tumours, it is difficult to sustain the view that
mutational inactivation of BAX could have been a
critical event early in carcinogenesis. These data
therefore raise some doubt as to the significance of
loss of BAX-dependent apoptosis pathways in colo¬
rectal carcinogenesis. Rather than indicating that
failure of apoptosis exerts a critical role in
carcinogenesis, some BAX mutations in colorectal
tumours may merely aid tumour progression, or
indeed may simply reflect the consequences of
mismatch repair deficiency without a functional
connotation.
Role of BAX mutations in colorectal carcinogenesis




Fresh tumour samples were collected from patients with
colorectal carcinoma undergoing surgery in the Royal
Infirmary of Edinburgh NHS Trust. Samples were collected
from the operating theatre within 30 min of resection and
transported to the Pathology Department. Two to seven
small tumour pieces and the matched normal tissues from
each case were frozen in liquid nitrogen, then stored at
— 70°C. DNA was extracted from frozen tissues by the
method of Goelz et al. (1985).
RER status analysis
Sixty tumours were originally screened for microsatellite
instability and only RER+ cases were analysed for BAX
gene mutation. All the samples were tested at five
microsatellite loci including the highly unstable BAT-26
locus, claimed to be sufficient alone for identifying the
RER status (Zhou et al., 1998; Hoang et a!., 1997). The
other 4 loci included L-myc, TGF/iRII, D13S160, and
D2S123 using the primers and conditions described
elsewhere (Young et a!.. 1995; Huang et al.. 1996).
A DNA segment of 94-base pairs encompassing the [(G)8]
tract in BAX was amplified by PCR using the primers
described by Rampino et al. (1997). PCR was carried out for
30 cycles, each consisting of denaturation for 30 s at 94°C,
annealing for 30 s at 55°C, extension for 30 s at 72°C.
Reactions consisted of 50 ul volume containing 100 ng
genomic DNA, 10 pmols of each primer, 200 um of each
dNTP (Advanced Biotechnologies Ltd), 1.5 mM MgCl2,
1.25 U of thermostable Taq DNA polymerase and buffer
consisting of 20 mM Tris-HCl (pH 8.4), 50 mM KC1 and
0.05% non-ionic detergent (Life Technologies UK). The PCR
hot start method was used. The products were analysed by
electrophoresis on 2% agarose gels for detection of the
amplified product.
The forward primer was end labelled with }>-33P-ATP using
T4 polynucleotide kinase according to the manufacturer's
instructions (Life Technologies UK). This primer was then
used to label the original PCR product by performing one
PCR cycle using the same conditions as described above. The
radio-labelled products were electrophoretically separated in
denaturing 6% polyacrylamide gel and subjected to
autoradiography for detection of band shifts. At the same
time, all the original PCR products were directly sequenced
with Thermosequenase radiolabeled terminator cycle sequen¬
cing kits (Amersham Life Science).
BAX gene analysis
Twelve RER+ cases with a total of 45 different tumour
sites and the matched normal tissue constituted in the
material for BAX gene mutational analysis.
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Letter to the Editor
Death pathway genes Fas (Apo~1/CD95) and B\k (Nbk) show
no mutations in colorectal carcinomas
Dear Editor,
Many proteins with an established role in carcinogenesis
and cancer progression (e.g. p53, RB, C-MYC, BCL2,
RAS & E1B 19K) can regulate apoptosis and altered
susceptibility to apoptosis may contribute to carcinogen¬
esis.1 Data from genetically manipulated animals show
that oncosuppressor deficiency may abrogate the apopto¬
sis of cells that have sustained DNA damage, thus
permitting survival and proliferation of cells bearing
mutations.2 Apoptosis is widely observed in tumours,
however, indicating that loss of ability to induce apoptosis
- if important in carcinogenesis - must be restricted to
particular pathways. Clear identification of these pathways
in human tumours becomes an important aim, as it would
help define the molecular basis not only of carcinogenesis
but also of tumour resistance to various therapeutic
measures. The study of colorectal cancers affords a
particular advantage in this respect because a proportion
have an underlying deficiency in DNA nucleotide mis¬
match repair (MMR), alternatively known as 'replication
error positive' (RER+) phenotype. A high proportion of
RER+ colorectal carcinomas do indeed bear clonally
expanded mutations in microsatellite loci or repetitive
sequences within cancer-related genes emphasising the
importance of such genes in the process of carcinogen¬
esis and cancer progression. Such mutated target genes
include APC, TGF/i-RII,3 and Bax4,5 all of which have
also been implicated in pathways initiating apoptosis.
Here, we provide information on two more death pathway
genes: Fas (Apo-1/CD95) and Bik-1 (Nbk).
Active FAS receptor triggers apoptosis in many cell
types and appears to be necessary for apoptosis
initiated by C-MYC and certain DNA-damaging che-
motherapeutic agents. Binding of the FAS ligand
induces trimerization of the receptor and this stimulates
the intracytoplasmic FAS death domain to recruit a
protein complex that includes caspase 8, thus activating
the caspase cascade and hence the terminal effector
events of apoptosis.6 Fas is an attractive potential target
for carcinogenic mutations. Individuals with the rare
Canal-Smith syndrome, in which Fas is constitutively
abnormal, have a high cancer incidence.7 Moreover, FAS
protein is constitutively expressed in normal colorectal
epithelium and most colorectal adenomas, but expression
is frequently less and sometimes undetectable in
carcinomas.8 The mechanism and significance of these
changes, however, has not been established. BIK is a
potent death-inducing protein sharing the BH3 domain of
the BCL2 protein family. It has capacity to interact with
the endogenous survival promoting proteins, BCL2 and
BCLxl, and their functional viral homologues BHRF1 and
E1B-19K. BIK can induce apoptosis independently of
p53 and BAX in some cell types9 but its role in
colorectal epithelium is unknown. We therefore studied
the genes encoding FAS and BIK proteins in a series of
primary colorectal carcinomas, to test the hypothesis that
mutation in these apoptosis-promoting genes may be
implicated in the process of human colorectal carcino¬
genesis.
DNA was extracted from frozen samples of 24 selected
colorectal carcinomas (and normal mucosa) including 12
RER- and 12 RER+ after testing for microsatellite
instability at 5-11 microsatellite loci (Figure 1a). Of the
12 RER+ tumours ten were right sided, ten had poor or
mucinous differentiation, and six were immunohisfochemi-
cally positive for p53 accumulation. The 12 RER tumours
included three right-sided tumours, three with mucinous or
poor differentiation and nine that were p53 positive by
immunohistochemistry.
a
IN IT 2N 2T 13N 13T
b
IN IT 2N 2T
Figure 1 (a) Denaturing polyacrylamide gel showing RER characterisation at
the BAT26 microsatellite locus: samples 1 and 2 show band shifts in the
tumour lane (T) compared to the normal (N), consistent with derivation from
RER+ cancers, whereas sample 13 does not show any band shifts and is
derived from a RER- cancer, (b) SSCP for Fas exon 91 for samples 1 and 2
from RER+ tumours, showing no band shifts in the tumour (T) compared to the
normal (N) lanes, (c) SSCP for Bik for samples 1 and 2 from RER+ tumours,
showing no band shifts in the tumour (T) compared to the normal (N) lanes
Letter to the Editor
388
Ten primer pairs were designed to PCR-amplify the nine
Fas exons. Bik was examined less comprehensively,
focusing on a potential target site for MMR deficiency
mutations: a repetitive sequence containing CTG triplets
[(CTG)2 GCG (CTG)5 GCG (CTG)3 CCG CTG] occupying
positions 409-450, included within the Bik coding
sequence. The PCR products were analyzed for mutations
using single strand conformation polymorphism (SSCP).10
Heteroduplex analysis11 was performed on the PCR
products from Fas exon 5 because these were difficult to
resolve by SSCP. Where abnormal banding patterns were
observed DNA was directly sequenced. By these criteria
there was no evidence of mutation in any of the 24 cancer
or normal mucosa samples examined, either in all the Fas
gene exons (Figure 1b), or in the target repeat sequence in
the Bik gene (Figure 1c).
On searching the coding sequence of Fas for nucleotide
repeats we found a [(T)7] tract in exon 4, an [(A)6] tract in
exon 9 and a [(T)5] tract in exon 3 in addition to some
shorter repeat tracts. Other studies have shown that
mononucleotide repeats of similar length are susceptible
to MMR deficiency mutation and there is thus little doubt
that Fas provides several intra-exonic targets for mutation
in RER+ cells. The mutation screening method (SSCP)
detects 80-90% of mutations when applied to single
strand DNA between 150-250 nucleotides in length. We
designed the PCR primers to generate products to fit this
range as far as possible. Hence it is improbable that
mutations in Fas or in the tandem repeat region identified
in Bik are frequent in human colorectal cancers, even
when these bear the mutation-susceptible RER+ pheno-
type.
The importance of clonal selection in carcinogenesis and
tumour progression has recently been re-emphasised.12
Our results contrast with the high incidence of mutation in
RER+ colorectal cancers in other genes, notably TGF/i-R//
(75%),3 and Bax (50%).4,5 This failure to identify any
instance of clonal expansion of cells bearing Fas or Bik
mutations thus suggests that such mutations confer no
substantial growth advantage in colorectal carcinogenesis.
The question remains why FAS protein expression
should be subnormal in a high proportion of colorectal
carcinomas. The present results and those of others using
Southern blot technology13 exclude structural alterations in
the gene. An obvious alternative mechanism would be
depressed transcription secondary to reduced availability of
wild type p53, since the first intron of Fas includes a p53
responsive element.14 Of our 24 cases, 15 showed clear
abnormality in p53, exhibited by immunohistochemical
stabilisation affecting a high proportion of the nuclei.
Although Fas down-regulation has the capacity to reduce
cellular responses to lethal stimuli, it is significant that
mutational inactivation of the gene is not observed in
cancer tissues in which mutational events in other genes
are common and clonally expanded. We conclude that Fas

















1. Arends MJ and Wyllie AH (1991) Apoptosis-mechanisms and roles in
pathology. Int. Rev. Exp. Pathol. 32:223-254
2. Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, Wyllie AH and
Greaves M (1997) Absence of p53 permits propagation of mutant cells following
genotoxic damage. Oncogene 14:523-531
3. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW and
Vogelstein B (1995) Microsatellite instability and mutations of the transforming
growth factor beta type-ll receptor gene in colorectal cancer. Cancer Res. 55:
5548-5550
4. RampinoN,YamamotoH, lonovY, LiY, SawaiH, ReedJCandPeruchoM(1997)
Somatic frameshift mutations in the Bax gene in colon cancers of the
microsatellite mutator phenotype. Science 275:967 - 969
5. Abdel-Rahman WM, Georgiades IB, Curtis LJ, Arends MJ and Wyllie AH (1999)
Role of Bax mutations in mismatch repair-deficient colorectal carcinogenesis.
Oncogene (in press)
6. Yuan YJ (1997) Transducing signals of life and death. Curr. Opin. Cell Biol. 9:
247-251
7. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL and Elkon KB (1996) Fas gene
mutations in the Canale-Smith syndrome, an inherited lymphoproliferative
disorder associated with autoimmunity. N. Engl. J. Med. 335:1643 -1649
8. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A and
Krammer PH (1994) Expression of APO-1 (CD95), a member of the NGFTNF-
receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer
57:371-377
9. BoydJM, GalloGJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG,
Subramanian T, Chittenden T, Lutz RJ and Chinnadurai G (1995) Bik, a novel
death inducing protein shares a distinct sequence motif with BCL-2 family
proteins and interacts with viral and cellular survival promoting proteins.
Oncogene 11:1921 -1928
10. Orita M, Suzuki Y, Sekiya T and Hayashi K (1989) Rapid and sensitive detection
of point mutations and DNA polymorphisms using the polymerase chain reaction.
Genomics5: 874-879
11. White MB, Carvalho M, Derse D, O'Brien SJ and Dean M (1992) Detecting single
base substitutions as heteroduplex polymorphisms. Genomics 12:301 -306
12. Tomlinson I and Bodmer W (1999) Selection, the mutation rate and cancer:
ensuring that the tail does not wag the dog. Nat. Med. 5:11 -12
13. Butler LM, Hewett PJ, Butler WJ and Cowled PA (1998) Down regulation of Fas
gene expression in colon cancer is not a result of allelic loss or gene
rearrangement. Br. J. Cancer 77:1454-1459
14. Muller M, WilderS, Bannasch D, Israeli D, Lehlbach K, Li-weber M, Friedman SL,
Galle PR, Stremmel W, Oren M and Krammer PH (1998) p53 activates the CD95
(Apo-1/Fas) gene in responseto DNA damage by anticancer drugs. J. Exp. Med.
188:2033-2045
